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Summary
Fucosidosis is a rare lysosomal storage disease caused by the deficiency of the lysosomal
glycosidase α-L-fucosidase resulting in the accumulation of fucosylated glycocompounds.
Human fucosidosis patients are mainly characterized by progressive mental retardation and
neurological deterioration leading to premature death. In this study, the generation of a con-
stitutive fucosidosis mouse model is reported. The gene for the lysosomal α-L-fucosidase
(Fuca1) was disrupted by gene targeting resulting in the complete absence of α-L-fucosidase
activity in Fuca1(-/-) mice. The phenotype of the mouse model closely resembled that of a
milder form of the human disease and due to animal welfare, the Fuca1(-/-) mice had to be
euthanized at 9 - 11 months of age. A lysosomal storage pathology was detected in nearly all
investigated organs of the mouse model, e. g. in liver, kidney, spleen as well as in the CNS, and
was characterized by foam-like storage vacuoles to variable degree. An immense accumula-
tion of water-soluble fucosylated glycocompounds was demonstrated and the glycoasparagine
Asn-GlcNAc-Fuc was identified as main storage material in kidney and brain and was also
excreted with the urine of the Fuca1(-/-) mice. The neuropathological alterations of the mouse
model were analyzed in more detail, as these are the leading symptoms in human fucosido-
sis. The Fuca1(-/-) mice exhibited neuroinflammatory signs including prominent micro- and
astrogliosis and suffered from progressive loss of Purkinje cells. Particularly the latter might
contribute to behavioral abnormalities of the animals including progressive coordinatory and
motor deficits as well as a reduced overall activity and cognitive impairment.
In order to enable the development of an enzyme replacement therapy (ERT) for the fucosi-
dosis disease, an expression system for the production of the human α-L-fucosidase was
generated in CHO-K1 cells. While a purification strategy for the His6-tagged enzyme was
established using a Ni2+-affinity chromatography followed by a strong cation exchange chro-
matography, the purification of the untagged α-L-fucosidase was more challenging and needs
further efforts. Finally, a Fuca1(-/-) mouse was intravenously treated with purified His6-tagged
enzyme resulting in an efficient uptake of the recombinant α-L-fucosidase into visceral or-
gans and in a complete clearance of storage material in the spleen. These preliminary results
provide promising data with regard to develop an ERT also for human fucosidosis patients.
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Zusammenfassung
Fucosidose ist eine seltene lysosomale Speichererkrankung. Sie wird durch die Defizienz der
lysosomalen Glykosidase α-L-Fucosidase verursacht, sodass es zu einer Anreicherung von
fucosylierten Glykokonjungaten kommt. Die Leitsymptome humaner Fucosidose-Patienten
sind eine fortschreitende mentale Retardierung sowie eine Verschlechterung neurologischer
Fähigkeiten, sodass die betroffenen Patienten frühzeitig versterben. In der vorliegenden Ar-
beit wird die Generierung eines konstitutiven Fucosidose Mausmodells beschrieben. Dafür
wurde das Gen für die lysosomale α-L-Fucosidase (Fuca1) gezielt zerstört (gene targeting).
Der resultierende, vollständige Verlust der Enzymaktivität der α-L-Fucosidase führt zu einem
Phänotyp des Mausmodells, welcher stark dem einer milderen Form der humanen Erkrankung
ähnelt. Die Fuca1(-/-)-Tiere mussten aus Tierschutzgründen im Alter von 9 - 11 Monaten eu-
thanasiert werden. In nahezu allen untersuchten Organen, z. B. in der Leber, Niere, Milz und
auch im ZNS, wurde ein lysosomaler Speicherphänotyp mit unterschiedlich vielen Speicher-
vakuolen festgestellt, welche ein schaumartiges Aussehen aufwiesen. Dabei akkumulierten
fucosylierte Glykokonjungate in großen Mengen. Das Glykoasparagin Asn-GlcNAc-Fuc,
welches auch mit dem Urin der Tiere ausgeschieden wurde, wurde als Hauptspeichermaterial.
Desweiteren wurden die neuropathologischen Veränderungen des Mausmodells detailliert un-
tersucht, da diese die Leitsymptome humaner Fucosidose-Patienten darstellen. Im Gehirn der
Fuca1(-/-)-Mäuse wurden entzündliche Prozesse in Form von Mikro- und Astrogliose sowie
eine progressive Degenerierung von Purkinje-Zellen festgestellt. Vor allem letzteres könnte
zur Entwicklung von Verhaltensauffälligkeiten der Tiere, wie progressiven Koordinations- und
Bewegungsschwierigkeiten, einer verminderten Aktivität sowie einer geringeren kognitiven
Leistungsfähigkeit beitragen.
Um die weitere Entwicklung einer Enzymersatztherapie (enzyme replacement therapy; ERT)
zu ermöglichen, wurde für die humane α-L-Fucosidase ein Expressionssystem in CHO-K1-
Zellen etabliert. Für das His6-getaggte Enzym konnte erfolgreich eine Aufreinigungsstrategie
mittels einer Ni2+-Affinitätschromatographie und einer starken Kationen-Austauschchromato-
graphie erarbeitet werden. Die Entwicklung einer Aufreinigungsstrategie für das ungetaggte
Enzym erwies sich als schwieriger, sodass hier noch weitere Studien nötig sind. In einem
finalen Experiment wurde einer Fuca1(-/-)-Maus die aufgereinigte, His6-getaggte α-L-Fuco-
sidase intravenös appliziert, welche dann vor allem in viszeralen Organen nachweisbar war,
was in der Milz zu einem vollständigen Abbau des Speichermaterials führte. Diese ersten
Experimente liefern vielversprechende Daten in Hinblick auf die Entwicklung einer ERT für
humane Fucosidose-Patienten.
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1 Introduction
1.1 The lysosome
Lysosomes are specialized, membrane-enclosed organelles and represent the main degradative
compartment in eukaryotic cells. Initially, lysosomes were described by Christian de Duve as
membrane-enclosed vesicles which sedimented during differential cell centrifugation together
with a subset of acidic hydrolases (de Duve et al. 1955) and represent the terminal degradative
compartment of eukaryontic cells (de Duve 1963). More recently, it was recognized that the
lysosome is not only the terminal compartment of catabolic processes but also participates in
the regulation of signaling, nutrient sensing, antigen presentation and programmed cell death
(Fraldi et al. 2016, Carmona-Gutierrez et al. 2016). Until now, more than 60 soluble (Lübke
et al. 2009) as well as more than 100 lysosomal transmembrane proteins (Schwake et al. 2013)
have been identified, although the analysis of the lysosomal proteome is still ongoing. The sol-
uble proteins are mainly acidic hydrolases which degrade macromolecules like proteins, oligo-
and polysaccharides, complex lipids, RNA and DNA. The resulting monomers (amino acids,
monosaccharides, fatty acids, cholesterol and nucleotides) leave the lysosome through specific
membrane-bound efflux transporter proteins and can be re-utilized in biosynthetic processes
within other cell compartments. Hence, the lysosome has an important impact on the regula-
tion of the cellular homeostasis (Micsenyi and Walkley 2013). The lysosomal hydrolases are
characterized by an acidic pH optimum (acidic hydrolases) and the lysosome itself exhibits
an acidic luminal pH which is maintained through ATP-dependent proton pumps (Cuppoletti
et al. 1987).
The uptake of compounds into the lysosome is mediated by three major pathways: a biosyn-
thetic, an endocytotic and an autophagic pathway. Lysosomal proteins are synthesized at
the rough endoplasmatic reticulum (rER) and are further transported towards the lysosomal
compartment via the Golgi apparatus and endosomes (see also section 1.1.1). Extra- and
intracellular material that is designated for further degradation reach the lysosome via en-
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docytosis and autophagy, respectively (Micsenyi and Walkley 2013). In case of endocytosis,
extracellular material is invaginated into transport vesicles at the plasma membrane of the cell,
either receptor-mediated or receptor-independent, and is further transported towards the lyso-
some via early and late endosomes (van Meel and Klumperman 2008). Intracellular material
reaches the lysosome by autophagy, which can be further divided into macroautophagy, mi-
croautophagy and chaperone-mediated autophagy. Macroautophagy describes the formation
of a double membrane which engulfs cytosolic material or entire organelles and the further
generation of autophagosomes. The invaginated material is recognized by adaptor molecules
like heat-shock proteins that mediate their specific uptake into the autophagosome (Micsenyi
and Walkley 2013). In contrast, microautophagy does not involve the de novo generation of
double membrane structures but rather mediates uptake of cytosolic material into lysosomes
by a pinocytosis-like process (Platt et al. 2012). Chaperone-mediated autophagy targets selec-
tively proteins containing a KFERQ motif for proteolysis. The proteins are recognized by the
Hsc-70 chaperone, which promotes protein unfolding. The lysosome-associated membrane
protein type 2A (Lamp2A) mediates the further transport of the targeted proteins across the
lysosomal membrane (Dice 2007).
1.1.1 Synthesis of lysosomal proteins
The expression of many lysosomal proteins is regulated by the transcription factor EB (TFEB).
Due to lysosomal stress or nutrient depreviation, cytoplasmic TFEB becomes activated by
phosphorylation and is transferred into the nucleus, where it promotes the transcription of
genes harboring a CLEAR (coordinated lysosomal expression and regulation) element. The
phosphorylation is carried out by the rapamycin complex 1 (mTORC1) kinase, which is a mas-
ter regulator of cell homeostasis and growth (Bar-Peled and Sabatini 2014) in dependency of
e. g. the availability of amino acids. The latter is sensed in the lysosome by the lysosomal nu-
trient sensing machinery (LYNUS), a multi-protein complex consisting of e. g. the v-ATPase
(Fraldi et al. 2016). In cells with sufficient amino acid levels, the v-ATPase promotes the GTP-
loading of different GTPases, which results in the recruitment of mTORC1 to the lysosomal
surface and its activation leading to promoted cell growth, whereas autophagy is inhibited. At
the lysosomal surface, mTORC1 kinase phosphorylates TFEB at Ser211, which results in the
retainment of the transcription factor in the cytosol. Under nutrient-depreviative conditions,
mTORC1 is inactivated, resulting in the dephosphorylation of TFEB and its translocation
into the nucleus, where it promotes the transcription of genes for many lysosomal proteins
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and autophagy-related proteins (Bar-Peled and Sabatini 2014). Moreover, the expression of
several proteins associated with proper lysosomal function (e. g. receptors essential for lyso-
somal targeting: MPR300 and MPR46) is also regulated by TFEB, whereas the lysosomal
α-L-fucosidase, which is the focus of this work, is expressed independently from TFEB re-
gulation (Sardiello et al. 2009). Recently it was demonstrated, that the transcription factor E3
(TFE3) acts in a similar manner as TFEB. TFE3 is also regulated by the mTORC1 pathway
and promotes transcription of genes harboring CLEAR elements (Martina et al. 2014).
Lysosomal proteins are synthesized at the rough endoplasmatic reticulum (rER) and the nascent
peptide chain is co-translationally translocated into the ER lumen. This process is mediated
by a N-terminal signal peptide of 15 - 30 amino acids, that is proteolytically cleaved after ER
translocation. During the further transport of lysosomal proteins through ER and Golgi, the
proteins are post-translationally modified, e. g. most soluble lysosomal hydrolases receive a
mannose-6-phosphorylation (M6P) signal which is specifically recognized in the trans-Golgi
network and directs lysosomal targeting. (see also section 1.1.2; Braulke et al. 1987).
Most lysosomal proteins are highly N-glycosylated, a co-translational modification that is also
important for proper protein folding, oligomerization, quality control and further transport
(Braulke et al. 1987). N-glycans are attached to asparagine residues at the outer surface of pro-
teins within the recognition motif Asn-X-Ser/Thr, where X stands for any amino acid except
proline. Initially, the oligosaccharide chain is synthesized on a lipid anchor (dolichol phos-
phate) and consists of two N-acetylglucosamine, nine mannose and three glucose residues.
After transfer of the oligosaccharide chain to the protein, the three terminal glucose as well as
one mannose residue is cleaved off by the sequential action of α-glucosidases I and II and the
α-mannosidase I. The glycosylated proteins are transported to the Golgi apparatus, where the
N-glycans are further trimmed, but the core-structure consisting of two N-acetylglucosamine
and three mannose residue is always maintained. In parallel, different saccharide residues can
be added, so that the final N-glycans are divided into a mannose-rich, a complex and a hybrid
type (figure 1.1): Lysosomal proteins exhibit mainly mannose-rich N-glycans consisting of
two N-acetylglucosamine core-residues followed by a variable number of mannose-residues.
The complex type N-glycans contain the core-saccharide unit described above which can be
extended by mannose, N-acetylglucosamine, galactose and sialic acid. Moreover a fucose
residue can be added α1-6 at the N-acetylglucosamine linked to the asparagine residue or at
the peripheral residues α1-3 /α1-4 to N-acetylglucosamine or α1-2 to galactose. The hybrid
type is a mixed N-glycan, where one antenna is composed of a mannose-rich N-glycan and
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another antenna belongs to the complex N-glycan (Kornfeld and Kornfeld 1985).
Figure 1.1: N-glycan structures
N-glycans can be separated into a high-mannose type and a complex type. Moreover, hybrid type N-
glycans exhibit properties of both, high-mannose and complex type N-glycans. Modified from Kornfeld
and Kornfeld (1985).
1.1.2 Targeting of proteins towards the lysosome
Most soluble lysosomal proteins are targeted through the mannose-6-phosphate (M6P)-depen-
dent pathway (figure 1.2). The M6P residue is added to high-mannose-type N-glycans in
the Golgi apparatus. In detail, the UDP-N-acetylglucosamine 1-phosphotransferase (GNTP)
transfers a N-acetylglucosamine-1-phosphate to the C6-position of selected mannose residues
in the cis-Golgi network (Pohlmann et al. 1982, Kornfeld and Mellman 1989). The GNTP
specifically modifies N-glycans of lysosomal enzymes which are recognized by lysine residues
at the protein surface near the N-glycosylation site (Braulke and Bonifacino 2009). The N-
acetylglucosamine is subsequently removed by the N-acetylglucosamine-1-phosphodiester α-
N-acetylglucosaminidase (uncovering enzyme, UCE) in the trans-Golgi network, resulting in
the exposure of the M6P residue (Coutinho et al. 2012b). Two specific M6P receptors (MPRs)
are present in the trans-Golgi network: the cation-independent MPR with an molecular weight
of approximately 300 kDa (MPR300) and the cation-dependent 46 kDa MPR (MPR46). Both
receptors bind the M6P residue with high affinity at almost neutral pH and direct the further
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transport of lysosomal proteins in clathrin-coated vesicle towards the late endosomes. Due
to the acidification in late endosomes, the cargo is released from the receptors which are re-
cycled to the trans-Golgi network, whereas the M6P modified proteins reach the lysosomal
compartment probably by fusion of late endosomes and lysosomes. Interestingly, although
both receptors recognize the same sugar moiety, they exhibit different binding affinities to-
wards lysosomal proteins, which is probably caused by individual structures of the proteins
Figure 1.2: MPR-dependent targeting of soluble proteins towards the lysosome
Newly synthesized lysosomal proteins are co-translationally translocated into the rough endoplasmatic
reticulum (ER), where they are glycosylated. The proteins are further transferred towards the cis-
Golgi network, where a N-acetylglucosamine-1-phosphate is added on high-mannose type N-glycans
by GNTP. The lysosomal proteins are further transported towards the trans-Golgi network, where the
N-acetylglucosamine is removed by UCE resulting in the exposure of the M6P residue, which is re-
cognized by MPRs. The MPRs direct the transport of the proteins into late endosomes, where the
cargo is released from the MPRs due to the low pH value. The receptors are recycled to the Golgi,
whereas the soluble lysosomal proteins reach the lysosomal compartment by fusion of late endosomes
and lysosomes. A part of the newly synthesized lysosomal proteins escape the MPR recognition in
the trans-Golgi network and is secreted. These proteins can be recaptured by MPRs located at the cell
surface and are also transported towards late endosomes and lysosomes.
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(Coutinho et al. 2012b). Besides their localization in the trans-Golgi network and in late endo-
somes, both MPRs can be also found at the plasma membrane of cells, but only the MPR300
is able to mediate the endocytosis of M6P-modified proteins (Braulke and Bonifacino 2009).
This fact is of special importance, as approximately 5 - 20 % of all newly synthesized lyso-
somal proteins escape the lysosomal targeting in the trans-Golgi network and are initially
secreted (Markmann et al. 2015). At the plasma membrane, they can be recaptured by the
MPR300, a mechanism which is also the basis for an enzyme replacement therapy (section
1.2.1).
Besides the M6P-dependent pathway, some soluble lysosomal proteins reach the compart-
ment by other routes. It was shown, that the lysosomal integral membrane protein 2 (Limp2)
mediates the transport of the β -glucocerebrosidase (Reczek et al. 2007), whereas sortilin is
a receptor for the accessory proteins prosaposin and GM2 activator protein (Coutinho et al.
2012a) and participates in the lysosomal transport of the cathepsins D and H (Canuel et al.
2008). More recently, the Lrp1 and the LDL receptor were found to be involved in the lyso-
somal targeting of the cathepsins B and D (Markmann et al. 2015). In contrast, the lysosomal
targeting of the α-L-fucosidase is strictly dependent of the MPR-pathway (Kollmann et al.
2012, Markmann et al. 2015).
In contrast to soluble proteins, lysosomal membrane proteins contain a sorting signal in their
cytosolic tails, which is based either on a dileucine motif ([DE]XXXL[LI], X stands for any
amino acid) or on a tyrosine rich signal (YXXØ, Ø stand for a large hydrophobic amino acid).
The sorting signal is recognized by specific adaptor proteins mediating the lysosomal targeting
either directly in the trans-Golgi network or the membrane proteins are first secreted and then
recaptured at the plasma membrane (Braulke and Bonifacino 2009).
1.2 Lysosomal storage disorders
Lysosomal storage disorders (LSDs) are a class of more than 50 inherited, monogenetic di-
seases that are caused by an impaired lysosomal function (Hopwood 2013). 85 % - 90 % of
all diagnosed cases are due to the deficiency of a single lysosomal hydrolase (Winchester
2013a) resulting in progressive accumulation of undegraded macromolecules inside the lyso-
some (primary storage material). Thereby, the function of the entire endosomal-lysosomal
system is impaired leading to an decreased autophagic flux and the accumulation of toxic
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substances which can initiate cellular apoptosis. Moreover, LSDs result not only in the ac-
cumulation of macromolecules, but also in a reduced efflux of monomeric compounds out of
the lysosome and in a disturbed cellular homeostasis leading to metabolic insufficiency and
cellular stress (Platt et al. 2012). The immense storage burden of the endosomal-lysosomal
system often leads to an impaired function of other lysosomal proteins, which results in the
accumulation of secondary storage material, which is not a substrate of the deficient enzyme
itself (Micsenyi and Walkley 2013). During disease progression, these pathologic events result
in cell and multisystemic tissue dysfunction (Hopwood 2013).
LSDs can be divided into different subtypes according to the accumulating storage material:
sphingolipidoses (e. g. GM1-gangliosidosis), mucopolysaccharidoses (e. g. MPS I), glycopro-
teinoses (e. g. fucosidosis, section 1.2.3) and neuronal ceroid lipofuscinoses (e. g. CLN1
disease). Novel classifications are based on the kind of the deficient protein, where LSDs can
be due to defects in soluble lysosomal hydrolases, soluble lysosomal matrix proteins (non-
enzymatic), lysosomal membrane proteins or non-lysosomal proteins (Winchester 2013a).
LSDs are inherited in an autosomal recessive manner except Danon, Fabry and Hunter di-
sease, which are X-linked (Wraith and Beck 2013). Each LSD itself is a rare disease, but in
combination they have an incidence of 1 : 5000 (Lübke et al. 2009, Coutinho et al. 2012b) to
1 : 7000 live births (Hopwood 2013, Micsenyi and Walkley 2013). Moreover, the number of
undiagnosed or miss-diagnosed cases might by very high, particularly in non-industrial coun-
tries. Most LSDs are characterized by a broad spectrum of clinical presentations, although
neuropathological alterations of the CNS resulting in physical and mental deterioration are
very common features of this group of diseases. Moreover skeletal malformations, cardiac
diseases, current respiratory infections as well as organomegaly (enlargement of visceral or-
gans like liver, kidney, spleen) are often observed (Wraith and Beck 2013). The clinical onset
as well as the rate of disease progression often differ between patients of a single LSD. In-
fantile onsets are often connected with severe disease progression leading to death within the
first decade of life, whereas patients with an adult onset may live until the third or fourth
decade of live (Hopwood 2013). The initial LSD diagnosis is mainly based on the clinical
presentation, whereas the individual disease is then often identified by biochemical methods,
e. g. the detection of accumulating substrates which are also excreted into the blood or urine
of the patients. Finally the disease has to be confirmed by the absence of enzymatic activity
(in case of a deficient hydrolase) or by molecularbiological analysis of the affected gene and
identification of the disease-causing mutation (Winchester 2013b).
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1.2.1 Treatment of lysosomal storage disorders
Even today, the treatment of LSD is challenging, as there exists no cure and in most cases
even no specific therapy for the single LSDs is available. Nevertheless, symptomatic therapies
improving the LSD symptoms can provide great support for patients and their families, e. g.
skeletal malformations may be corrected by surgery (Cox 2013).
Bone marrow transplantation (BMT) is a classical treatment for LSDs, where haematopoietic
stem cells (HSCs) are engrafted into the immuno-suppressed recipient and may complement
the lacking enzyme activity. The transplanted cells secrete the deficient enzyme, which can be
endocytosed by the patient’s cells e. g. via the M6P-dependent pathway. However, the effects
of a BMT is dependent on the type and the stage of the disease as well as on the specific
glycosylation and modification of the enzymes and the secretion capacity of the enzyme-
producing cell line. BMT can have beneficial effects on visceral symptoms, but the effects
on bone diseases and neuropathological symptoms vary (Matzner 2005). As the BMT-related
mortality risk is high, the search for alternative therapies is ongoing (Cox 2013).
The most common treatment for LSDs is enzyme replacement therapy (ERT), which was first
suggested by de Duve (1964). ERT is based on the MPR300 localized at the plasma membrane
of cells. As mentioned in section 1.1.2, extracellular proteins harboring a M6P modification
can be recognized by the MPR300 and are further endocytosed and transported towards the
lysosome (Braulke and Bonifacino 2009). Hence, recombinant proteins can be administered
intravenously during ERT, are endocytosed and can correct the deficiency of the lysosomal
protein (Coutinho et al. 2012b). The aim of the ERT is to reverse or at least to stop the pro-
gression of the LSD phenotype and to degrade the accumulated storage material. The first ERT
approaches were performed in the 1970s, when human enzymes which were purified from e. g.
placenta were used (Desnick and Schuchman 2002). Today, the enzymes are recombinantly
produced in e. g. CHO cells and are purified from cell culture medium (Jayapal et al. 2007).
ERT is a well proven therapy for LSDs and is commonly used for treatment of e. g. Gaucher
and Fabry disease, for MPS I, MPS II, MPS VI and Pompe disease (Cox 2013). Although an
ERT might reverse years of substrate accumulation, it is no cure and the recombinant enzyme
has to be administered life-long (Desnick and Schuchman 2002). Moreover, ERTs have some
limitation regarding the biodistribution of the administered enzyme. Only minor amounts
reach the so-called "hard-to-treat" tissues like muscle cells, bones, lungs and particularly the
CNS, as the intravenously injected enzyme is unable to cross the blood-brain-barrier (Bur-
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row and Grabowski 2013, Acosta et al. 2015, Condori et al. 2016). In this context, ERT was
initially used for treatment of LSDs without neurological participation and no improvement
of neurological symptoms was observed in ERT-treated MPS I, MPS II and MPS VI patients
(Beck 2009). This limitation might be prevented by intrathecal administration, although it
bears a high risk for CNS infections (Burrow and Grabowski 2013). In addition, preclinical
studies using fusion constructs with so-called "Trojan horses" have shown great potential. The
lysosomal enzmes are fused to proteins, which are transported across the blood-brain-barrier
and might mediate also the uptake of the lysosomal enzyme (Boado et al. 2011, Acosta et al.
2015, Condori et al. 2016). Due to the intravenous injection of the enzymes, the ERT often
leads to development of antibodies, which might result in allergic reactions and / or neutralize
the enzyme. This might be prevented by premedication with antihistamines or in severe cases
by administration of methotrexate. However, in most cases the antibody titer decreases over
time and patients start to tolerate the recombinant enzyme (Desnick and Schuchman 2002).
Substrate reduction therapy is another treatment option for LSDs and aims to reduce the syn-
thesis of the accumulating storage material by administration of small-molecule inhibitors.
Moreover, the current investigations on pharmacological chaperones are promising. Here,
LSDs resulting from a mutation influencing the folding or stability of the lysosomal enzyme
are addressed. After binding to the chaperone, the enzyme is stabilized and may display a
residual activity sufficient to improve the LSD pathology (enzyme enhancement therapy EET;
Beck 2009, Cox 2013, Burrow and Grabowski 2013).
In the future, the most promising treatment seems a gene therapy. Here, induced pluripotent
stem cells (iPSCs) are generated from the patient’s fibroblasts, are genetically manipulated and
re-transferred into the patient, thereby avoiding graft-versus-host reactions. However, further
studies are necessary, as rejections of autologous transplanted iPSCs were observed in mice.
During in vitro culture of the iPSCs, the patients’ mutation in the affected lysosomal gene can
be corrected e. g. by homologous recombination or knock-in of the functional gene (Burrow
and Grabowski 2013).
1.2.2 Glycoproteinoses
Glycoproteinoses are a subgroup of LSDs that result from defects in glycoprotein metabolism
leading to accumulation of oligosaccharides and / or glycopeptides (table 1.1). They all are
rare diseases and represent less than 10 % of all LSDs with a combined incidence of 1 : 100 000
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(Malm et al. 2013). Most of the glycoproteinoses are caused by deficient lysosomal glycosi-
dases that are involved in the degradation of N-glycosylated proteins, which is a highly ordered
process. These participating exoglycosidases degrade N-glycans in a sequential manner, that
is given by the structure of the N-glycan and, hence, the deficiency of one glycosidase leads to
a termination of the N-glycan degradation and accumulation of defined oligosaccharides and
glycopeptides (Winchester 2005).
The degradation of N-glycans is a bidirectional process and happens sequentially from the
reducing and the non-reducing end of the N-glycan (figure 1.3). The first step is the pro-
teolysis of the polypeptide of the glycoprotein by different lysosomal proteases (cathepsins)
resulting in the release of the N-glycan that is still connected to the asparagine residue. This
intermediate state is a prerequisite for the further degradation of the N-glycan, that is de-
pendent on free α-amino and α-carboxyl groups of the asparaginyl moiety. The next step
is the removal of any fucose residue (terminal or core-fucose; section 1.1.1) of complex or
hybrid N-glycans catalyzed by the α-L-fucosidase. A deficiency of this enzyme results in
the LSD fucosidosis (see section 1.2.3) and the accumulation of fucosylated glycocompounds
(Winchester 2005). The removal of the asparagine is blocked in the presence of a core-fucose
residue, that sterically inhibits the aspartylglucosaminidase (Noronkoski and Mononen 1997).
The core-N-acetylglucosamine is removed by the endo-β -N-acetylglucosaminidase (chitobi-
ase) from the reducing end of the N-glycan. Interestingly, the deficiency of the chitobiase
does not result in an LSD, as the core-N-acetylglucosamine can also be removed as the fi-
nal step from the non-reducing end of the N-glycan catalyzed by the β -hexosaminidase. The
Table 1.1: Lysosomal storage disorders caused by defects in glycoprotein metabolism
disease deficient enzyme major storage material
fucosidosis α-L-fucosidase glycopeptides
aspartylglucosaminuria aspartylglucosaminidase glycopeptides
sialidosis neuraminidase (sialidase) oligosaccharides
GM1-gangliosidosis β -galactosidase gangliosides
galactosialidosis protective protein (cathepsin A) oligosaccharides
Sandhoff disease β -hexosaminidase gangliosides
α-mannosidosis α-mannosidase neutral oligosaccharides
β -mannosidosis β -mannosidase neutral oligosaccharides
Schindler / Kawasaki disease α-N-acetylgalactosaminidase glycopeptides
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Figure 1.3: Degradation of N-glycans
Complex N-glycans are degraded bidirectional from the reducing end as well as the non-reducing
end. The single exoglycosidases act in a sequential manner. The deficiency of one glycosidase
leads to termination of the N-glycan degradation, so that the residual N-glycan is accumulating in the
corresponding LSD (see also table 1.1). Modified from Winchester (2005).
residual N-glycan is degraded from the non-reducing end. In case of a complex or hybrid
N-glycan, sialic acid, galactose, N-acetylglucosamine and mannose residues are removed by
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the sequential action of the lysosomal enzymes sialidase, β -galactosidase, β -hexosaminidase,
α-mannosidase and β -mannosidase. Again, a prerequisite for this degradation is the removal
of terminal fucose residues by the α-L-fucosidase. In case of a high-mannose type N-glycan,
the α- and β -mannosidases as well as the β -hexosaminidase are required (Winchester 2005).
The deficiency of one particular enzyme leads to the corresponding LSDs, which are listed in
table 1.1. Of note, β -hexosaminidase and β -galactosidase are also participating in the degra-
dation of glycolipids and, hence, the major accumulating storage material in Sandhoff disease
and GM1-gangliosidosis are gangliosides, even though oligosaccharides are also accumulating
(Clarke 2013). Moreover, the LSD galactosialidosis is caused by the combined deficiency of
sialidase and β -galactosidase resulting from mutations in the gene encoding the protective
protein cathepsin A. Cathepsin A forms a multi-enzyme complex with both glycosidases and
directs their transport towards the lysosome as well as their intralysosomal activation and sta-
ble conformation (d’Azzo and Bonten 2013). In contrast, the β -N-acetylgalactosaminidase is
participating in the degradation of O-linked glycans and its deficiency results in the Schindler
disease, which is characterized by the accumulation of glycopeptides linked to serine or threo-
nine residues (Winchester 2005).
1.2.3 Deficiency of α-L-fucosidase results in fucosidosis
The α-L-fucosidase (EC 3.2.1.51) is a lysosomal hydrolase that was first mentioned by Levvy
and McAllan (1961). The enzyme is encoded by the Fuca1 gene located on chromosome 1
(1p34), which includes eight exons. The α-L-fucosidase consists of 439 amino acids and an
additional N-terminal signal peptide of 22 amino acids, that is cleaved off after co-translational
import into the ER. The enzyme contains two active site residues, D230 and E294 (Liu et al.
2009; there referred to as D225 and E289) and cleaves glycosidic bonds, in which L-fucose
is linked to galactose (α1-2, α1-3 or α1-6), N-acetylglucosamine (α1-3, α1-4 or α1-6) or
to glucosamine (α1-3) (Willems et al. 1991). α-L-Fucosidase has already been purified from
various human tissues, e.g. placenta (Wiederschain et al. 1971), kidney (Wiederschain et
al. 1973) and liver (Robinson and Thorpe 1973, Alhadeff et al. 1975a, Alhadeff and Freeze
1977) and was shown to form homooligomers (Chien and Dawson 1980, Alhadeff et al. 1975a,
Turner 1979). Up to seven isoforms of the α-L-fucosidase were isolated from human liver and
could be separated from each other by starch gel electrophoresis (Turner et al. 1974, Alhadeff
et al. 1974b). The isoforms exhibited distinct glycosylation patterns that differed in their
degree of sialic acid content resulting in a slightly altered α-L-fucosidase activity, isoelectric
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point and pH optimum (Alhadeff et al. 1978) as well as in different retention volumes of the
isoforms during size exclusion chromatography (Alhadeff 1978).
The deficiency of α-L-fucosidase causes the LSD fucosidosis (glycoproteinosis; OMIM
230000) that leads to the accumulation of fucosylated oligosaccharides, glycoproteins and
glycolipids (Willems et al. 1991). The enzyme is participating in the degradation of com-
plex N-glycans. Here, the presence of a core-fucose residue sterically inhibits the subsequent
removal of the asparaginyl residue by aspartylglucosaminidase (Noronkoski and Mononen
1997) and, hence, the deficiency of α-L-fucosidase leads to an accumulation of fucosylated
glycoasparagines (Yamashita et al. 1979, Michalski and Klein 1999). Moreover, several
oligosaccharides harboring terminal but no core-fucose residues were found to accumulate
in human patients (Tsay et al. 1976, Tsay and Dawson 1976, Nishigaki et al. 1978, Michal-
ski and Klein 1999). Here, the core-unit of the N-glycan (asparaginyl residue and the first
N-acetylglucosamine) could be removed, whereas the degradation from the non-reducing end
of the N-glycan was prevented by the presence of terminal fucose residues. A considerable
proportion of the accumulating glycopeptides as well as oligosaccharides is also excreted with
the urine and can be used for initial diagnosis by thin-layer chromatography (Willems et al.
1991, Michalski and Klein 1999). In addition, α-L-fucosidase is involved in the degradation
of fucosylated glycolipids harboring terminal blood group antigens (H-, A- and B-antigens as
well as Lewis antigens; figure 1.4). The H-antigen was found as the major storage material in
the liver of fucosidosis patients along with the Lewisx antigen (Dawson and Spranger 1971,
Tsay et al. 1976, Michalski and Klein 1999). At the microscopic level, the accumulation of fu-
cosylated glycocompounds results in the formation of foam-like storage vacuoles in multiple
organs of human patients, which appeared mainly empty in light microscopy analysis, indi-
cating water-soluble storage material. However, electron microscopy revealed also granular
or lamellar inclusions of moderate electron density, indicating highly heterogeneous storage
material (Willems et al. 1991).
Fucosidosis is an ultra-rare disease and only about 120 individuals suffering from that disease
have been reported until now. The first two patients, two italian sibs, were described by Durand
et al. (1966) and suffered from progressive mental retardation and neurological deterioration
leading to death before the age of 5 years. The disease was initially reported to exhibit Hurler-
like (MPS I) symptoms. Two years later, van Hoof and Hers (1968b) discovered a disease-
causing deficiency of α-L-fucosidase in several tissues of three patients suffering from similar
symptoms. The disease was then designated as mucopolysaccharidosis F (MPS F; van Hoof
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Figure 1.4: Structures of antigens containing L-fucose residues
The structures of antigens containing L-fucose residues are shown (H-, A-, B-blood group antigen as
well as Lewis blood group antigens). The antigens can occur as terminal moieties on glycoproteins and
glycolipids. Modified from Stanley and Cummings (2009).
and Hers 1968a). In parallel, Durand et al. (1968) also identified an α-L-fucosidase deficiency
in his first two patients along with an accumulation of fucosylated glycoceramides and rec-
ommended the term fucosidosis for this disease. Symptoms of fucosidosis are progressive
mental retardation, neurological deterioration, coarse facies appearance, growth retardations,
dysostosis multiplex and angiokeratoma corporis diffusum. Frequently, patients also develop
visceromegaly and suffer from seizures (Willems et al. 1991). Fucosidosis is inherited in an
autosomal recessive way (Willems et al. 1991). A severe form of the disease is known, where
the clinical manifestation starts in early childhood and the patients often die before the age
of ten years. A milder form of fucosidosis develops more slowly and patients may survive
until the third or fourth decade of life (Kanitakis et al. 2005). Also an intermediate form is
known, reflecting the continuous clinical spectrum of the disease. However, no strict rela-
tionship seems to exist between the genotypic condition and the phenotypic manifestation, as
clinical variability was found in patients carrying the same disease-causing mutation (Willems
et al. 1999). Most of the patients were found to harbor homozygous mutations, indicating a
high rate of consanguinity in fucosidosis (Willems et al. 1999, Malm et al. 2013). Until 1999,
22 disease-causing mutations were identified, of which four were missense mutations and 18
were inactivating mutations including several nonsense mutations, deletions, insertions and a
splice-site mutation (Willems et al. 1999) resulting in a complete absence or severely dimin-
ished (< 5 %) α-L-fucosidase activity (Willems et al. 1991). About 120 fucosidosis cases have
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been reported world-wide, but the incidence might be much higher, particularly in some re-
gions of Southern Italy and in the Mexican-Indian populations of New Mexico and Colorado
in the United States (Willems et al. 1991), in Cuba (Menéndez-Sainz et al. 2012), in United
Arab Emirates (Al-Jasmi et al. 2013) and in Tunisia (Turkia et al. 2008).
Until now, there is no therapy available for fucosidosis. In a few cases, BMT was performed
and resulted in a slight improvement of neurological symptoms. However, graft-versus-host
complications were also observed (Miano et al. 2001). The neurological manifestation of the
disease was extensively characterized in a naturally occurring dog model in English Springer
spaniel (Kelly et al. 1983, Kondagari et al. 2011b, Fletcher et al. 2011, Fletcher et al. 2014),
which closely resembled the human disease and was also used for ERT studies by intracisternal
enzyme infusion (Kondagari et al. 2011a). In addition, one naturally occurring fucosidosis
case in a domestic short-hair cat was reported (Arrol et al. 2011).
1.3 Aims of the study
Fucosidosis is a lysosomal storage disease caused by the deficiency of the lysosomal glycosi-
dase α-L-fucosidase resulting in the accumulation of fucosylated glycocompounds. In human
patients, the disease is mainly characterized by progressive mental retardation and neuro-
logical deterioration leading to premature death. In order to analyze the pathological cascades
underlying the fucosidosis disease as well as to enable the development of therapeutic strate-
gies, a constitutive fucosidosis mouse model was established. One aim of this study is the
validation of the Fuca1 gene knock-out on genomic, transcript and protein level. Moreover,
the phenotype of the fucosidosis mouse model will be characterized in detail including bio-
chemical, histological and behavioral analysis. The investigation of the fucosidosis storage
material as well as of neurological alterations of the mouse model is of particular interest, as
the latter are the leading symptoms in human fucosidosis.
A second objective of this study is the establishment of an expression system for human α-L-
fucosidase in CHO-K1 cells. Therefore, CHO-K1 cells will be transfected with an expression
plasmid encoding an untagged as well as a His6-tagged human α-L-fucosidase, respectively.
The cultivation of stable transfected cells in an adherent culture system is supposed to be
sufficient for initial experiments, but also an adaption of the cells to suspension conditions is
intended. A suspension culture might enable a more sufficient large-scale production of the
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recombinant enzyme under industrial conditions. Moreover, the establishment of a purification
strategy for the untagged and the His6-tagged human α-L-fucosidase is aimed, respectively.
The ultimate goal of this study is an enzyme replacement therapy of the fucosidosis mouse
model by intravenous application of purified human α-L-fucosidase. The benefits of this
therapeutic approach will be analyzed particularly with regard to the storage material and
a reduction of the lysosomal storage is expected which might also improve the phenotypic
disease severity.
At last, the generation of an α-L-fucosidase-specific antibody is intended, as no antibody is
currently commercial available. Therefore, Fuca1(-/-) mice will be immunized by ballistic
injection of coated gold particles carrying an expression plasmid for murine α-L-fucosidase.
The resulting B-lymphocytes will be fused with myeloma cells in order to establish hybridoma
cell lines secreting α-L-fucosidase-specific monoclonal antibodies. The specificity of the anti-
bodies has to be analyzed against the recombinant human enzyme and against genuine murine
α-L-fucosidase by Western blotting and immunofluorescence studies.
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2.1 Laboratory equipment
Item Manufacturer
ÄKTA Ettan LC system GE Healthcare
ÄKTA Explorer system GE Healthcare
Autoclave, Laboklav SHP Steriltechnik
Charge Coupled Device (CCD)-Kamera Fuji Film
with Luminescent Image Analyzer LAS 3000 Fuji Film
Cell counter Cedex XS Innovatis
Centrifuge, Eppendorf 5417 R Eppendorf
Centrifuge, Eppendorf 5810 R Eppendorf
Centrifuge, MIKRO 200R Hettich Zentrifugen
Centrifuge, OptimaTM L-80 Ultracentrifuge Beckmann Coulter
with rotor Sorvall R© T-1270
with rotor Sorvall R© TLA-55
Centrifuge, Sorvall R© ULTRA Pro 80 Thermo Scientific
with rotor Sorvall R© T-880
with rotor Sorvall R© TH-641
Centrifuge, Sorvall R© RC5B PLUS Thermo Scientific
with rotor Sorvall R© GS-3
Electrophoresis chamber for agarose gels, custom-made Bielefeld University
Electrophoresis chamber for polyacrylamide gels, custom-made Bielefeld University
Electrophoresis chamber for Western blots, custom-made Bielefeld University
Elektrophoresis Power Supply EPS200 Pharmacia Biotech
Freeze dryer, Christ alpha 2-4 LSC with SpeedVac RVC 2-18 Christ
Homogenizer Potter S B.Braun
Ice machine Ziegra
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Item Manufacturer
Incubator for bacterial cultures Heraeus
Incubator for cell cultures, HERAcell Heraeus
Incubator shaker Inova 4300 New Brunswick Scientific
Microplate reader infite M200 Tecan
Microscope, confocal, LSM700 Zeiss
Microscope, Leica DMIL Leica
Microscope, Leica DM IRB Leica
with DC 300F camera
Microscope, epi-fluorescence, Leica DM5000 B Leica
with DFC350 FX camera
Microtome SM 2000R Leica
Microwave Siemens
NanoDrop ND-1000 PeqLab
pH meter, SevenMulti Mettler Toledo
Pipetboy, pipetus Hirschmann Laborgeräte
Pipettes Gilson
Rocking platform VWR
Rotator, SB3 Stuart
Sonifier, Model 450 Branson
Sonifier, wather bath Bandelin-Sonorex
Step One Plus Real- Time PCR cycler Applied Biosystems
Sterile laminar flow workbench, HERAsafe Heraeus
Thermocycler PTC-200 MJ Research
Thermomixer, Eppendorf 5417 Eppendorf
TLC tanks, custom-made Bielefeld University
Transilluminator PeqLab
ULTRA-TURRAX IKA
Vortex-Genie 2 Scientific Industries
Water filtration system, Milli-Q Millipore
Water bath Memmert
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2.2 Laboratory material
Item Manufacturer
10 ml (Mobicol) Columns with Bayonet Joint Lid Mo Bi Tec
96 well microtiter plates, polystyrene, flat bottom, transparent Greiner Bio-One
96 well microtiter plates, Microlon, flat bottom, black Greiner Bio-One
Amicon R© Ultra-4 Centrifugal Filter, 10,000 NMWL, 4 ml Millipore
Butterfly needle, Multifly R© Set 21G tubing 8” Sarstedt
Cell counting chamber, Cedex XS Smart Slide Innovartis
Cell culture cryotubes Sarstedt
Cell culture flasks, T25 and T75 with cap filters Nunc
Cell culture plates, 4, 6, 12 and 24 wells Nunc
Cell culture plates, 6, 10 and 15 cm Nunc
Cell scraper Sarstedt
CNBr-activated sepharose beads GE Healthcare
ConA SepharoseTM 4B GE Healthcare
Corning R© shake flask 125 ml Corning
Cover slips 18 x 18 mm Marienfeld
Dialysis tubing, MWCO 14 kDa Roth
Glass beads, 3 mm diameter Roth
Glass rings, for cell culture clone isolation, custom-made Bielefeld University
HisTrap HP 1 ml column GE Healthcare
HiTrap DEAE FF 1 ml GE Healthcare
HiTrap NHS-activated HP 1 ml column GE Healthcare
HiTrap SP HP 1 ml column GE Healthcare
Mouse restrainer Sigma
Object holder 76 x 26 x 1 mm Marienfeld
Roti-PVDF Membran Roth
Sep-Pak R© Vac 6cc (1 g) C18 cartridges Waters
Silica gel F60 plates Merck
Superdex 200 10/30 GL column GE Healthcare
Syringe filters, Filtropur S 0.2 µm Sarstedt
Syringe for intravenous injections, BD Micro-Fine R© + Demi,
30G x 8 mm
BD Medical
Whatman filter paper for Western blots GE Healthcare
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2.3 Chemicals and reagents
All general chemicals were obtained in analytical quality (p.A.) from Invitrogen, Merck,
Sigma or Roth.
Item Manufacturer
Agarose Standard Roth
Ammonium persulfate Merck
Ampicillin sodium salt Roth
BSA, Albumin Standard 2 mg/ml Thermo Scientific
BSA, Albumin fraction V Roth
Coomassie Brilliant Blue G250 Serva
Corning R© PF medium Corning
Cytochrom C from horse heart Sigma
Deoxynucleoside triphosphates dATP, dTTP, dCTP and dGTP Roche
Dabco Roth
DAPI Sigma
Diethylpyrocarbonat (DEPC) Roth
Dulbecco’s modified Eagle medium (DMEM) dry powder Invitrogen
DNA markers, 100 bp and 1 kb DNA ladders New England Biolabs
DMSO Invitrogen
Escherichia coli DH5α Invitrogen
Ethidium bromide, p.A., 1 % solution Roth
Fetal calf serum (FCS) Lonza
Filipin III from Streptomyces filipinensis Sigma
L-fucose Roth
G418 Calbiochem
Gel Filtration Calibration Kit HMW GE Healthcare
β -glycerophosphate disodium salt hydrate Sigma
Glucose-6-phosphate disodium salt hydrate Sigma
L-Glutamin, 200 mM Lonza
Glutaraldehyde 25 % Roth
Goat-serum Gibco, Invitrogen
Hybrido DIF 1000 Biochrom
Hydrogen peroxide Sigma
Hygromycin PAA
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Item Manufacturer
Mannose-6-phosphate sodium salt Carbosynth
4-methylumbelliferone Sigma
4-methylumbelliferyl-α-L-fucopyranoside Carbosynth
Milk powder, non fat TSI
Mitomycin C Sigma
Mixed-bed ion exchange resin (AG 501-X8, 20 - 50 mesh) BioRad
Mowiol Roth
N-(ε-aminocaproyl)-β -L-fucopyranosylamine Carbosynth
para-nitrophenyl-α-D-mannopyranoside Sigma
para-nitrophenyl-α-L-fucopyranoside Roth
para-nitrophenyl-α-N-acetyl-β -D-glucosaminide Roth
Nuclear Fast Red Roth
OptiMEM medium Gibco, Invitrogen
Orcinol monohydrate from Lichens Sigma
para-formaldehyde Roth
PEI MW 40 000 Polyscience Europe
Penicillin/Streptomycin, 10 U each Lonza
Percoll Amersham Bioscience
Poly-L-lysine Sigma
Protein marker, Precision Plus Protein Standards All Blue BioRad
Rotiphorese R© Gel 30 (30 % acrylamide and 0.8 % bis-
acrylamide (37.5 : 1))
Roth
Saponin from Quillaja Bark AppliChem
Sodium dodecyl sulfate (SDS), research grade Roth
Sodium deoxycholate Serva
Sudan Black B Serva
Ponceau S Merck
SuperSignal West Femto Chemiluminescent Substrate Pierce
SuperSignal West Pico Chemiluminescent Substrate Pierce
Trichloro acetic acid Sigma
TEMED Roth
TheraPEAKTM (FGM-CD) medium Lonza
Trizol reagent Invitrogen
Tyloxapol (Triton WR-1339), BioXtra Sigma
Trypan blue (0.4 %) Sigma
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2.4 Kits
Kit Supplier
DC Protein Assay Kit BioRad
High Pure PCR Product Purification Kit Roche
HRP substrate Kit VectorLabs
iScript cDNA Synthesis Kit BioRad
KAPA HIFI Hot Start Ready Mix PeqLab
KAPA Mouse Genotyping Hot Start Kit PeqLab
KAPA SYBR Fast Universal Kit PeqLab
QIAGEN Plasmid Midi Kit Quiagen
QIAprep Spin Miniprep Kit Quiagen
RNeasy Midi Kit Quiagen
2.5 Enzymes
Enzyme Supplier
Antarctic Phosphatase, 5 000 U/ml New England Biolabs
BIOTAQ DNA Polymerase Bioline
DNAse I Roche
DpnI restriction endonuclease, 20 000 U/ml New England Biolabs
EndoH Roche
NheI-HF restriction endonuclease, 20 000 U/ml New England Biolabs
NotI-HF restriction endonuclease, 20 000 U/ml New England Biolabs
PfuUltra II Fusion HS DNA Polymerase Agilent Technolgies
PNGase F Roche
Proteinase K, ≥ 30 U/mg Roth
T4 DNA Ligase 400 000 mU/ml New England Biolabs
TrypLETM Express Gibco, Invitrogen
Trypsin-EDTA Gibco, Invitrogen
XhoI restriction endonuclease, 20 000 U/ml New England Biolabs
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If not stated otherwise, all primary antibodies were of IgG isotype.
Primary antibody Species
Dilution
WB
Dilution
IF
Supplier
α-Aquaporin2 goat – 1 : 200 kind gift from Prof. Schmidt-Ott,
Max-Delbrück-Center for Molecu-
lar Medicine, Berlin, Germany
α-Calbindin mouse – 1 : 500 Sigma
α-mCD68 (FA-11) rat – 1 : 500 AbD Serotec
α-mCtsD (KIIS9) rabbit 1 : 1500 1 : 100 internal available, Braulke et al.
(1987)
α-F4/80 rat – 1 : 100 internal available, Austyn and Gor-
don (1981)
α-Fuca1 (A112/A180) mouse 1 : 1000 1 : 500 generated during this thesis in
cooperation with Prof. Koch-
Nolte, University Medical Center
Hamburg-Eppendorf, Germany
α-GAPDH (FL-335) rabbit 1 : 500 – R&D Systems
α-GFAP (GA5) mouse 1 : 2000 1 : 500 Sigma
α-GM2 (IgM isotype) mouse – 1 : 5 kind gift from Prof. Dobrenis (Al-
bert Einstein College of Medicine,
New York, USA)
α-mHSP70 mouse 1 : 1000 – kind gift from Prof. Fischer von
Mollard (Bielefeld University, Ger-
many)
α-Iba1 rabbit – 1 : 500 GeneTex
α-mLamp1 (1D4B) rat 1 : 250 1 : 250 Santa Cruz
α-MBP rat 1 : 1000 1 : 500 Millipore
α-mNeuN (A60) mouse 1 : 2000 1 : 1000 Millipore
α-Plbd2 (G9) rabbit 1 : 500 1 : 50 internal available, Deuschl et al.
(2006)
α-RGS-His6 mouse 1 : 3000 1 : 100 Quiagen
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Lectin
Dilution
WB
Dilution IF Supplier
biotinylated Aleuria aurentia lectin 0.5 µg/ml 5 µg/ml VectorLabs
biotinylated Lens culinaris lectin 5 µg/ml 5 µg/ml VectorLabs
Secondary antibody WB Species Dilution Supplier
α-mouse IgG-HRP goat 1 : 5000 Invitrogen
α-rabbit IgG-HRP goat 1 : 5000 Dianova
α-rat IgG-HRP goat 1 : 5000 Dianova
Streptavidin-HRP – 0.25 µg/ml VectorLabs
Secondary antibody IF
α-goat IgG-Alexa Flour R© 555 donkey 1 : 500 Invitrogen
α-mouse IgG-Alexa Flour R© 488 goat 1 : 2000 Invitrogen
α-mouse IgM-Alexa Flour R© 488 goat 1 : 2000 Invitrogen
α-mouse IgM-HRP goat 1 : 2000 Dianova
α-rabbit IgG-Alexa Flour R© 488 goat 1 : 2000 Invitrogen
α-rat IgG-Alexa Flour R© 647 donkey 1 : 2000 Dianova
Streptavidin-DyeLight R© 594 – 5 µg/ml VectorLabs
2.7 Oligonucleotide primers
2.7.1 Primers for cloning of human and murine α-L-fucosidase cDNA
Primer TM/◦C Sequence 5’→3’
mFuca1 fw NheI
61
TTCCGCTAGCTGGGATGCTGCTGCTGCTG
mFuca1 rev NotI TTCCGCGGCCGCGTCAGTTCACCTTTGTCAGCTTCAG
hFuca1 fw NheI
62
ACGCTAGCACCATGCGGGCTCCGGGGATGAGGTCGC
GGCCGGCGGGTCC
hFuca1 rev XhoI CCTCGAGGTTACTTCACTCCTGTCAGCT
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Primer TM/◦C Sequence 5’→3’
hFuca1 fw NheI
60
ACGCTAGCACCATGCGGGCTCCGGGGATGAGGTCGC
GGCCGGCGGGTCC
hFuca1 rev His6 XhoI
GTACTCGAGGTATCATCCGTGATGGTGATGGTGATGC
GATCCTCTTCCCTTCACTCCTGTCAGCTT
2.7.2 Colony PCR primers
Primer TM/◦C Sequence 5’→3’
T7 (fw)
55
TAATACGACTCACTATAGGG
Bgh (rev) CCTCGACTGTGCCTTCTA
2.7.3 Primers for site-directed mutagenesis
Primer TM/◦C Sequence 5’→3’
hFuca1-D230N (fw)
57
GATCTGGTCTAATGGGGAGTGG
hFuca1-D230N (rev) CCACTCCCCATTAGACCAGATC
hFuca1-E294Q (fw)
62
TCACAAGTGGCAGATGTGCAC
hFuca1-E294Q (rev) GTGCACATCTGCCACTTGTGA
2.7.4 Primers for Fuca1 gene knock-out generation and validation
Primer TM/◦C Sequence 5’→3’
E1 (fw)
65
CCAAGTTCGGGGTGTTCGTGCAC
E1 (rev) CCTGAAAGAGTTCGGCCCACTG
F4 (fw)
58
TTTTCCCACTGATCCCTAACGA
AK31-as (rev) CCTGCGTGCAATCCATCTTG
F1 (fw)
63
GACTGGCAGAGCTTGGACTC
R2 (rev) AGCAGTCTGGCTTGTTACTTCC
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Primer TM/◦C Sequence 5’→3’
AK31 (fw)
54
CAAGATGGATTGCACGCAGG
R1 (rev) GTGTGTTGCCCTCTTTGGTT
F4 (fw)
58
TTTTCCCACTGATCCCTAACGA
R3 (rev) CTCGTCTTTAGCGTCCTTCC
2.7.5 Primers for routine mouse genotyping
Primer TM/◦C Sequence 5’→3’
F2 (fw)
62
GGTTCGATGAGGCCAAGTTC
AK30-R (fw) CGGCTGCATACGCTTGATCCG
R3 (rev) CTCGTCTTTAGCGTCCTTCC
2.7.6 Real-Time primers
Target gene Primer fw 5’→3’ Primer rev 5’→3’
CD68 TGGATTCAAACAGGACCTACATC TGAATGTCCACTGTGCTGC
CtsB CTCTTGTTGGGCATTTGGG GTAGACTCCACCTGAAACCA
Fuca1 TGCGGAAGAGGAACATACG TGTCAGGACACTCCCACTC
Fuca2 TGTATAATGAAAGCCCAGTTCGG GTTTCCACAAGTTTCTTCACCAAC
Gapdh GCAGTGCCAGCCTCGTCCC CAGGCGCCCAATACGGCCA
GFAP AAGGTTGAATCGCTGGAGGA GCTGTGAGGTCTGGCTTGG
Glb1 (βGal) TGCTCTGAGAAAGTTCAAGAC GTTGTTCGGTACAGCACATA
HexB TTTCGGGACTTTCACCATC GATAAGGGAAAGACTGGTCG
Iba1 GGATCAACAAGCAATTCCTCG AACTCCATGTACTTCACCTTGA
Lamp1 CAGCATCTCCAACCATTCAC CACTCTTCCACAGACCCAAA
Man2B1 (αMan) TATTACGGCATCCTGAGTGA ACATAGATGAAGCGACGGG
Manba (βMan) TGGGATAATGGTGTGGCAG GATGATGGAGGGGTGAGATT
MBP GTACAAGGACTCACACACGA CTTGGGATGGAGGTGGTGT
Plp1 GCTGAGTTCCAAATGACCTTCC TGAAGGTGAGCAGGGAAACT
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2.8 Plasmids
Vector maps are attached in the appendix.
Plasmid Size Resistance
pcDNA3.1Hygro(+) 5597 bp ampicillin/
hygromycin
pcDNA3.1Hygro(+)hFuca 6918 bp ampicillin/
hygromycin
expression of human α-L-fucosidase
pcDNA3.1Hygro(+)hFuca-
His6
6953 bp ampicillin/
hygromycin
expression of His6-tagged human α-L-
fucosidase
pcDNA3.1Hygro(+)hFuca-
His6-D230N
6953 bp ampicillin/
hygromycin
expression of His6-tagged human α-L-
fucosidase carrying a mutation at posi-
tion 230 (aspartate→ asparagine)
pcDNA3.1Hygro(+)hFuca-
His6-E294Q
6953 bp ampicillin/
hygromycin
expression of His6-tagged human α-L-
fucosidase carrying a mutation at posi-
tion 294 (glutamate→ glutamine)
pcDNA3.1Hygro(+)hFuca-
His6-D230N-E294Q
6953 bp ampicillin/
hygromycin
expression of His6-tagged human α-L-
fucosidase carrying two mutations at po-
sitions 230 and 294 (enzymatically inac-
tive fucosidase)
pMSSVLT 5.4 kb ampicillin/
neomycin
expression of the SV40-large T-antigen
(for immortalization of mouse embryonic
fibroblasts)
2.9 Buffers, solutions and media
Buffer, solution, medium Composition
Coomassie-staining solution 0.2 % (w/v) Coomassie Brilliant Blue G250
45 % (v/v) ethanol
10 % acetic acid
DEPC-H2O 2 ml DEPC diluted in 1 L H2O
solution is stirred over night and autoclaved
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Buffer, solution, medium Composition
DMEM (Dulbecco’s 13.38 g/L DMEM dry powder
modified Eagle medium) 3.4 g/L NaHCO3
8 ml/L 1 M HCl
0.1 g/L phenol red, adjusted to pH 7.4
sterile filtered, stored at 4 ◦C
DMEM cryo medium DMEM standard medium
+ 10 % DMSO, sterile filtered
DMEM standard medium DMEM including
1 % (v/v) penicillin/streptomycin (100 x solution)
2 mM L-glutamine solution
10 % (v/v) fetal calf serum (FCS)
DNA-loading dye 0.15 % (w/v) bromophenol blue
0.15 % (w/v) xylene cyanol
40 % (w/v) sucrose
in 1 x TAE
HisTrap binding buffer 20 mM Tris-HCl, adjusted to pH 7.4
500 mM NaCl
50 mM imidazole
HisTrap elution buffer 20 mM Tris-HCl, adjusted to pH 7.4
500 mM NaCl
500 mM imidazole
Laemmli buffer (4 x) 320 mM Tris/HCl, pH 6.8
8 % (w/v) SDS
40 % (v/v) glycerol
0.04 % (w/v) bromophenol blue
2 % (v/v) β -mercaptoethanol
Luria-Bertani (LB) medium 1 % (w/v) peptone
0.5 % (w/v) yeast extract
0.5 % (w/v) NaCl, adjusted to pH 7.4
autoclaved for 20 min at 121 ◦C, antibiotics were added at tem-
peratures < 50 ◦C
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Buffer, solution, medium Composition
LB agar LB medium
1.2 % (w/v) agar-agar
autoclaved for 20 min at 121 ◦C, antibiotics were added at tem-
peratures < 50 ◦C
PB Buffer (pH 7.4) 19 ml 0.2 M NaH2PO4
81 ml 0.2 M Na2HPO4
100 ml dH2O
10 x PBS 1.4 M NaCl
27 mM KCl
100 mM Na2HPO4
18 mM KH2PO4
Mowiol/Dabco 8 g Mowiol
20 ml 0.2 M Tris-HCl, adjusted to pH 8.5
20 ml glycerin
2.5 % Dabco
SCX binding buffer 50 mM NaOAc, adjusted to pH 5.0
SCX elution buffer 50 mM NaOAc, adjusted to pH 5.0
1 M NaCl
SDS-PAGE running buffer 1.92 M glycine
(10 x) 0.5 M Tris base
1 % (w/v) SDS
SOC medium 0.5 % (w/v) yeast extract
2 % (w/v) tryptone
10 mM NaCl
2.5 mM KCl
10 mM MgSO4
2 mM glucose, adjusted to 7.4
10 x TAE 2 M Tris
50 mM EDTA, adjusted to pH 8.0 with acetic acid
10 x TBS 100 mM Tris-HCl
1.5 M NaCl, adjusted to pH 7.4
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Buffer, solution, medium Composition
TBS-T 0.1 % Tween-20 (v/v) in 1 x TBS
Western blot anode buffer 75 mM Tris-HCl, adjusted to pH 7.5
20 % (v/v) methanol
Western blot cathode buffer 40 mM 2-aminohexanoic acid
25 mM Tris -HCl, adjusted to pH 9.0
20 % (v/v) methanol
2.10 Mammalian cell lines
Cell line Origin
CHO-K1 Chinese hamster ovary cells
CHO-K1 hFuca #C1/A5 CHO-K1 cells stably transfected with
pcDNA3.1Hygro(+)hFuca for overexpression of human
α-L-fucosidase
CHO-K1 hFuca-His6 #C2/C1 CHO-K1 cells stably transfected with
pcDNA3.1Hygro(+)hFuca-His6 for overexpression of hu-
man His6-tagged α-L-fucosidase
Mouse embryonic fibroblasts
(MEFs, wildtype or Fuca1(-/-))
embryonic fibroblasts derived from mouse embryos (wildtype
or Fuca1(-/-)) at embryonic day E12.5
MEFs MLII GNPTAB(-/-); mucolipidosis II
Neu2A murine neuroblastoma cell line
2.11 Software
Software Supplier/website
AIDA (advanced image data an-
alyzer) Version 4.06
Fujifilm
i-control Tecan
Image J 1.45s National Institutes of Health
Image Reader LAS 300 Fujifilm
Leica application suite 1.8.0 Leica
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2.11 Software
Software Supplier/website
NetSurfP prediction program
version 1.1
Petersen et al. 2009
Oligo Analyzer 3.1 online tool IDT
Primer3web online tool version
4.0.0
Untergasser et al. 2012
UNICORN 5.0 GE Healthcare
Zen Zeiss
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3.1 Molecular biological methods
3.1.1 Primer design
In order to clone the human α-L-fucosidase (untagged as well as C-terminal His6-tagged)
and the murine α-L-fucosidase (untagged) into the pcDNA3.1Hygro(+) plasmid, their cDNA
sequences were derived from National Center for Biotechnology Information (NCBI; http://
www.ncbi.nlm.nih. gov) and used to design specific primer pairs. The forward primer started
right at the beginning of the ATG-translation start codon and contained a Kozak consensus
sequence as well as a 5’ overhanging restriction site. The reverse primer ended either right
before the translational stop codon and contained an additional glycine residue followed by
a RGS-His6-tag, a second glycine residue, a translational stop codon and a 5’ overhanging
restriction site (His6-tagged enzyme) or ended right after the translational stop codon and
contained only a 5’ overhanging restriction site (untagged enzyme).
Primer pairs for Real-Time PCR analysis (section 3.1.6.5) were designed exon-spanning to
receive PCR products with a length of 100 - 250 bp.
The Primer3web online tool (version 4.0.0; Untergasser et al. 2012; http://primer3.ut.ee) was
used to design primer pairs for genotyping Fuca1(-/-) mice (section 3.1.6.4). The genomic
sequence of the murine α-L-fucosidase gene was obtained from the UCSC Genome Browser
(https://genome.ucsc.edu).
All primers were analyzed with respect to a sufficient GC-content, minimal hairpin structures,
self- and hetero-dimers using the Oligo Analyzer 3.1 online tool from IDT (http://eu.idtdna.
com/calc/analyzer). The specificity as well as the optimal melting temperature of each primer
pair was determined using the Primer-BLAST online tool from NCBI.
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3.1.2 Isolation and purification of RNA
RNA was purified either from mouse tissues or from MEF cells. RNA from mouse tissues was
further transcribed into cDNA and used for cloning approaches or Real-Time PCR analysis,
whereas RNA from MEF cells was used to verify a successful transfection of these cells on
transcript level.
3.1.2.1 Isolation of RNA from mouse tissues
Mice were sacrificed by cervical dislocation and mouse tissues were dissected and either flash
frozen in liquid N2 or immediately homogenized using an ULTRA-TURRAX (IKA). RNA
was isolated from approximately 100 - 150 mg fresh weight tissue using the RNeasy Midi Kit
(Quiagen). 4 ml Buffer RLT containing 10 µl/ml β -mercaptoethanol were added to the fresh
tissue and homogenized for approximately 15 sec. The further isolation steps were performed
according to the manufacturer’s instructions including the digestion of DNA directly on the
column. The RNA was eluted using 100 µl RNase-free water. The concentration was mea-
sured using a NanoDrop ND-1000 spectrophotometer (PeqLab) and the RNA was stored at
-80 ◦C.
3.1.2.2 Isolation of total RNA from MEFs
MEF cells were transfected (section 3.3.3.1) at 80 % confluence (10 cm dish) and further cul-
tivated for 48 h. The cells were harvested by trypsination and pelleted by centrifugation at
250 x g for 3 min. The cell pellet was washed with PBS, divided into two equal amounts and
again centrifuged at 250 x g for 3 min. The supernatant was discarded. Half of the cells was
further used for RNA isolation (see below), whereas the other half was lysed in order to obtain
cell homogenates (section 3.2.2).
The cell pellet was resuspended in 2 ml Trizol. 400 µl chloroform were added, the sample was
rigorously shaken for 15 sec and incubated at room temperature for 5 min. The sample was
centrifuged at 12 000 x g for 15 min at 4 ◦C, subsequently. The aqueous phase was transferred
into a new tube and 1 ml isopropanol was added. The sample was rigorously mixed, incubated
at -20 ◦C for 60 min and centrifuged at 12 000 x g for 30 min at 4 ◦C. The supernatant was
discarded and the pellet was washed with 70 % ethanol (in DEPC water, section 2.9). Again,
the sample was centrifuged at 12 000 x g for 10 min at 4 ◦C. The supernatant was discarded
and the pellet was dried at 37 ◦C. The RNA pellet was subsequently resuspended in 50 µl
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DEPC water (section 2.9), the RNA concentration was measured using a NanoDrop ND-1000
spectrophotometer (PeqLab) and the RNA was stored at -80 ◦C.
3.1.3 Northern blot
RNA was isolated from different mouse tissues as described in section 3.1.2.1. The abundance
of the Fuca1 mRNA transcript was analyzed using a Northern blot. Agarose gelelectrophore-
sis of RNA samples, Northern blotting, radioactive labeling of the DNA probe as well as the
hybridization and processing of the blot was performed by Prof. Lübke (Bielefeld University,
Germany). Briefly, 10 µg RNA were applied to RNA-agarose gelelectrophoresis (denaturat-
ing in the presence of formaldehyde). The separated RNA was subsequently blotted onto a
positively-charged membrane by capillary forces and immobilized using UV-irradiation. In
parallel, a radioactive labeled DNA probe was generated. Double-stranded DNA was am-
plified from cDNA of Fuca1 and Gapdh (as loading control). The probes were labeled by
random priming using P32-αdCTP. The Northern Blot was incubated with a hybridization
mixture containing the Fuca1 DNA probe, was washed and developed by phosphor imaging.
Then, the blot was stripped and developed using the Gapdh DNA probe.
3.1.4 cDNA synthesis
Freshly isolated RNA (section 3.1.2) was used for cDNA synthesis according to the iScript
cDNA Synthesis Kit (BioRad). 1 µg RNA was added to 4 µl of 5 x iScript reaction mix and
1 µl of iScript reverse transcriptase. The reaction was filled up to 20 µl with nuclease-free
water. The samples were incubated for 5 min at 37 ◦C, following by 30 min at 42 ◦C and 5 min
at 85 ◦C. The cDNA was stored at -20 ◦C.
3.1.5 Isolation of genomic DNA from mouse tissues or cells
In order to identify individual mice, they were numbered consecutively by piercing their ears.
The tissue material of the ear holes was collected and genomic DNA was extracted in order to
genotype the mice using the KAPA Mouse Genotyping Hot Start Kit (PeqLab). 88 µl dH2O,
10 µl extraction buffer as well as 2 µl of extraction enzyme were added to the tissue pieces and
were rigorously shaken for 20 min at 75 ◦C. Afterwards, the sample was incubated for 5 min
at 95 ◦C and spun down. 0.5 µl of the supernatant was used in the genotyping PCR (section
3.1.6.4).
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Alternatively, genomic DNA was extracted from confluent MEF cells. Therefore, the cells
were harvested by trypsination and pelleted by centrifugation (3 min at 250 x g). The cell
pellet was washed with PBS, centrifuged again and resuspended in extraction buffer. The
genomic DNA was extracted as described above.
3.1.6 Polymerase chain reaction
DNA was amplified during polymerase chain reactions (PCRs) using specific primer pairs.
The reactions were used to amplify cDNAs for further cloning strategies, to control the inte-
gration of inserts after ligation and transformation of chemically competent bacteria, to deter-
mine the genotype of mice as well as to analyze the expression of certain mRNA targets.
3.1.6.1 Add-on PCR
An add-on PCR system was used to amplify the cDNA of human and murine α-L-fucosidase.
In case of the human enzyme, a C-terminal RGS-His6-tag was added simultaneously. The
reactions were prepared as shown in table 3.1 and incubated in a thermocycler according to
the protocol shown in table 3.2. In order to minimize possible PCR-derived mutations, a proof-
reading polymerase was used. 30 µl of the reaction batch were mixed with 6 µl of 6 x DNA
loading dye (section 2.9) and loaded on a 1 % agarose gel (section 3.1.7). The correct size of
the PCR product was checked and the band was cut out from gel, purified (section 3.1.8) and
used for further cloning steps.
Table 3.1: Setup for add-on PCR
Component Volume
PfuUltra II fusion HS DNA polymerase 1 µl
10x PfuUltra II reaction buffer 5 µl
Forward primer, 10 µM 1 µl
Reverse primer, 10 µM 1 µl
dNTPs, 10 mM each 0.5 µl
or DNA (pcDNA3.1Hygro(+)hFuca) 0.5 µl
murine cDNA 0.5 µl
dH2O 41 µl
50 µl
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Table 3.2: Temperature program for add-on PCR
Temperature Time Cycles
Initial denaturation 95 ◦C 3 min 1
Denaturation 95 ◦C 15 sec
35
Annealing optimal melting temperature see
section 2.7.1
15 sec
Amplification 72 ◦C 2 min
Final amplification 72 ◦C 3 min 1
Cooling 4 ◦C ∞ 1
3.1.6.2 Colony PCR
After transformation of chemically competent bacteria (section 3.1.14) colonies were received
and screened for the cloned cDNA sequence using a colony PCR. The colonies were picked
with a pipette tip and resuspended in 20 µl dH2O. 1 µl of this solution was used as template.
Amplification was performed using sequencing primer flanking the multiple cloning site of
the pcDNA3.1Hygro(+) plasmid. The reactions were prepared as shown in table 3.3 and
incubated in a thermocycler according to the protocol shown in table 3.4. Afterwards 5 µl of
the amplicon were mixed with 1 µl 6 x DNA loading dye (section 2.9) and loaded on a 1 %
agarose gel (section 3.1.7) in order to control the correct size of the PCR product.
Table 3.3: Setup for colony PCR
Component Volume
BIOTAQTM DNA polymerase 0.2 µl
10x NH4 reaction buffer 2 µl
MgCl2, 50 mM 0.5 µl
Forward primer (T7), 10 µM 0.5 µl
Reverse primer (Bgh), 10 µM 0.5 µl
dNTPs, 10 mM each 0.5 µl
Template 1 µl
dH2O 14.8 µl
20 µl
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Table 3.4: Temperature program for colony PCR
Temperature Time Cycles
Initial denaturation 95 ◦C 3 min 1
Denaturation 95 ◦C 15 sec
35Annealing 55 ◦C 15 sec
Amplification 72 ◦C 3 min
Final amplification 72 ◦C 10 min 1
Cooling 4 ◦C ∞ 1
3.1.6.3 Validation of the Fuca1 knock-out allele
In order to validate the correct integration of the bacterial npt I gene into Exon 1 of the Fuca1
gene, the 5’ homologous recombination site was amplified from genomic mouse DNA (sec-
tion 3.1.5). The forward primer was located in the promoter region of the gene, whereas the
reverse primer was located within Exon 1 (after the insertion site of the neomycin-cassette). A
wildtype PCR product of 4108 bp and a knock-out PCR product of 5287 bp was received. The
PCR reactions were prepared as shown in table 3.5 and incubated in a thermocycler according
to the protocol shown in table 3.6. Afterwards 5 µl of the amplicon were mixed with 1 µl 6 x
DNA loading dye (section 2.9) and loaded on a 1 % agarose gel (section 3.1.7) and the DNA
was separated according to their size. The PCR products were further isolated from the gel
(section 3.1.8) and analyzed by sequencing (section 3.1.17).
Table 3.5: PCR setup for validation of the Fuca1 knock-out allele
Component Volume
KAPA HIFI Hot Start Ready Mix 12.5 µl
Forward primer (F4), 10 µM
0.75 µl
Reverse primer (R3), 10 µM
DMSO 1.25 µl
Template 100 ng
dH2O x µl
25 µl
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Table 3.6: PCR temperature program for validation of the Fuca1 knock-out allele
Temperature Time Cycles
Initial denaturation 95 ◦C 5 min 1
Denaturation 98 ◦C 20 sec
35Annealing 58 ◦C 15 sec
Amplification 72 ◦C 5 min
Final Amplification 72 ◦C 5 min 1
Cooling 4 ◦C ∞ 1
3.1.6.4 PCR for routine mouse genotyping
Genomic DNA was extracted from tissue material received during mouse ear piercing (section
3.1.5) and was applied as template for mouse genotyping. A multiplex PCR approach was
established using the KAPA HIFI Hot Start Ready Mix Kit (PeqLab). The forward primer was
located at the beginning of Exon 1 of the Fuca1 gene (before the insertion site of the neomycin-
cassette). One reverse primer was located at the end of Exon 1 (after the insertion site of the
neomycin-cassette), thereby producing a PCR product of 350 bp in case of a wildtype gene.
In contrast, the second reverse primer was located within the neomycin casette and enabled
a PCR product of 735 bp in case of a knock-out gene. Heterozygous mice gave rise to both
PCR products. The PCR reactions were prepared as shown in table 3.7 and incubated in a
thermocycler according to the protocol shown in table 3.8. Afterwards, 5 µl of the amplicon
were mixed with 1 µl 6 x DNA loading dye (section 2.9), loaded on a 1 % agarose gel (section
3.1.7) and the DNA was separated according to their size.
Table 3.7: Genotyping PCR setup
Component Volume
KAPA HIFI Hot Start Ready Mix 6.25 µl
Forward primer (F2), 10 µM
0.185 µlReverse primer (R3), 10 µM
Reverse primer (AK30-R), 10 µM
DMSO 0.625 µl
Template 0.5 µl
dH2O 4.57 µl
12.5 µl
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Table 3.8: Genotyping PCR temperature program
Temperature Time Cycles
Initial denaturation 95 ◦C 2 min 1
Denaturation 98 ◦C 20 sec
35Annealing 62 ◦C 15 sec
Amplification 72 ◦C 30 sec
Final Amplification 72 ◦C 5 min 1
Cooling 4 ◦C ∞ 1
3.1.6.5 Real-Time PCR
The differential mRNA expression of selected genes in tissues of Fuca1(-/-) mice versus wiltype
tissues was monitored using a Real-Time PCR approach. After isolation of mRNA (section
3.1.2.1), cDNA was synthesized (section3.1.4). The Real-Time PCR reactions were prepared
in a 96-well plate using the KAPA SYBR Fast Universal Kit (PeqLab) as shown in table 3.9
and incubated in a Step One Plus Real-Time PCR cycler (Applied Biosystems) according to
the protocol shown in table 3.10. Each reaction was prepared as triplicates. A no-template-
control (NTC) was done for each primer pair in duplicates as internal quality control using
water instead of cDNA. Primer pairs were designed as stated in section 3.1.1.
Table 3.9: Real-Time PCR setup
Component Volume
KAPA Master Mix (2x) 6 µl
KAPA Rox 0.25 µl
Primer mix (forward + reverse), each 10 µM 2 µl
cDNA 2 µl
dH2O 1.75 µl
12.0 µl
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Table 3.10: Real-Time PCR temperature program
Temperature Time Cycles
Initial denaturation 95 ◦C 20 sec 1
Denaturation 95 ◦C 3 sec
35
Annealing and amplification 60 ◦C 30 sec
Denaturation 95 ◦C 15 sec
Annealing 60 ◦C 1 min melting curve
Heating to 95 ◦C 0.3 ◦C every 15 sec 30 min
Cooling 4 ◦C ∞ 1
Amplification of the target gene was recorded in real time based on the increase in fluorescence
of the SYBR Green intercalating dye. The Rox reference dye was used for internal norma-
lization to compensate slight variations in SYBR Green fluorescence detection due to minimal
differences in reaction volume and position of the wells. As the PCR reactions reached a
plateau phase during the late amplification cycles, the early phase of the reaction was used
for quantification. The CP value (crossing point) was determined using the Step One Plus
Real-Time PCR cycler software (Applied Biosystems) and is defined as the cycle at which
the fluorescence rises substantially above the background. The CP value is directly linked to
the amount of template cDNA present in the reaction mix. Following the mathematical model
from Pfaffl (2001), the relative fold change (R) in mRNA expression can be calculated as
shown in equation 3.1.
R= 2−∆∆CP (3.1)
∆∆CP = ∆CP(knock-out)−∆CP(wildtype)
∆CP =CP(target gene)−CP(Gapdh)
R values greater than 1 indicate an elevated mRNA expression of the target gene in the
Fuca1(-/-) tissue compared to the wildtype tissue, whereas values less than 1 represent a de-
creased expression.
The specificity of the Real-Time PCR reactions was shown by a melting curve. The amplicons
were annealed followed by a gradually temperature increase up to 95 ◦C. The denaturation of
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the PCR product occurred at a temperature specific to each amplicon leading to a decrease in
SYBR Green fluorescence. Homogeneous PCR products resulted in a single peak, whereas
multiple peaks were obtained in case of additional unspecific PCR products. The amplicons
were also analyzed by agarose gel electrophoresis (section 3.1.7) and only data from homoge-
neous amplicons were evaluated.
3.1.7 Agarose gel electrophoresis
In order to determine the size of DNA fragments, an agarose gel electrophoresis was used. 1 %
Agarose (w/v) was dissolved in TAE buffer (section 2.9) using a microwave oven and ethidium
bromide was added to a final concentration of 1 µl/ml. The gel was poured into gel chambers
and sample pockets were formed by an appropriate comb. The hardened gel was covered with
TAE and the DNA samples were mixed with 6 x loading dye (section 2.9) and loaded into the
pockets. For size determination a 100 bp or 1 kb DNA ladder was also loaded. Electrophoresis
was performed at a constant voltage of 90 V for 45 - 60 min. Afterwards the DNA bands
were visualized by UV light (312 nm) on a transilluminator (Peqlab) and photographed for
documentation.
3.1.8 Purification of DNA from agarose gels
For cloning strategies a 50 µl PCR setup (section 3.1.6.1) was performed. 30 µl of amplicon
were mixed with 6 µl 6 x DNA loading dye (section 2.9). The DNA samples were separated
according to their size by agarose gel electrophoresis (section 3.1.7). The DNA bands were
documented and cut out with a scalpel. The DNA was purified using the High Pure PCR
Product Purification Kit (Roche) according to the manufacturer’s instructions. The DNA was
eluted from the purification column with 50 µl dH2O.
3.1.9 Restriction digest
Restriction endonucleases were used either to control a ligated plasmid DNA or to digest and
prepare DNA for ligation and cloning purposes.
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3.1.9.1 Analytical restriction
After a successful ligation approach the purified plasmid DNA (section 3.1.16) was checked
for correct insert integration. 1 µg plasmid DNA was treated with 0.2 µl of specific restriction
enzymes flanking the insert sequence. The DNA was dissolved in the buffer recommended by
the manufacturer using a total reaction volume of 20 µl. The samples were incubated for 1 h
at 37 ◦C and separated according to their size by agarose gel electrophoresis (section 3.1.7).
3.1.9.2 Quantitative restriction
For cloning approaches, the cDNA of murine or human α-L-fucosidase was amplified by PCR
in order to add additional restriction sites (section 3.1.6.1) and was purified from an agarose
gel (section 3.1.8). The DNA insert as well as the target plasmid were digested with the same
restriction endonucleases. NheI and XhoI were used to clone the human α-L-fucosidase into
the pcDNA3.1Hygro(+) vector. NheI and NotI were used for the murine enzyme. 43 µl of
insert DNA and 2 µg of plasmid DNA were digested with 1 µl of each restriction enzyme.
5 µl of buffer recommended by the manufacturer were added and the samples were filled up
to a final volume of 50 µl. The reactions were incubated for 2 h at 37 ◦C.
3.1.10 Dephosphorylation of DNA fragments
In order to prevent re-alignment of the plasmid backbone during ligation (section 3.1.11),
the plasmid DNA had to be dephosphorylated after enzyme restriction (section 3.1.9.2). 1 µl
of Antarctic Phosphatase and 6 µl of Antarctic Phosphatase buffer were added to the entire
restriction sample (50 µl) and incubated for 15 min at 37 ◦C. The Antarctic Phosphatase was
inactivated by incubation at 65 ◦C for 5 min.
3.1.11 Ligation
Prior to ligation, the DNA insert and plasmid backbone were purified using the High Pure
PCR Product Purification Kit (Roche) according to the manufacturer’s instructions. The DNA
was eluted with 50 µl dH2O and quantified using a NanoDrop ND-1000 spectrophotometer
(PeqLab). 50 ng plasmid DNA were ligated with insert DNA in a molar ration of 1 : 5 (plas-
mid : insert). The reaction was filled up with dH2O to a volume of 17 µl, was incubated at
65 ◦C for 5 min in order to destroy secondary structures and then immediately placed on ice.
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2 µl ligation buffer and 1 µl T4-ligase were added and the ligation was performed at 4 ◦C over
night.
3.1.12 Site-directed mutagenesis
The catalytic activity of the human α-L-fucosidase is carried out by an aspartate residue
(D230) and a glutamate residue (E294) (Liu et al. 2009; there referred to as D225 and E289).
An inactive variant of the enzyme was generated by site-directed mutagenesis, thereby re-
placing the aspartate by an asparagine (D230N) and the glutamate by a glutamine residue
(E294Q). These mutations required only a single base exchange (appendix A.4). Complemen-
tary primers were designed that contained the desired mutation and flanked the site of mutation
by approximately 10 nucleotides in each direction. The whole vector containing the wildtype
α-L-fucosidase cDNA sequence (pcDNA3.1Hygro(+)hFuca or pcDNA3.1Hygro(+)hFuca-
His6) was amplified by PCR. The samples were prepared as shown in table 3.11 and incubated
according to table 3.12. In order to minimize possible PCR-derived mutations, a proof-reading
polymerase was used. In a first approach both single mutations were introduced separately fol-
lowing the protocol described below and were then applied to a second mutagenesis step to
obtain the cDNA sequence of the human α-L-fucosidase carrying both mutations.
Following PCR, 40 µl of the amplicon were added to 4.5 µl of DpnI Buffer and 1 µl of DpnI
restriction enzyme and incubated for 4 h at 37 ◦C in order to digest the template plasmid that
was purified from E. coli and therefore contained DAM-methylated sites. DpnI specifically
recognizes and digests this methylation pattern. The newly synthesized plasmid containing
Table 3.11: PCR setup for site-directed mutagenesis
Component Volume
PfuUltra II fusion HS DNA polymerase 0.5 µl
10x PfuUltra II reaction buffer 5 µl
Forward primer, 10 µM 1.5 µl
Reverse primer, 10 µM 1.5 µl
dNTPs, 10 mM each 1 µl
DNA 1 µg
dH2O 39.5 µl
50 µl
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Table 3.12: PCR temperature program for site-directed mutagenesis
Temperature Time Cycles
Initial denaturation 95 ◦C 3 min 1
Denaturation 95 ◦C 30 sec
35Annealing optimal melting temperature see section 2.7.3 ◦C 30 sec
Amplification 72 ◦C 5 min
Final Amplification 72 ◦C 10 min 1
Cooling 4 ◦C ∞ 1
the desired mutation is not DAM-methylated and thus it is not recognized by DpnI. After
the digest, 5 µl of the sample were added to 1 µl of 6 x DNA loading buffer (section 2.9)
and analyzed on a 1 % agarose gel (section 3.1.7). Thereby the sample was checked for a
sufficient amount of synthesized DNA as well as for its correct size. 2 µl of the sample were
transformed into chemically competent cells and plated on LB plates containing 100 µg/ml
ampicillin (section 3.1.14).
3.1.13 Preparation of chemically competent bacteria
Chemically competent E. coli bacteria (DH5α) were generated according to the CaCl2 method
(Sambrook and Russel 2001). A 250 ml culture was inoculated with a fresh overnight culture
of the DH5α strain to a final OD600 of 0.5 (37 ◦C, 200 rpm). The cells were chilled on ice for
10 min and harvested at 4 000 x g for 10 min at 4 ◦C. The supernatant was discarded and the
cell pellet was resuspended in 65 ml ice-cold 100 mM MgCl2. The culture was kept on ice for
5 min and centrifuged again. The cell pellet was resuspended in 13 ml ice-cold 100 mM CaCl2
and kept on ice for 20 min. Again, the cells were pelleted at 4 000 x g for 10 min at 4 ◦C. The
supernatant was discarded and the cell pellet was resuspended in 2.6 ml of ice-cold 85 mM
CaCl2 containing 15 % glycerol (v/v). 50 µl aliquots were flash frozen in liquid N2 and stored
at -80 ◦C.
3.1.14 Transformation of chemically competent bacteria
Chemically competent E. coli were transformed with plasmid DNA or ligated DNA samples
(section 3.1.16 and 3.1.11) according to the heat shock method (Sambrook and Russel 2001).
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Therefore 50 µl of chemically competent DH5α were thawed on ice. 2 µl of DNA were added
and mixed by gently stirring with the pipette tip. After incubation for 30 min on ice the heat
shock was performed at 42 ◦C for 30 sec. Then the cells were incubated on ice for 2 min
and 250 µl of pre-warmed SOC medium (section 2.9) were added. The cells were shaken at
200 rpm for 1 h at 37 ◦C. Finally the cell suspension was plated on pre-warmed LB agar plates
(section 2.9) containing 100 µg/ml ampicillin as selection marker. The plates were incubated
upside-down at 37 ◦C over night.
3.1.15 Glycerol cultures of bacteria
Glycerol cultures of respective E. coli clones were used for long term storage (Sambrook and
Russel 2001). 2 ml over night culture were pelleted at 10 000 x g for 1 min. 1.6 ml of the
supernatant were discarded. The bacterial cell pellet was resuspended in the remaining 0.4 ml
and 100 µl of 87 % glycerol (sterile) were added to receive a final glycerol concentration of
17 % (v/v). The cultures were immediately stored at -80 ◦C.
3.1.16 Purification of plasmid DNA
Plasmid DNA was purified from overnight cultures of respective E. coli clones received after
transformation (section 3.1.14). An analytical preparation was performed to control the se-
quence of cloned plasmids by further sequencing (section 3.1.17). A quantitative preparation
was used to receive a higher concentration and purity of plasmid DNA for further transfection
approaches (section 3.3.3). DNA concentrations were measured using a NanoDrop ND-1000
spectrophotometer (PeqLab).
3.1.16.1 Analytical preparation
The respective E. coli clones were inoculated in 6 ml LB medium (section 2.9) containing
100 µg/ml ampicillin and cultivated over night at 37 ◦C and 250 rpm. The cells were pel-
leted stepwise in a 2 ml tube at 8 000 x g. Plasmid DNA was isolated using the QIAprep Spin
Miniprep Kit (Quiagen) according to the manufacturer’s instructions. The DNA was eluted
using 50 µl dH2O and stored at -20 ◦C.
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3.1.16.2 Quantitative preparation
The respective E. coli clones were inoculated in 200 ml LB medium (section 2.9) containing
100 µg/ml ampicillin and cultivated at 37 ◦C and 250 rpm over night. 100 ml of over night
culture were used for DNA purification. The cells were pelleted stepwise in a 50 ml tube at
8 000 x g. Plasmid DNA was isolated using the QIAGEN Plasmid Midi Kit (Quiagen) ac-
cording to the manufacturer’s instructions. Finally the DNA pellet was resuspended in 100 µl
dH2O and stored at -20 ◦C.
3.1.17 Sequencing
Cloned and purified plasmid DNA (section 3.1.16) was sequenced in order to exclude muta-
tions and PCR-derived errors. Therefore specific primer pairs framing the multiple cloning
site of the pcDNA3.1Hygro(+) plasmid were used (section 2.7.2). The insert was sequenced
by the sequencing core facility (CeBiTec, Bielefeld, Germany) on Applied Biosystems Abi
Prism 377, 3100 and 3730 sequencers using BigDye-terminator v3.1 chemistry. Premixed
reagents were purchased from Applied Biosystems. The plasmid sequences are attached in
the appendices A.1 and A.3.
3.2 Biochemical methods
3.2.1 Isolation of lysosome-enriched fractions
3.2.1.1 Isolation of tritosomes from mouse liver
Mouse liver lysosomes were enriched according to the method described Leighton et al.
(1968). Usually, lysosomes exhibit the same density as mitochondria thereby challenging
a proper separation of the organelles by a conventional centrifugation using density gradients.
However, the density of lysosomes can be decreased by the use of tyloxapol (Triton WR-1339)
that inhibits the lipoprotein lipase (Hayashi et al. 1981) resulting in an increased amount of
LDL-particles in the mouse serum, which are further transported to the liver lysosomes for
degradation. Due to the increased lipid content, the density of liver lysosomes is decreased
and they are further referred to as tritosomes. Tritosomes are isolated by differential cen-
trifugation of organelles followed by a discontinuous sucrose gradient. All work was done at
4 ◦C.
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Figure 3.1: Isolation of lysosome-enriched fractions from mouse liver
Schematic outline of the isolation of lysosome-enriched fractions from mouse liver.
Mice were peritoneally injected with 4 µl of 17 % tyloxapol (in 0.9 % NaCl) per 1 g body
weight 3 - 4 days prior to tritosome isolation. The animals were sacrificed by cervical dislo-
cation. The liver was dissected and homogenized in 5 ml of 0.25 M sucrose by 1 stroke in a
Potter S homogenizer (B. Braun; pestle speed: 1 500 rpm). The homogenate was centrifuge
at 1 000 x g for 10 min (figure 3.1). The pellet was resuspended in 3.5 ml 0.25 M sucrose, ho-
mogenized by 1 stroke in a Potter S homogenizer and again centrifuged. The pellet contained
cell debris, nuclei and intact cells and was referred to as pellet N. Both supernatants were
combined (supernatant E) and centrifuged at 56 000 x g for 7 min (Sorvall R© ULTRA Pro 80
centrifuge, Thermo Scientific, rotor T-880). The pellet was carefully resuspended in 8.5 ml of
0.25 M sucrose and again centrifuged. Both supernatant were combined and contained micro-
somes and cytosolic proteins (supernatant PS). The pellet L contained lysosomes and mito-
chondria and was further applied to a discontinuous sucrose gradient. The pellet was carefully
resuspended in 2.5 ml of sucrose (density of ρ = 1.21), homogenized by 1 stroke in a Potter
S homogenizer (pestle speed: 200 rpm) and transferred into a centrifugation-tube. The sam-
ple was carefully overlaid with 2.25 ml of sucrose (ρ = 1.15) followed by 2.25 ml of sucrose
(ρ = 1.14) and finally 1 ml of sucrose (ρ = 1.06). The sample was centrifuged at 111 000 x g
for 150 min in a swing-out rotor (Sorvall R© ULTRA Pro 80 centrifuge, Thermo Scientific, rotor
TH-641). During centrifugation the tritosomes were concentrated at the interphase between
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the sucrose densities 1.06 and 1.14 forming a brownish layer (F2 fraction: ˜ 1 ml), that was
carefully transferred into a new tube.
For some purposes it was necessary to further concentrate the tritosomes or to enable a quick
buffer exchange without dialysis. As the tritosomes were still intact after isolation they could
be pelleted at 100 000 x g for 40 min (OptimaTM L-80 Ultracentrifuge, Beckmann Coulter,
rotor TLA-55) and were resuspended in a smaller volume (e. g. 100 µl) of buffer of choice.
The tritosomes were stored at -20 ◦C until usage. Lysis was performed by addition of 0.5 %
Triton X-100 (v/v) and sonification at 4 ◦C using a sonifier 450 (Branson; 3 x 20 sec pulses,
40 % intensity). After incubation on ice for 30 min insoluble particles were pelleted at 18 000 x g
for 15 min and the supernatant was further subjected to activity measurements (section 3.2.6),
Western blot analysis (section 3.2.5) or gel filtration studies (section 3.2.10).
3.2.1.2 Isolation of lysosome-enriched fractions from mouse brain
Lysosome-enriched fractions from brain were isolated as described by Caimi et al. (1989) by
differential centrifugation followed by a continuous Percoll gradient. All work was done at
4 ◦C.
Mice were sacrificed by cervical dislocation. The whole brain was dissected and homoge-
nized in 4 ml SED buffer (0.32 M sucrose containing 1 mM EDTA) by 5 strokes in a Potter S
homogenizer (B. Braun; pestle speed: 500 rpm). The homogenate was cleared by centrifuga-
tion at 1 000 x g for 10 min (figure 3.2). The pellet was resuspended in 3 ml SED buffer and
again centrifuged. The pellet contained cell debris, nuclei and intact cells. Both supernatants
were combined and intact organelles were pelleted at 17 500 x g for 1 h (OptimaTM L-80 Ultra-
centrifuge, Beckmann Coulter, rotor T-1270). The supernatant containing cytosolic proteins
and microsomes was removed. The pellet was resuspended in 1 ml SED buffer. Percoll was
made isocratic by adding 9 ml Percoll to 1 ml 2.5 M sucrose containing 10 mM EDTA (100 %
Percoll) and diluted to 27 % (v/v) with SED buffer. The resuspended organelles (1 ml) were
layered over 9 ml of 27 % Percoll solution and centrifuged for 90 min at 20 000 x g (OptimaTM
L-80 Ultracentrifuge, Beckmann Coulter, rotor T-1270). The gradient was collected from
top to bottom in eight fractions of 1 ml volume and four fractions of 0.5 ml volume. 0.1 %
Triton X-100 (v/v) was added and the organelles were lysed by sonification at 4◦C using
a sonifier 450 (Branson; 3 x 20 sec pulses, 40 % intensity). The lysosome-enriched fraction
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was identified by determining the specific β -hexosaminidase activity (section 3.2.7). The α-
L-fucosidase activity (section 3.2.6) as well as the protein concentration (section 3.2.3) was
further determined.
Figure 3.2: Isolation of lysosome-enriched fractions from mouse brain
Schematic outline of the isolation of lysosome-enriched fractions from mouse brain.
3.2.2 Preparation of tissue and cell homogenates
For the preparation of tissue homogenates, mice were sacrificed by cervical dislocation. Mouse
organs were either directly used or frozen in liquid nitrogen and stored at -80 ◦C until usage.
Approximately 150 mg of tissue (fresh weight) were homogenized in the 20 x volume of TBS
containing 0.5 % Triton X-100 as well as protease inhibitors by 6 strokes in a Potter S homo-
genizer (B. Braun; pestle speed: 1 500 rpm). The resulting samples were lysed by sonification
at 4◦C using a sonifier 450 (Branson; 3 x 20 sec pulses, 40 % intensity).
Cell lysates were produced by pelleting trypsinized cells at 200 x g for 3 min. The cell pellet
was washed once with 1 x PBS and centrifuged again. The supernatant was discarded and the
cell pellet stored at -20 ◦C. For cell lysis, 100 µl (large cell pellets) or 50 µl (small cell pellets)
of TBS containing 0.1 % Triton X-100 as well as protease inhibitors were added. The cells
were sonified at 4 ◦C using a sonifier 450 (Branson; 3 x 20 sec pulses, 40 % intensity).
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After sonification the tissue or cell homogenates were placed on ice for 30 min, were rigo-
rously shaken and centrifuged at 18 000 x g for 15 min at 4 ◦C. 10 µl were used for determina-
tion of protein concentrations (1 : 10 diluted; section 3.2.3).
3.2.3 Determination of protein concentration
Protein concentrations of distinct samples (e. g. cell and tissue homogenates (section 3.2.2) or
lysosome-enriched fractions (section 3.2.1)) were determined using the DC Protein Assay Kit
(BioRad). The assay is based on a method described by Lowry et al. (1951). The first step is
a Biuret reaction including a complex formation between peptide bonds and Cu(II) ions. In
a second step, Cu(II) is reduced to Cu(I), which in turn reduces the yellow folin reagent to
molybdenum blue. The blue dye can be quantified by measuring the absorbance at 750 nm.
Usually, 10 µl of tissue and cell homogenates (1 : 10 diluted) or 5 µl of lysosome-enriched
(undiluted) were used. The samples were added to dH2O in a 96-well microtiter plate (fi-
nal volume of 100 µl). 1 ml of Reagent A was mixed with 20 µl of Reagent S and 25 µl of
the mixture were applied to each sample. Then 200 µl of Reagent B were added. The reac-
tions were incubated for 15 min at room temperature and their absorbencies were measured at
750 nm using the Infinite 200 microplate reader (Tecan). Blank values were taken from sam-
ples using a appropriate amount of dH2O instead of sample. The protein concentration was
determined from a reference curve using different amounts of bovine serum albumin (BSA;
0 - 16 µg). All measurements were done as duplicates.
3.2.4 SDS polyacrylamide gel electrophoresis
Proteins were separated according to their size by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS - PAGE). Therefore gels were polymerized between glass plates using
spacers according to table 3.13 and sample wells were formed by an appropriate comb. Sam-
ples from tissue and cell homogenates (section 3.2.2), lysosome-enriched fractions (section
3.2.1) or α-L-fucosidase purification fractions (section 3.2.8) were mixed with an appropri-
ate volume of 4 x Laemmli buffer (section 2.9), denatured for 5 min at 95 ◦C and loaded onto
the gel. For electrophoresis, gels were placed in SDS running buffer (section 2.9) at a con-
stant current of 20 - 40 mA. Afterwards the proteins were either blotted onto PVDF mem-
branes (Western blotting, section 3.2.5) or were stained (coomassie or silver stainings, section
3.2.4.1).
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Table 3.13: Preparation of separating and stacking gels for SDS - PAGE
separating gel stacking gel
Acrylamide concentration 10 % 15 % 5 %
dH2O 12.6 ml 7.70 ml 6.10 ml
Rotiphorese R© Gel 30 (30 % acrylamide
and 0.8 % bis-acrylamide (37.5 : 1))
9.80 ml 14.7 ml 1.30 ml
1.5 M Tris, pH 8.8 7.50 ml 7.50 ml –
0.5 M Tris, pH 6.8 – – 2.50 ml
TEMED 25 µl 25 µl 10 µl
10 % APS solution 250 µl 250 µl 100 µl
Total volume 30 ml 10 ml
3.2.4.1 Coomassie and silver staining
The purity of fractions received during α-L-fucosidase purification (section 3.2.8) was ana-
lyzed on a SDS-PAGE by coomassie or silver staining. After gelelectrophoresis, the proteins
were fixed and stained with coomassie by incubating the gel in coomassie staining solution
(section 2.9) over night with gentle agitation. The background of the gel was destained at the
next day using 50 % methanol. The gel was washed intensively with dH2O and documented
using a CCD-camera (Fuji-Film).
If the concentration of the analyzed proteins was too low, the coomassie staining produced
only slightly visible protein bands. A silver staining was performed to improve the detection.
Silver ions (Ag2+) attach at negatively charged amino acids. They can be reduced to elemental
silver by addition of formaldehyde resulting in a staining of the proteins. The gel was sensi-
tized by gentle shaking in 0.02 % sodium thiosulfate solution (w/v in dH2O) for 1 min. Then
the gel was washed three times with dH2O for 20 sec and stained with 0.2 % silver nitrate solu-
tion (w/v in dH2O) containing 0.05 % formaldehyde for 20 min at 4 ◦C under gentle agitation.
Again, the gel was washed for three times with dH2O for 20 sec and transferred into a clean
dish. For development the gel was incubated in 3 % sodium carbonate solution (w/v in dH2O)
containing 0.05 % formaldehyde under gentle agitation. The reaction was stopped by washing
the gel in dH2O for 20 sec followed by an incubation in 5 % acetic acid (in dH2O). The gel
was documented using a CCD-camera (Fuji-Film).
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3.2.5 Semi-dry Western blotting
After SDS-PAGE (section 3.2.4) proteins were transferred onto a PVDF-membrane in order
to enable a specific protein detection using antibodies. Two layers of Whatman paper as well
as the gel were equilibrated in cathode buffer (section 2.9) and arranged on the cathode site
of the blotting equipment. The PVDF-membrane was activated for 30 sec in methanol and
afterwards also equilibrated in cathode buffer. The membrane was applied to the blotting
aperture and covered by another two layer of Whatman paper equilibrated in anode buffer
(section 2.9). The proteins were transferred at a constant current of 1 mA/cm2 for 80 min.
After the protein transfer, the membrane was blocked for 1 h using 5 % milk powder in TBS-T
(section 2.9). The primary antibody was applied in TBS-T containing 5 % milk powder and in-
cubated overnight with gentle agitation. The membrane was subsequently washed 4 times for
10 min with TBS-T before the secondary antibody was applied in TBS-T containing 5 % milk
powder for 1 h at room temperature. Again the membrane was washed 4 times with TBS-T.
The secondary antibody is conjugated to horseradish peroxidase (HRP) and the proteins were
detected by enhanced chemiluminescence (ECL) signals. 1 ml luminol reagent was mixed
with 1 ml peroxide solution (SuperSignal West Pico Chemiluminescent Substrate, Pierce).
The solution was applied to the membrane that was then covered with a transparent sheet. The
horseradish peroxidase converts luminol in the presence of H2O2 to 3-aminophthalate which
is produced in an excited state. Light is emitted during the transition to the basic state. The
emitted light signals were detected by a LAS 3000 luminescent image analyzer (Fuji-Film). If
the detected signal were only weak, 40 µl of enhancer solutions A and B (SuperSignal West
Femto Chemiluminescent Substrate, Pierce), respectively, were added in order to increase the
ECL signals.
3.2.5.1 Stripping of Western blot membranes
Western Blot membranes were developed with a specific primary and secondary antibody (sec-
tion 3.2.5). In order to enable further detections using other specific antibodies, the membrane
was incubated in 1 M NaOH for 2 min at room temperature under gentle agitation. Afterwards
the membrane was intensively washed with dH2O followed by 4 washing steps with TBS-
T (section 2.9) for 10 min. Then 5 % milk powder was applied for 1 h to block unspecific
interactions. The further protein detection was performed as described above.
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3.2.5.2 Ponceau S staining
Ponceasu S staining was used as loading control on Western blots. The staining solution
(section 2.9) was added to the blot after stripping the membrane (section 3.2.5.1). Protein
bands were visible within 1 - 2 min. The background of the blot was destained by incubation
in dH2O under gentle agitation. The staining was documented using a CCD-camera (Fuji-
Film).
3.2.6 Determination of α-L-fucosidase activity
The α-L-fucosidase activity was measured using artificial pseudosubstrates. The enzyme con-
verts 4-methylumbelliferyl-α-L-fucopyranoside (4-MUF; tissue and cell homogenates, lyso-
some-enriched fractions) to the fluorogenic product 4-methylumbelliferone (4-MU) thereby
enabling a very sensitive detection of fucosidase activity. For activity measurements of puri-
fied recombinant enzyme it was sufficient to use the less sensitive substrate para-nitrophenyl-
α-L-fucopyranoside (pNPF) that is converted to the chromogenic product para-nitrophenol
(pNP). All measurements were done in duplicates. The background was determined by ana-
lyzing a substrate black value (addition of water instead of enzyme/sample) as well as an
enzyme black value of each sample (addition of activity buffer without substrate). Reactions
were prepared as stated below.
Regarding 4-MUF activity measurements, tissue homogenates (10 µl) or lysosome-enriched
fractions (5 µl for liver or 25 µl for brain) were incubated with 150 µl of 0.75 mM 4-MUF in
0.1 M sodium citrate pH 5.5 including 0.2 % BSA and 0.04 % sodium azide for 16 h (tissue
homogenates) or 6 h (liver lysosomes) or 4 h (brain lysosomes) at 37 ◦C and stopped by the
addition of 150 µl of 1 M sodium carbonate (pH 10.4). The amount of liberated 4-MU was
determined by fluorescence measurements (excitation: 360 nm; emission: 465 nm) using the
Infinite 200 microplate reader (Tecan) and was calculated using a reference curve (0 – 10 nmol
of 4-MU). The α-L-fucosidase activity was calculated as stated in equation 3.2. If necessary,
tissue homogenates were diluted 1 : 10 - 1 : 100 to reach a linear range. For analysis of α-L-
fucosidase pH dependency, McIlvaine’s buffer (McIlvaine 1921) was used instead of 0.1 M
sodium citrate and adjusted to the stated pH values.
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Activity [mU/ml] =
liberated 4−MU [nmol]
Vsample volume [ml] · t [min] ·F (3.2)
t = incubation time
F = dilution factor
In case of pNPF activity measurements, up to 50 µl of the fractions received during α-L-
fucosidase purification (section 3.2.8) were filled up with dH2O to a final volume of 100 µl
and were added to 100 µl of 2 mM pNPF in 0.1 M sodium citrate pH 5.5 including 0.2 % BSA
and 0.04 % sodium azide. The reaction was incubated for 1 h at 37 ◦C and stopped by the
addition of 1 ml of 0.4 M glycine in NaOH (pH 10.4). The amount of liberated pNP was
determined in a 96-well plate (in 300 µl) by measuring the absorbence at 405 nm using the
Infinite 200 microplate reader (Tecan). The fucosidase activity was calculated according to
the Lambert-Beer law (A = e * c * d) as stated in equation 3.3. Purified fractions containing a
high amount of recombinant enzyme had to be diluted up to 1 : 1000 to reach a linear range
(absorbance value < 1).
Activity [mU/ml] =
∆E ·106
ε [ Lmol·cm ] ·d [cm] · t [min]
· Vassay volume [µl]
Vsample volume [µl]
·F (3.3)
∆E = Esample – Eenzyme blank – Esubstrate blank
ε450 nm = molar extinction coefficent (18 500 L mol-1 cm-1)
d = layer thickness (300 µl = 0.85 cm)
t = incubation time (1 h)
Vassay volume = volume after reaction stop (1200 µl)
F = dilution factor
3.2.7 Activity assays of other lysosomal glycosidases
The activities of lysosomal glycosidases (β -hexosaminidase and α-mannosidase) were mea-
sured in mouse tissue homogenates using artificial pseudosubstrates (para-nitrophenyl-N-
acetyl-β -D-glucosaminide and para-nitrophenyl-α-D-mannopyranoside, respectively). The
substrates were converted to para-nitrophenol (pNP) and the amount of liberated pNP was
measured at 405 nm using the Infinite 200 microplate reader (Tecan). The molar extinction
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coefficient of pNP at 405 nm accounts to ε405 = 18 500 M-1cm-1. The light path length in a
96-well microtiter plate with 300 µl volume is 0.85 cm (d = 0.85 cm). All measurements were
done in duplicates. The background was determined by analyzing a substrate black value (ad-
dition of water instead of enzyme/sample) as well as a enzyme black value of each sample
(addition of activity buffer without substrate). Reactions were prepared as stated below.
For α-mannosidase, up to 100 µl of tissue homogenates were used and added to 50 µl of 2 x
activity buffer (0.2 M sodium citrate pH 4.2 including 0.4 % BSA and 0.08 % sodium azide)
and 50 µl substrate (10 mM in dH2O). The reactions were filled up with dH2O to a final vo-
lume of 200 µl and were incubated at 37 ◦C for 16 h (visceral tissues) or 6 days (brain). The
reactions were stopped by adding 1 ml of 0.4 M glycine in NaOH (pH 10.4). The absorbance
of liberated pNP was measured in a microtiter plate using 300 µl of the reactions.
Regarding the β -hexosaminidase activity, the tissue homogenates had to be diluted 1 : 5 -
1 : 20. 10 µl were added to 100 µl of substrate (10 mM in 0.1 M sodium citrate pH 4.6 in-
cluding 0.2 % BSA and 0.04 % sodium azide). The reactions were filled up with dH2O to a
final volume of 200 µl and were incubated at 37 ◦C for 2h. The reactions were stopped by
adding 1 ml of 0.4 M glycine in NaOH (pH 10.4). The absorbance of liberated pNP was mea-
sured in a microtiter plate using 300 µl of the reactions. The β -hexosaminidase activity of
enriched brain lysosomes was determined using up to 25 µl of percoll fractions. The reactions
were prepared as described above and incubated for 30 min at 37 ◦C.
3.2.8 Purification of His6-tagged α-L-fucosidase
The His6-tagged human α-L-fucosidase was produced using a stable transfected CHO-K1 cell
line (#C2 / C1). The cells were grown adherently (section 3.3.4.1), the conditioned medium
was applied to an ammonium sulfate precipitation and the enzyme was subsequently puri-
fied by a Ni2+-affinity chromatography followed by a strong cation exchange chromatography
(SCX) as described below. All steps were carried out at 4 ◦C.
3.2.8.1 Ammonium sulfate precipitation
Conditioned medium from the cell line CHO-K1-hFuca-His6 #C1 / C2 was harvested every
two days (section 3.3.4.1) and immediately centrifuged at 8 000 x g for 30 min at 4 ◦C in order
to remove death cells. 50 % (NH4)2SO4 (w/v) were added and rigorously stirred for 1 h at
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room temperature. The solution was subsequently stirred over night at 4 ◦C and stored at 4 ◦C
for one week at the most.
3.2.8.2 Ni2+-affinity chromatography
Approximately 1 L of conditioned medium was used for enzyme purification and precipitated
as described above. The precipitate was centrifuged at 8 000 x g for 30 min at 4 ◦C and the
protein pellet was resuspended in a minimal volume of HisTrap binding buffer (approximately
20 ml; including 50 mM imidazole; section 2.9) and dialyzed overnight at 4 ◦C with gentle
stirring in a dialysis tube (MWCO 14 000) against 5 L of HisTrap binding buffer. The dialysate
was harvested and centrifuged at 18 000 x g for 30 min at 4 ◦C and was transferred into a new
tube for three times. Afterwards it was filtrated using 0.22 µm syringe filters.
A Ni2+-affinity chromatography was performed using the ÄKTA Explorer system (GE Health-
care). A 1 ml HisTrap HP column (GE Healthcare) was equilibrated with 5 CV of HisTrap
binding buffer, washed with 5 CV of HisTrap elution buffer and was re-equilibrated with 5 CV
of HisTrap binding buffer. A constant flow of 1 ml/min was used during the whole purifi-
cation protocol. The clarified sample was loaded using a 50 ml Superloop. The loop was
emptied with a distinct volume of HisTrap binding buffer that corresponded to the amount of
loaded sample. Afterwards the column was washed with 10 ml of binding buffer. The elution
was performed in a one-step procedure by applying 100 % of HisTrap elution buffer (500 mM
imidazole) for 15 ml, collecting 15 fraction of 1 ml each. The α-L-fucosidase activity was
measured in each fraction (section 3.2.6). Usually fractions 2 - 5 contained the highest amount
of enzyme and were pooled for further purification.
In order to apply a second purification step, the pooled fractions were immediately diluted
1 : 10 in SCX binding buffer (section 2.9) and were subsequently applied to the SCX as de-
scribed below.
3.2.8.3 Strong cation exchange chromatography (SCX)
As a second purification step, a strong cation exchange chromatography (SCX) was performed
using a 1 ml HiTrap SP HP column (GE Healthcare) connected to the ÄKTA Explorer system
(GE Healthcare). A constant flow of 1 ml/min was used during the whole purification protocol.
The column was equilibrated with 5 CV of SCX binding buffer (section 2.9), washed with
5 CV of SCX elution buffer and again was re-equilibrated with 5 CV of binding buffer. The
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sample was loaded using a 50 ml Superloop. The loop was emptied with approximately 40 ml
of SCX binding buffer and afterwards the column was washed with 10 ml of binding buffer.
The further washing procedure was performed using a segmented protocol. In a first step,
a linear gradient from 0 % to 40 % (400 mM NaCl) of SCX elution buffer over a length of
5 ml was used. The column was further washed with 40 % SCX elution buffer for 10 ml.
The elution of the enzyme was performed in one step by applying 100 % (1 M NaCl) of SCX
elution buffer for 15 ml. Fractions of 1 ml volume were collected and the α-L-fucosidase
activity was measured in each sample (section 3.2.6). Usually, fractions 17 - 19 contained the
highest amount of enzyme and were pooled and re-buffer into PBS as described below.
3.2.8.4 Buffer exchange via centricon
During SCX, the enzyme was eluted in an acidic buffer containing a high amount of NaCl
and had to be re-buffered into PBS prior to intravenous injection into Fuca(-/-) mice (section
3.7.3). The pooled sample (˜ 3 ml) was given into an Amicon
R© Ultra-4 Centrifugal Filter
(10,000 NMWL, for volumes up to 4 ml; Millipore) hereinafter referred to as centricon. The
sample was concentrated to 500 µl by centrifugation at 4000 x g at 4 ◦C in a swing-out rotor
(for approximately 30 min). 3.5 ml of PBS were added and the sample was again concentrated
to 500 µl by centrifugation (for approximately 45 min). This step was repeated. The final
sample was flash-frozen in liquid nitrogen and the enzyme was stored at -80 ◦C.
3.2.9 Purification of the untagged α-L-fucosidase
3.2.9.1 Fucose-affinity chromatography
Fucose-affinity chromatography was carried out using a self-made affinity matrix. N-(ε-
aminocaproyl)-β -L-fucopyranosylamine (hereinafter referred to as ligand) was coupled on
CNBr-activated sepharose beads (GE Healthcare) or on a HiTrap NHS-activated HP column
(GE Healthcare), respectively. Initially, the affinity matrices were tested separately, while the
matrices were pooled in further experiments.
5 mg of the ligand were resuspended in 300 µl H2O and were coupled to CNBr-activated
sepharose beads according to the manufacturer’s instructions. 150 µl of the ligand were di-
luted in 5 ml of coupling buffer (0.1 M NaHCO3, 0.5 M NaCl, pH 8.3). 1 g of CNBr-activated
sepharose beads was washed with 1 mM HCl and was transferred into a Mobicol column (Mo-
BiTec). The beads were incubated with the coupling solution over night at 4 ◦C by rotation
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and the affinity column was subsequently washed with 20 ml coupling buffer. In order to block
non-coupled reactive groups, the column was washed with buffers with alternating pH values
(0.1 M NaOAc pH 4.0 containing 0.5 M NaCl; 0.1 M Tris pH 8.0 containing 0.5 M NaCl) for
three times and was stored in 20 % ethanol at 4 ◦C.
2.5 mg of the ligand were resuspended in 1 ml coupling buffer (0.1 M NaHCO3, 0.5 M NaCl,
pH 8.3). The NHS-activated column was washed with 2 ml of 1 mM HCl for three times using
a syringe and the ligand was incubated on the column for 30 min at room temperature. The
affinity column was subsequently washed with 3 ml coupling buffer followed by three washing
steps using buffers with alternating alternating pH values (0.1 M NaOAc pH 4.0 containing
0.5 M NaCl; 0.1 M Tris pH 8.0 containing 0.5 M NaCl). The column was stored in 20 mM Tris
pH 7.4 containing 20 % ethanol at 4 ◦C.
Both affinity matrices were pooled and transferred into a Mobicol column. The α-L-fucosidase
purification was carried out at 4 ◦C by gravity flow. The untagged enzyme was produced using
adherently grown CHO-K1 cells (clone # C1 / A5, section 3.3.4.1). The conditioned medium
was precipitated using ammonium sulfate (section 3.2.8.1). The precipitate was centrifuged
at 8 000 x g for 30 min at 4 ◦C and the protein pellet was resuspended in a minimal volume
of binding buffer (50 mM NaOAc, 500 mM NaCl, pH 5.0). The sample was incubated on
the affinity matrix for 2 h at 4 ◦C by rotation. The flow trough was collected and the col-
umn was washed with 10 ml binding buffer. Elution was performed using 15 ml of 50 mM
NaOAc, 500 mM NaCl, 100 mM L-fucose, pH 5.0 and 1 ml fractions were collected. The
α-L-fucosidase activity (section 3.2.6) was measured in load, flow trough and washing frac-
tions, while the elution fractions were analyzed by SDS-PAGE and subsequent silver-staining
(section 3.2.4 and 3.2.4.1) and / or Western blotting (section 3.2.5).
3.2.9.2 Concanavalin A-chromatography
1 ml Concanavalin A (ConA)-beads were transferred into a Mobicol column and equilibrated
with binding buffer (20 mM Tris, 500 mM NaCl, 1 mM CaCl2, 1 mM MnCl2, pH 7.4). The pu-
rification of the untagged α-L-fucosidase was carried out at 4 ◦C by gravity flow as described
in section 3.2.9.1. 50 mM NaOAc, 500 mM NaCl, 1 M α-D-methylglucoside, pH 4.5 was used
as elution buffer. The α-L-fucosidase activity (section 3.2.6) was subsequently measured in
each fraction.
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3.2.9.3 Ion exchange and Ni2+-affinity chromatography
The untagged α-L-fucosidase was produced using adherently grown CHO-K1 cells (clone
# C1 / A5, section 3.3.4.1). The conditioned medium was precipitated using ammonium sul-
fate (section 3.2.8.1). The precipitate was centrifuged at 8 000 x g for 30 min at 4 ◦C and
the protein pellet was resuspended in a minimal volume of binding buffer. The sample was
clarified by centrifugation for three times at 18 000 x g for 30 min at 4 ◦C and subsequent filtra-
tion using 0.22 µm syringe filters. The α-L-fucosidase was purified either by a strong cation
exchange chromatography (HiTrap SP HP 1 ml column, GE Healthcare), a weak anion ex-
change chromatography (HiTrap DEAE FF 1 ml column, GE Healthcare) or a Ni2+-affinity
chromatography (HisTrap HP 1 ml cloumn, GE Healthcare). The columns were connected
to the ÄKTA Explorer system (GE Healthcare) and were washed with 5 ml binding buffer,
followed by 5 ml elution buffer and were re-equilibrated with 5 ml binding buffer. The clari-
fied sample was loaded using a 5 ml sample loop and the column was subsequently was with
10 ml binding buffer. Elution was performed using an linear elution gradient from 0 % - 100 %
elution buffer over 15 ml followed by a washing step using 100 % elution buffer over 5 ml.
Fractions of 1 ml were collected and analyzed for α-L-fucosidase activity (section 3.2.6). The
purity of the enzyme was determined by SDS-PAGE (section 3.2.4) and subsequent silver-
staining (section 3.2.4.1).
HiTrap SP HP binding buffer 50 mM NaOAc pH 4.0 or 4.5 or 5.0 or 7.4
HiTrap SP HP elution buffer 50 mM NaOAc, 1 M NaCl pH 4.0 or 4.5 or 5.0 or 7.4
HiTrap DEAE FF binding buffer 10 mM Tris pH 4.6 or 8.0
HiTrap DEAE FF elution buffer 10 mM Tris, 1 M NaCl pH 4.6 or 8.0
HisTrap HP binding buffer 10 mM Tris, 500 mM NaCl pH 7.4
HisTrap HP elution buffer 10 mM Tris, 500 mM NaCl, 500 mM imidazole pH 7.4
3.2.10 Size-exclusion chromatography
A possible oligomerization of the α-L-fucosidase was analyzed by size exclusion chromato-
graphy. The native murine as well as the recombinant human enzyme (untagged and His6-
tagged) were analyzed at different pH values. With respect to the murine α-L-fucosidase,
freshly isolated tritosomes were pelleted (section 3.2.1.1), resuspended in 100 µl PBS pH 7.4
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or McIlvaine’s buffer pH 4.6 (McIlvaine 1921) supplemented with 140 mM NaCl and were
lysed by sonification. The sample was loaded using a 100 µl loop. The human His6-tagged
enzyme was purified by a Ni2+-affinity chromatography followed by an strong cation ex-
change chromatography (section 3.2.8.2 and 3.2.8.3) whereas the untagged enzyme was puri-
fied by SCX only (section 3.2.9.3). The fractions containing the highest α-L-fucosidase ac-
tivity were dialyzed over night against PBS pH 7.4 or McIlvaine’s buffer pH 4.6 supplemented
with 140 mM NaCl. 100 µl sample were loaded on a Supderdex 200 10/300 GL column (GE
Healthcare) connected to the Äkta Ettan LC system (GE Healthcare) at a constant flow rate
of 0.3 ml/min. Fractions of 250 µl volume were collected. The α-L-fucosidase was detected
by activity measurements (section 3.2.6). As an internal control the oligomerization of the
β -hexosaminidase as well as the Plbd2 was analyzed using the fractions received during ana-
lysis of tritosomes. β -hexosaminidase was detected by activity measurements (section 3.2.7)
whereas Plbd2 oligomerization was detected by Western blotting (section 3.2.5).
Prior to the sample runs, identical standard runs in PBS as well as in McIlvaine’s buffer
pH 4.6 supplemented with 140 mM NaCl were performed. Thyroglobulin (669 kDA), ferritin
(440 kDa), bovine serum albumin (65 kDa), ovalbumin (45 kDa) and cytochrom C (12.5 kDa)
were applied and detected by measuring the UV absorbance. The corresponding calibration
curve was used to determine the molecular weight of the α-L-fucosidase.
3.2.11 Affinity chromatography using a mannose-6-phosphate receptor
(MPR) matrix
A mannose-6-phosphate receptor (MPR) matrix was used to quantify the amount of mannose-
6-phosphorylation on purified His6-tagged α-L-fucosidase (section 3.2.8). 20 µg of the en-
zyme were diluted in 1 ml of MPR-binding buffer and loaded over night at 4 ◦C on an Affigel-
10-based-affinity matrix (Bio-Rad) to which a 1 : 1 mixture of MPR46 : MPR300 (2.5 mg/ml;
purified from goat) was immobilized (Braulke et al. 1990; kind gift of Siva Kumar, Hyderabad,
India). Prior to sample loading the column was equilibrated using 10 ml of binding buffer. All
steps were carried out by gravity flow using pre-cooled buffers. The flow through was col-
lected and the column was washed with 8 ml of binding buffer followed by 6 ml of washing
buffer. The enzyme was eluted using 10 ml of elution buffer. Finally the column was washed
with 5 ml of acidic elution buffer and subsequently stored at 4 ◦C in 20 % ethanol. The α-L-
fucosidase activity was measured using pNPF as substrate and 50 µl of each fraction (section
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MPR binding buffer 50 mM imidazole-HCl, pH 6.5
0.15 M NaCl
5 mM sodium β -glycerophosphate
10 mM MgCl2
2 mM EDTA
0.05 % Triton X-100
0.02 % sodium azide
MPR washing buffer MPR binding buffer
+ 5 mM glucose-6-phosphate
MPR elution buffer MPR binding buffer
+ 5 mM mannose-6-phosphate
acidic elution buffer 0.1 M sodium acetate, pH 4,5
1 M NaCl
0.05 % Triton X-100
0.02 % sodium azide
3.2.6). Moreover 1/20th of each fraction was pelleted by TCA-precipitation and analyzed by
Western blotting (section 3.2.12).
3.2.12 TCA-precipitation
TCA-precipitation was used to pellet low-concentrated protein samples. In order to reach the
critical protein concentration for precipitation, cytochrom C (10 mg/ml in dH2O) was added
to a final concentration of 1 mg/ml. 0.02%˙ sodium deoxycholate was added and the samples
were mixed and incubated on ice for 30 min. Afterwards 15 % (v/v) trichloroacetic acid was
added and the samples were mixed and incubated over night at 4 ◦C. At the next day, the
samples were centrifuged at 4 ◦C for 10 min at 15 000 x g. The supernatant was discarded
and the protein pellet resuspended in 1 ml of ice-cold acetone. The samples were vigorously
mixed, incubated at room temperature for 5 min and again centrifuged. This step was repeated.
Finally the dried protein pellet was resuspended in 50 µl of 2 x Laemmli buffer (section 2.9)
by incubation at 37 ◦C for 30 min and was then denatured at 95 ◦C for 5 min. The samples
were further analyzed by Western blotting (section 3.2.5).
66
3.3 Cell culture methods
3.3 Cell culture methods
3.3.1 General cell culture conditions in the presence of 10 % FCS
Usually, cell lines were grown adherently in sterile cell culture flasks in DMEM standard
medium containing 10 % FCS (section 2.9) at 37 ◦C, 5 % CO2 and 99 % humidity. After 2 -
3 days the cells had reached confluence and had to be passaged. The culture medium was
discarded, the cells washed once with PBS and treated with 1.5 ml or 0.5 ml trypsin-EDTA (in
case of a T75 or a T25 flask, respectively). After a few minutes it was verified microscopically
that the cells had detached from the surface. 8.5 ml or 4.5 ml of DMEM standard medium
were added and the cells were resuspended by pipetting. The cultures were split in a ration of
1 : 2 to 1 : 10 depending on the desired cell density. The cell culture flask was filled up with
DMEM standard medium to 10 ml or 3 ml in case of a T75 or a T25 flask, respectively.
3.3.2 Cryo-conservation and thawing
For cryo-conservation, the cells were grown to confluence in a T75 flask. They were trypsinized
as described above and pelleted by centrifugation at 250 x g for 3 min. The supernatant was
discarded and the cells were resuspended in a suitable volume of cryo-conservation medium
(section 2.9). They were frozen in 1 ml aliquots in cryotubes overnight at -80 ◦C. For long
term storage the cultures were transferred to -150 ◦C.
Frozen cells were thawed in a water bath at 37 ◦C and immediately transferred into 10 ml
of culture medium (usually DMEM standard medium containing 10 % FCS). The cells were
pelleted at 250 x g for 3 min and the supernatant was discarded to remove DMSO from the
cryo-conservation medium. The cells were resuspended in 3 ml of culture medium and trans-
ferred to a T25 cell culture flask.
3.3.3 Transfection
Transfections were performed using Polyethylenimine (PEI) as transfection reagent. PEI is
a highly branched polymer and contains positively charged amino groups on its surface that
interact with the negatively charged DNA. The PEI-DNA complex is endocytosed by the cells
and enters the cytoplasm. During cell divisions the DNA can be incorporated into the nucleus
and can be randomly integrated into the host cell genome (stable transfection). Otherwise the
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transfected DNA gets lost within a few cell cycles (transient transfection). For transfection,
cells were grown to 70 - 80 % confluence. The transfection mixture was prepared using serum-
free OptiMEM medium, to avoid interactions of FCS during DNA-PEI complex formation.
The transfection mixture was incubated for 15 min at room temperature. Meanwhile the cell
culture medium of the cells was exchanged. The transfection mixture was added to the cells,
incubated for 5h under standard cell culture conditions (section 3.3.1) and the cell culture
medium was subsequently exchanged to reduce toxicity of the PEI reagent.
3.3.3.1 Transient transfection
Transient transfections promote high expression rates of the transfected gene. However, cells,
that have stably integrated the desired DNA sequence are not selected. For transient trans-
fections, cells were usually seeded in a 6 cm cell culture dish. The transfection mixture was
prepared by adding 1 µg DNA and 3 µl PEI solution to 100 µl OptiMEM medium. The cells
were harvested after 24 - 72 h and cell homogenates were prepared as described in section
3.2.2.
For immunofluorescence, cells were seeded on PLL-coated cover slips (section 3.4.1) in 24-
well plates and transfected using 0.5 µg DNA and 1.5 µl PEI solution (in 100 µl OptiMEM
medium). Immunofluorescence staining (section 3.4.2) was performed after 24 h - 48 h.
3.3.3.2 Stable transfection and isolation of single cell clones
CHO-K1 cells were stable transfected with an expression plasmid carrying either the co-
ding sequence for the human His6-tagged α-L-fucosidase or the human untagged enzyme
(pcDNA3.1Hygro(+)hFuca-His6 or pcDNA3.1Hygro(+)hFuca). Cells were grown to 70 - 80 %
confluence in a 6-well plate. 5 µg of the respective plasmid were added to 15 µl PEI solution
and 100 µl OptiMEM medium. After 24 h, the cells were trypsinized and 1/5 of the cells was
seeded on a 10 cm cell culture dish in DMEM standard medium (section 2.9) supplemented
with 100 µg/ml hygromycin to select stable transfected cells. At the next day the hygromycin
concentration was raised to 800 µg/ml (selective growth medium). All untransfected cells
died within a few days, whereas the transfected cells survived. Single cell clones were visible
within 2 - 3 weeks and trypsinized using cloning rings. The cell clones were seeded in 24-
well plates and grown to confluence in selective growth medium. Then the cells were treated
with FCS-free DMEM to promote secretion of the fucosidase. The cell culture supernatant
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was harvested after 24 h and the cells were further grown in selective growth medium. The
supernatant was used to measure the α-L-fucosidase activity (section 3.2.6). The cell clone
possessing the highest enzyme production capacity was further expanded and then subjected to
a limited dilution assay. Therefore the cells were trypsinized, the cell number was determined
and the cells were seeded with a concentration of 0.5 cells/well in several 96-well plates using
selective growth medium. Due to this cell concentration, it was ensured, that one cell at a ma-
ximum was seeded per well. Single cell clones were grown to confluence after approximately
3 weeks and were further expanded in 24-well plates. As described above, the α-L-fucosidase
activity was measured in the cell culture supernatant. The cell clones possessing the highest
enzyme production capacity was further expanded using DMEM standard medium and used
for enzyme production (section 3.3.4).
3.3.4 Cell culture conditions for protein production
Stable transfected CHO-K1 cells (section 3.3.3.2) were used for production of recombinant
human α-L-fucosidase (either untagged or His6-tagged). Conditions for maximal enzyme
secretion were initially established for adherent cells. Later, cells were also adapted to FCS-
free suspension conditions.
3.3.4.1 Adherent culture conditions in the presence of 0.5 % FCS
The α-L-fucosidase was produced in the presence of 0.5 % FCS. Cells were adherently grown
on 16 cm cell culture dishes (usually 25 - 30 dishes were used for one production cycle) using
DMEM standard medium (section 2.9) supplemented with 10 % FCS. After reaching conflu-
ence, cells were thoroughly washed with PBS for two times and then cultivated using DMEM
standard medium supplemented with 0.5 % FCS. The diminished FCS concentration inhibited
further cell divisions and promoted enzyme production and secretion. However, a cultivation
in FCS-free DMEM was not possible, as the cells died within a few days. 20 ml of production
medium was added to each 16 cm dish and the cell culture supernatant was harvested every
second day for four times. A further cultivation was not efficient as the α-L-fucosidase pro-
duction decreased massively after the fourth harvest. The supernatant was further processed as
described in section 3.2.8 and used for α-L-fucosidase purification. Usually the supernatants
of the first and second as well as of the third and fourth harvest were combined, respectively
(approximately 1 L) and purified immediately.
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3.3.4.2 Conditions for serum-free suspension culture
A cultivation under serum-free suspension conditions is often favorable, because the FCS as a
contaminant is removed and eases protein purification. Moreover the cells often reach a higher
protein production capacity under serum-free culture conditions.
Stably transfected CHO-K1 cells were usually grown adherently in DMEM standard medium
containing 10 % FCS. During adaption to serum-free conditions, the standard medium was
mixed with serum-free Corning R© PF medium (Corning). Culture conditions of 36.5◦C, 6 %
CO2 and 99 % humidity were chosen. Initially, a concentration of 25 % serum-free medium
was used and then raised to 50 %, 75 %, 90 % and finally 100 % of Corning R© PF medium was
used. The cells were grown under each condition for a minimum of two passages. Starting
with 75 % of serum-free medium, the cells were detached from the culture flask using the Try-
pLE reagent instead of trypsin-EDTA, as the diminished amount of FCS was not sufficient to
inhibit trypsin. After two passages in 100 % Corning R© PF medium, the cells detached auto-
matically from the cell culture flask and started to grow as spheres in suspension. They were
harvested by centrifugation at 250 x g for 3 min and were separated by resuspension in TrypLE
reagent and incubation at 37 ◦C. Afterwards, the cells were resuspended in PBS, pelleted by
centrifugation at 250 x g for 3 min and finally resuspended in Corning R© PF medium. The cell
number was measured (section 3.3.7) and adjusted to 5 x 105 viable cells/ml. The cells were
grown as 30 ml culture in Corning R© shake flasks at 36.5 ◦C, 6 % CO2, 99 % humidity and
125 rpm. After two weeks of adaption, the starting cell culture concentration was decreased to
3 x 105 viable cells/ml. A density of 3 - 4 x 106 viable cells/ml was reached after 4 - 5 days and
a subculturing was performed by dilution of an appropriate amount of cells.
3.3.5 Primary mouse embryonic fibroblasts (MEFs)
3.3.5.1 Isolation of MEFs
Primary mouse embryonic fibroblasts (MEFs) were isolated from mouse embryos obtained
from matings of heterozygous Fuca1+/- mice. Hence, wildtype, Fuca1+/- and Fuca1-/- em-
bryos were obtained. MEFs were isolated at embryonic day 12.5. The embryos were washed
with PBS. The visceral tissues were removed and the head was dissected and used for geno-
typing (section 3.1.6.4; heterozygous cultures were discarded immediately after genotyping).
The remaining embryonic tissue was transferred into a 2 ml tube, covered with 0.5 ml trypsin-
EDTA and cut into small pieces. The tissue was transferred into a sterile Erlenmeyer flask
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containing two layers of glass beads (3 mm diameter) and was dissociated by incubation for
15 min at 37 ◦C meanwhile shaking every 5 min. Afterwards the tissue was resuspended by
adding 5 ml of DMEM standard medium containing 10 % FCS (section 2.9). The cells were
dissociated by pipetting with a Pasteur pipette, transferred into a 15 ml tube and centrifuged
at 250 x g for 3 min. The supernatant was discarded and the cells were resuspended in 5 ml of
DMEM standard medium containing 10 % FCS and grown in a T25 cell culture flask. On the
following day the medium was changed to remove dead cells. Approximately after two days
the cells had grown to confluence and were trypsinized and splitted (passage 1). A part of the
cells was collected as backup by cryo-conservation (section 3.3.2). Usually at passage 2 the
cells were transfected for further immortalization as described below.
3.3.5.2 Immortalization of MEFs
Wildtype and Fuca1-/- MEFs were immortalized by transfecting the pMSSVLT plasmid car-
rying the CDS of the SV40 large T-antigen as well as a neomycin resistance cassette. MEFs
were grown to 80 % confluence in a T25 cell culture flask (usually at passage 2). 5 µg of the
pMSSVLT plasmid were added to 100 µl OptiMEM medium and mixed with 15 µl PEI. The
sample was incubated for 15 min at room temperature. Meanwhile the cell culture medium of
the MEFs was exchanged. The transfection mixture was added to the cells, incubated for 5 h
under standard cell culture conditions (section 3.3.1) and afterwards the cell culture medium
was exchanged. Transfected cells were selected after 24 h by adding G418 (500 µg/µl) to the
medium.
Due to selection with G418 untransfected wildtype cells died within a few days. Transfected
cell clones were visible after 2 - 3 weeks. Cells were trypsinized and mixed cell clones were
established. The wildtype MEF cell lines were intensively passaged every 2 - 3 days for up to
6 weeks to promote selection of rapidly dividing (immortalized) cells. An increase in proli-
feration rate was observed over time.
Selection of transfected Fuca1-/- cells was not possible using G418 as all Fuca1-/- cells already
contained a neomycin resistance cassette that was integrated into exon 1 of the Fuca1 gene to
disrupt its open reading frame (section 4.1.1). However, transfected cells were enriched by
intensive passaging of the Fuca1-/- cultures using selection medium. Approximately after
passage 5 - 8, a massive decrease in proliferation rate was observed as all untransfected cells
reached the Hayflick limit and entered a cell cycle arrest. Further passages were not necessary
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until cell clones of transfected Fuca1-/- cells were visible after several weeks. Of note, the
immortalization of the Fuca1-/- MEFs could have also occurred spontaneously rather than by
transfection. As described for the wildtype cell lines, mixed cell clones were established and
immortalized Fuca1-/- cells were further selected by intensive passaging for up to 6 weeks.
Again, an increase in proliferation rate was observed over time.
3.3.6 Endocytosis
For endocytosis experiments, wildtype and Fuca1-/- MEFs were grown to 80 % confluence in
6 cm cell culture dish. The cell culture medium was discarded and the cells were washed with
PBS for two times. The cells were subsequently cultured in 1.5 ml of DMEM containing 0.1 %
BSA. After 1 h, purified recombinant His6-tagged α-L-fucosidase was added (20 µg/ml) and
incubated for 5 h under standard cell culture conditions (section -3.3.1). Finally the cells were
harvested by trypsination, cell lysates were prepared (section 3.2.2) and the α-L-fucosidase
activity was determined (section 3.2.6). Of note, a thorough trypsination was mandatory, as
the recombinant enzyme sticked tightly to the surface of the cells. Hence, the cell surface
proteins had to be thoroughly digested with trypsin, as false positive results were obtained,
when the cells were harvested by scraping.
3.3.7 Determination of cell numbers
For determination of cell numbers, an aliquot of trypsinized cells or an aliquot of cells cul-
tivated under suspension conditions was used. 20 µl of the cell suspension were mixed with
20 µl of trypan blue solution (1 : 4 diluted in PBS) and 10 µl were added into a cell counting
chamber (Innovartis). Cell number was measured in duplicates using the cell counter Cedex
XS (Innovartis).
3.4 Cell biological methods
3.4.1 Coating of cover slips with poly-L-lysine
For immunofluorescence stainings, mammalian cells were seeded on cover slips, that were
coated with Poly-L-lysine (PLL). The cover slips were treated with acetone for 30 min and
washed thoroughly with dH2O for three times. 0.01 % PLL (w/v) was added and incubated
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over night at 4 ◦C. Again the cover slips were washed with dH2O for three times, dried for
2 h in a sterile air flow and were sterilized with UV-light for 10 min. Coated cover slips were
stored at room temperature until usage.
3.4.2 Immunofluorescence staining of mammalian cells
For immunofluorescence staining, mammalian cells were seeded on PLL-coated cover slips
(section 3.4.1) in 24-well plates. After attachment, cells were either transfected and grown
for 24 h - 48 h (section 3.3.3.1) or were directly processed. Fixation was performed either
by using 4 % para-formaldehyde (PFA) or by using methanol. All steps were performed in
24-well plates, except for the antibody and DAPI stainings. Therefore, the cover slips were
incubated up-side down in a 50 µl drop of staining solution in a wet chamber.
Regarding PFA-fixation, cells were washed three times with PBS and incubated for 20 min
in 4 % PFA-solution (in PBS). Afterwards the cells were washed again with PBS for three
times and permeabilized for 5 min with 0.2 % saponin (in PBS; S-PBS). Autofluorescence was
quenched by incubation in 0.12 % glycine (in S-PBS) for 10 min. The cells were washed with
S-PBS and blocked for 30 min in 10 % FCS (in S-PBS) and were further applied to antibody
staining as described below.
For methanol fixation, cells were washed with PBS for three times and incubated with cold
methanol for 10 min at -20 ◦C. For re-hydration the cells were thoroughly washed with PBS for
three times. An additional permeabilization step was not necessary, as methanol automatically
permeabilized the cells. A blocking step was performed by incubation for 30 min in 1 % BSA
(in PBS). The cells were further applied to the antibody staining as described below.
After blocking of unspecific binding sites, the cells were incubated over night with the pri-
mary antibody in 1 % goat-serum (in S-PBS) at 4 ◦C. At the next day, the cells were washed
with S-PBS for four times and incubated with the Alexa Fluor R©-coupled secondary antibody
(1 : 2000 in 1 % goat-serum in S-PBS) for 2 h at room temperature. Again, the cells were
washed for four times in S-PBS followed by two washing steps in dH2O. Cell nuclei were
stained in DAPI solution (1 : 1000 in S-PBS; DAPI stock: 1 mg/ml) for 20 sec. Afterwards the
cover slips were shortly dipped in dH2O and mounted in Mowiol/Dabco on an object holder.
The mounting solution was allowed to dry over night at room temperature and the immuno-
fluorescence staining was documented using a confocal laser-scanning microscope (LSM700,
Zeiss).
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3.5 Histological methods
3.5.1 Generation of tissue sections
All histological stainings were performed using 35 µm-thick free-floating tissue sections.
Therefore, mouse organs were actively perfused with 4 % para-formaldehyde (section 3.7.2)
and placed on the organ holder of an SM 2000R microtome (Leica). The microtome was
cooled down with dry ice. Organs were frozen on a layer of 5 % sucrose (in PB-buffer) and
embedded using 30 % sucrose (in PB-buffer). The organs were cut into 35 µm-thick sections
and transferred into 24-well plates with an brush. The tissue sections were stored at 4 ◦C in
PB-buffer containing 0.02 % sodium azide.
3.5.2 Immunofluorescence staining of tissue sections
Free-floating tissue sections (section 3.5.1) were transferred into 24-well plates using a brush
and washed three times with PB-buffer to remove sodium azide. Permeabilization of the
sections and blocking of unspecific binding sites was performed by incubation in PB-buffer
containing 0.5 % Triton X-100 as well as 4 % goat serum (blocking solution) for 2 h at room
temperature. Then the tissue sections were treated with primary antibody diluted in blocking
solution over night at 4 ◦C. At the next day, the sections were washed three times with PB-
buffer containing 0.25 % Triton X-100 (washing solution) and incubated with Alexa Fluor R©-
coupled secondary antibody (1 : 2000 in washing solution) for 2 h at room temperature. The
sections were washed once. Cell nuclei were stained for 10 min in DAPI solution (1 : 1000 in
washing solution; DAPI stock: 1 mg/ml). The sections were washed once again in PB buffer
without Triton X-100 and then transferred onto object holders using a brush. The sections
were mounted with Mowiol/Dabco and the mounting solution was allowed to dry over night
at room temperature. The immunofluorescence staining was documented using a confocal
laser-scanning microscope (LSM700, Zeiss).
Lectins are complex carbohydrate-binding proteins. They exhibit a high specificity for certain
sugar moieties but possess no intrinsic enzyme activity. Biotinylated lectins were used in
histological analyses and detected using Alexa Flour R©-coupled streptavidin. Unfortunately,
a co-staining with other antibodies (e. g. Lamp1 for lysosomes) was not possible, due to
incompatible blocking steps during the staining protocol. However, an α-aquaporin2 antibody
could be applied and was used as a marker for renal collecting ducts. For immunofluorescence
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stainings using lectins (Aleuria aurentia and Lens culinaris) all blocking steps were performed
using 1 % BSA instead of 4 % goat serum. The lectins were detected using Dye-Light R© 594-
coupled streptavidin.
3.5.3 Staining of unesterified cholesterol using filipin
Filipin staining was performed on free floating sections (section 3.5.1). Sections were per-
meabilized, blocked and autofluorescence was quenched with 1 % BSA, 0.15 % glycine and
0.02 % saponin in PBS for 1.5 h (washing solution). Filipin was resuspended as 0.1 % stock-
solution in 10 % DMSO in PB buffer. Unesterified cholesterol was stained by applying
0.005 % Filipin (diluted in PBS) for 30 min. The sections were washed for three times with
washing solution, followed by three washes with PBS and were finally mounted with Mowiol/
Dabco and were analyzed with a Leica DM5000B epi-fluorescence microscope (excitation
filter BP340-380; dichromatic mirror 400; suppression filter LP425).
3.5.4 Staining of lipids using sudan black
1 g Sudan Black B was resuspended in 100 ml 70 % ethanol by boiling. The solution was im-
mediately used after cooling down and filtration. The staining was performed on free floating
sections (section 3.5.1). The sections were treated with 50 % ethanol for 10 min, covered with
the Sudan Black B solution for 5 min and washed three times with 70 % ethanol. Sections were
incubated in dH2O for 10 min and counterstained with Nuclear Fast Red for 5 min and finally
washed three times with dH2O. The sections were mounted with Mowiol and documented
with a Leica DM IRB microscope.
3.5.5 Light and transmission electron microscopy (TEM)
Histological analysis of mouse organs by light and transmission electron microscopy (TEM)
was done by Prof. Dr. Renate Lüllmann-Rauch (University of Kiel, Germany). Briefly, mice
were perfused with glutaraldehyde (section 3.7.2) and tissue blocks were post-fixed with 2 %
osmium tetroxide and embedded in araldite. Semithin sections were stained with toluidine
blue. Ultrathin sections were processed with uranyl acetate and lead citrate and analyzed with
a Zeiss EM 900 electron microscope (Zeiss).
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3.6 Glycobiological methods
3.6.1 Isolation of neutral oligosaccharides
Neutral oligosaccharides were isolated from mouse tissues according to the method described
by Stinchi et al. (1999). 100 mg tissue (fresh weight) were homogenized in the 20 x volume
of dH2O using an ULTRA-TURRAX (IKA) and were lysed by sonification at 4 ◦C using a
sonifier 450 (Branson; 3 x 20 sec pulses, 40 % intensity). 2.6 ml methanol were added per
600 µl tissue homogenate, were rigorously mixed and centrifuged at 3650 x g for 10 min at
4 ◦C. The pellet was resuspended in 1.3 ml of 80 % methanol per 600 µl tissue homogenate,
was mixed and again centrifuged. Both supernatants were combined and 910 µl chloroform
were added per 600 µl tissue homogenate, mixed and centrifuged at 2000 x g for 5 min at 4 ◦C.
The supernatant was mixed with 2.72 ml dH2O per 600 µl tissue homogenate and centrifuged
at 3650 x g for 10 min at 4 ◦C. The water-soluble fraction was collected and incubated with
250 mg of a mixed-bed ion exchange resin (AG 501-X8, 20-50 mesh) over night at 4 ◦C.
The unbound material was lyophilized and resuspended in 1 µl dH2O per 1 mg tissue (fresh
weight).
3.6.2 In-vitro digest of fucosidosis storage material
Neutral oligosaccharides were isolated from mouse tissues as described in section 3.6.1. 20 µl
(according to 20 mg of fresh weight tissue) were treated with 100 mU of purified His6-tagged
α-L-fucosidase (section 3.2.8). 100 µl of activity buffer (0.1 M sodium citrate pH 5.5 includ-
ing 0.2 % BSA and 0.04 % sodium azide) were added and the reactions were filled up with
dH2O to a final volume of 200 µl. As internal control, reactions were prepared adding activity
buffer instead of enzyme. All reactions were performed as triplicates and incubated at 37 ◦C
for 3 days. The proteins were precipitated by incubation at 95 ◦C for 5 min and centrifugation
at 18 000 x g for 15 min. The supernatant was desalted by incubation with 50 mg of a mixed-
bed ion exchange resin (AG 501-X8, 20-50 mesh) over night at 4 ◦C. The unbound material
was lyophilized and resuspended in 20 µl dH2O.
3.6.3 Isolation of lipids
Lipids were isolated from mouse tissues according to the method described by Kyrklund
(1987). 150 mg tissue (fresh weight) were homogenized in the 13.33 x volume of methanol
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(2 ml) using an ULTRA-TURRAX (IKA). 1 ml chloroform was added, mixed and incubated
at room temperature for 15 min. The samples were centrifuged at 1000 x g for 10 min at 4 ◦C
and the pellet was resuspended in 2 ml methanol. Again, 1 ml chloroform was added, mixed
and incubated at room temperature for 15 min. The samples were centrifuged and both super-
natants were combined.
The isolated lipids were desalted using Sep-Pak R© Vac 6cc (1g) C18 cartidges (Waters) and
were separated into two fraction by a sequentional elution procedure. Fraction I contained
gangliosides, acidic phospholipids and sulfatides whereas fraction II contained neutral phos-
pholipids. The columns were washed with 6 ml chloroform : mehtanol (1 : 2) followed by
3 ml methanol. 6 ml isolated lipids were added to 8 ml methanol : dH2O (1 : 1) and applied
to the column. The flow through was collected and 8 ml methanol : 0.9 % NaCl (1 : 1) were
added and applied to the same column. This step was repeated. The final flow through
was discarded and the column washed with 2 ml dH2O to remove contaminating salts. Frac-
tion I was eluted using 8 ml methanol : dH2O (12 : 1) whereas fraction II was eluted using 8 ml
chloroform : methanol (1 : 2). The column was washed with 5 ml methanol, equilibrated with
8 ml chloroform : methanol : 0.1 M KCl (3 : 48 : 47) and stored at room temperature. The lipid-
containing fractions were lyophilized and resuspended in 1 µl methanol per 1 mg tissue (fresh
weight).
3.6.4 Thin-layer chromatography (TLC)
Isolated neutral oligosaccharides (section 3.6.1) or lipids (section 3.6.3) were separated by
thin-layer chromatography (TLC) on silica gel F60 plates (20 x 20; Merck). Prior to sample
application, the plates were heated at 120 ◦C for 15 min. The samples were spotted semi-
automated on the plates using the Linomat 5 application system (Camag) and a Hamilton
syringe. For analytical TLCs, material corresponding to 10 mg of mouse tissues was loaded
whereas material corresponding up to 25 mg of mouse tissue was loaded for preparative TLCs.
The plates were dried for 1 h at room temperature and developed in running buffer (table 3.14)
in a saturated atmosphere in TLC tanks for 16 h (neutral oligosaccharides), 1.75 h (lipids,
fraction I) or 1 h (lipids, fraction II). The plates were dried for 1 h at room temperature and
5 min at 120 ◦C and were sprayed with staining solution (table 3.14). The plates were heated at
120 ◦C for approximately 5 min until the desired staining intensity was reached. The staining
was documented using a CCD-camera (Fuji-Film).
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Table 3.14: TLC running buffers and staining solutions
running buffer for neutral oligosaccharides acetic acid : dH2O (75 : 25)
running buffer for lipids (fraction I) chloroform : methanol : 0.25 % CaCl (60 : 35 : 8)
staining solution for neutral oligosaccha-
rides and lipids (fraction I)
0.2 % orcinol in 20 % H2SO4 in dH2O
running buffer for lipids (fraction II) chloroform : methanol : dH2O (65 : 25 : 4)
staining solution for lipids (fraction II) 20 % H2SO4 in dH2O
3.6.5 Identification of fucosidosis storage material by mass spectrometry
Neutral oligosaccharides were separated on a preparative TLC. The TLC was done as duplicate
(section 3.6.4). One TLC plate was stained for carbohydrates. The retention-values of single
glycocompounds were measured and the corresponding material was scraped off from the
second undeveloped plate. The compounds were dissolved from the silica material by adding
100 µl dH2O and incubation for 30 min at room temperature and were analyzed by HPLC-
MS by Dr. Hans Christian Beck (Odense University Hospital, Denmark). Urine material was
directly analyzed by HPLC-MS. Briefly, the samples were centrifuged at 14 000 x g for 20 min
and 10 µl extract were mixed with 10 µl of a 0.01 nmol/µl maltotriose internal standard. The
mixture was dried in an Eppendorf Concentrator and re-dissolved in 10 µl derivatization buffer
(64 mg/ml sodium-cyanoborohydride and 41 mg/ml 2-aminobenzamide dissolved in a mixture
of dimethylsulfoxide and acetic acid (v/v 7 : 3)) and incubated for 3 h at 70 ◦C followed by
evaporation to dryness. After drying, the samples were re-dissolved in 50 µl acetonitrile/0.1 %
TFA and were analyzed by hydrophilic interaction chromatography (HILIC) using a Dionex
Ultimate 3000 HPLC system coupled to a Q-Exactive Orbitrap mass spectrometer (Thermo
Scientific).
The oligosaccharides were separated on a 100 mm x 100 µm ID column packed with TSK-gel
Amide-80 column material (Tosoh Bioscience LLC, PA, USA) by a 5 min gradient from 95 %
to 86 % organic solvent (100 % ACN/0.1 % TFA) followed by a 30 min gradient from 86 % to
70 % organic solvent at a 900 nl/min flow.
The 2-AB-derivatized internal standard and the storage material of unknown structure were
quantified by correlating the peak area obtained from 2-AB-derivatized internal standard (2-
AB-maltodextrose; m/z 625.24) with peak areas of the detected species of unknown concen-
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trations. The identities of the unknown storage material were based on molecular weights and
fragmentation patterns as determined by electrospray ionization tandem mass spectrometry.
3.6.6 PNGase F digest
The glycosylation pattern of the recombinant His6-tagged α-L-fucosidase was determined by
PNGase F and EndoH digest. 10 µl (approximately 80 µg) of the purified enzyme were used
and 10 µl H2O, 5 µl 2 % SDS and 5 µl 1 M β -mercaptoethanol were added and the sample
was denatured for 5 min at 95 ◦C. Afterwards, 5 µl 1 M Tris-HCl, 100 mM EDTA pH 8.0 in
case of PNGase F or 100 mM NaOAc pH 5.5 were added as well as 5 µl 10 mM PMSF, 5 µl
10 % Triton X-100 and 2 µl PNGase F or 2 µl EndoH. The reactions were incubated at 37 ◦C
over night and were further processed for SDS-PAGE (section 3.2.4) and were analyzed by
Western blotting (section 3.2.5).
3.7 Animal handling
3.7.1 Mouse housing
Mice were housed in the central animal facility of the Bielefeld University (Germany) under
standard and sterile housing conditions. Animals were allowed to eat and drink ad libidtum.
3.7.2 Perfusion
Mice were narcotized using 0.65 mg ketamine per 10 g body weight for analgesia and 0.13 mg
xylazin and 0.02 mg acepromazin per 10 g body weight for narcosis. After approximately
ten minutes the animals were free of pain reactions. The thorax was opened using scissors
and a butterfly needle was introduced into the left ventricle of the heart. PB-buffer including
1 % procaine (washing solution) was injected with a flow rate of 10 ml/min using a peristaltic
pump. Directly after starting the perfusion, the right ventricle of the heart was cut open. After
injecting 50 ml of washing solution, the mouse tissues were fixed with 50 mL 4 % (w/v) para-
formaldehyde or 6 % glutaraldehyde (v/v) in PB-buffer including 1 % procaine (perfusion so-
lution). The PFA-fixed tissues (liver, kidney, spleen and brain) were dissected, subsequently
treated with perfusion solution for 24 h and then stored at 4 ◦C in 30 % (w/v) sucrose in PB-
buffer. The tissues were further cut into free-floating sections (section 3.5.1). Glutaraldehyde-
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fixed animals were transferred into a 50 ml falcon, stored in perfusion solution and shipped to
the University of Kiel (Germany) for further light and electron microscopic analysis (section
3.5.5) by Prof. Dr. Renate Lüllmann-Rauch.
3.7.3 Intravenous injection
Purified His6-tagged α-L-fucosidase (section 3.2.8) or PBS (as control) was injected intra-
venously into the tail vein of mice. The animals were fixed using a mouse restrainer and
the tail was pre-warmed in warm water to enhance visibility of the tail vein. 250 mU of pre-
warmed enzyme per 1 g body weight (according to approximately 200 µl) were injected.
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4.1 Generation and characterization of a constitutive
fucosidosis mouse model
4.1.1 Generation of Fuca1(-/-) mice
α-L-Fucosidase knock-out mice (Fuca1(-/-)) were generated by a gene targeting strategy. A
6-kb fragment of the murine Fuca1 gene including exon 1 and exon 2 was amplified from
genomic DNA (primer pair E1fw / E1rev, section 2.7.4) and was cloned into the pKO Scram-
bler V901-DT vector (figure 4.1 A). This vector included a diphtheria toxin A (DTA)-coding
sequence, which was further used as a negative selection marker. The neomycin phosphotrans-
ferase gene (nptI) was inserted into exon 1 of the Fuca1 gene using AfeI restriction sites and
the knock-out construct was electroporated into murine embryonic stem cells (D3 / 129S2 /
SvPas). Geneticin (G418)-resistant ES cell clones were screened for homologous recombi-
nation events by PCR. The 5’-homologous recombination site was validated using the primer
pair F4/AK31as and the 3’-homologous recombination site was identified in a nested PCR ap-
proach using the primer pairs F1/R2 and AK31/R1. Two ES cell clones carrying the Fuca1(-/-)
allele were identified and ES cells (clone #39) were microinjected into blastocysts (strain
C57BL/6) which were then implanted into pseudo-pregnant mice. The resulting chimeric
mice were crossed with C57BL/6 mice and germline transmission was validated as described
in section 4.1.2. The heterozygous offspring was intercrossed to obtain homozygous mice
with a mixed genetic background (C57BL/6 & 129S2/SvPas).
Cloning of the Fuca1(-/-) construct as well as ES cell electroporation and screening was done
by Prof. Lübke (Bielefeld University, Germany). Blastocyst injection was performed by Dr.
Hermans-Borgmeyer (Center for Molecular Neurobiology Hamburg, Germany).
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Figure 4.1: Validation of the Fuca1 gene knock-out on genomic and transcript level
(A) Fuca1(-/-) mice were generated by a gene targeting strategy. The wildtype allele, the Fuca1-
targeting vector as well as the Fuca1(-/-) allele are shown schematically. Primer pairs used for knock-
out validation and mouse genotyping are marked by arrows. nptI = neomycin phosphotransferase gene;
DTA = diphtheria toxin A-coding sequence (B) Ethidium bromide-stained agarose gel of PCR products
from Fuca1 knock-out validation (upper panel, primer pair F4/R3) and routine genotyping (lower panel,
primer pairs F2/AK30-R/R3). ES = ES cell clone #39 (used for blastocyst injection); NTC = no tem-
plate control. (C) Validation of the 5’ homologous recombination site as well as the integration site of
the neomycin phosphotransferase gene (nptI) was done by sequencing a PCR product of the Fuca1(-/-)
allele shown in (B, upper panel). (D) The Fuca1 mRNA expression was analyzed in several tissues
of Fuca1(-/-) mice (3-month-old) using a Northern blot. Results were kindly provided by Prof. Lübke
(Bielefeld University, Germany). (E) The Fuca1 transcript expression was monitored by Real-Time
PCR on cDNA from several wildtype and Fuca1(-/-) tissues (5-month-old mice). Gapdh was used for
normalization. ***p < 0.0005
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4.1.2 Validation of the Fuca1 gene knock-out
The Fuca1 gene knock-out was validated on mouse genomic DNA by PCR amplification
resulting in a 4.1-kb fragment for the wildtype allele and a 5.1-kb fragment for the Fuca1(-/-)
allele (figure 4.1 A and B, upper panel). The homologous recombination was confirmed by
subsequent sequencing of the PCR products (figure 4.1 C). Routine genotyping was carried
out using a multiplex PCR approach resulting in a 350-bp fragment for the wildtype allele and
a 735-bp fragment for the Fuca1(-/-) allele (figure 4.1 A and B, lower panel).
On transcript level, a Northern blot revealed a markedly decreased expression of Fuca1 tran-
script in several tissues of the Fuca1(-/-) mice (figure 4.1 D; results were kindly provided
by Prof. Lübke, Bielefeld University, Germany). A detailed analysis using Real-Time PCR
showed that the Fuca1 transcript expression was reduced by approximately 99 % in Fuca1(-/-)
liver and kidney (figure 4.1 E). A significant reduction of Fuca1 transcript by 80 %, 88 % and
90 % was detected in spleen, cerebrum and cerebellum, respectively.
In order to exclude, that the residual Fuca1 transcript translates into functional protein, α-
L-fucosidase activity was measured at pH 5.5 in several tissue homogenates and was found
to be completely absent in all Fuca1(-/-) tissues (figure 4.2 A). Moreover, lysosome-enriched
fractions from liver were analyzed and no α-L-fucosidase activity was measured in Fuca1(-/-)
lysosomes at pH 5.5 (figure 4.2 B). In addition, brain lysosomes were isolated on a self-
forming Percoll gradient (figure 4.2 C and D) and fractions were analyzed for protein content,
α-L-fucosidase and β -hexosaminidase activity, respectively. In wildtype, the lysosomal en-
zymes showed the highest activity in fraction 3 and 11, of which fraction 11 displayed the
highest specific activity for lysosomal enzymes. In contrast, Fuca1(-/-) brain did not show α-
L-fucosidase activity in any Percoll gradient fraction, but also displayed the highest specific
activity for β -hexosaminidase in fraction 11.
Besides the lysosomal α-L-fucosidase encoded by the Fuca1 gene, the Fuca2 gene encodes
another putative fucosidase that was termed as plasma α-L-fucosidase. In order to exclude,
that this second fucosidase might affect the Fuca1 gene knock-out, kidney homogenates of
wildtype, Fuca1(+/-) and Fuca1(-/-) mice were analyzed at different pH values ranging from
pH 4.0 to 8.0 (figure 4.2 E). No α-L-fucosidase activity was measured in Fuca1(-/-) kidney.
Moreover, lysosome-enriched fractions from Fuca1(-/-) liver did not show α-L-fucosidase ac-
tivity at pH 7.5 (figure 4.2 B), thus excluding α-L-fucosidase 2 as a source of residual activity.
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Figure 4.2: Validation of the Fuca1 gene knock-out on enzyme level
(A) Specific α-L-fucosidase activity was measured at pH 5.5 in several tissue homogenates of 5-month-
old mice. No α-L-fucosidase activity was detected in Fuca1(-/-) tissues. (B) Specific α-L-fucosidase
activity was determined in isolated liver lysosomes of wildtype, Fuca1(+/-) and Fuca1(-/-) mice at pH
5.5 and 7.5, respectively. Brain lysosomes from wildtype and Fuca1(-/-) mice were analyzed at pH 5.5.
No α-L-fucosidase activity was detected in lysosomes from Fuca1(-/-) mice. (C and D) Lysosome-
enriched fractions were isolated from brains of 5-month-old animals using a self-forming Percoll gra-
dient. 1 ml-fractions (F1-8) or 0.5 ml-fractions (F9-12) were collected and analyzed for protein content
as well as β -hexosaminidase activity and α-L-fucosidase activity, respectively. In wildtype, the lyso-
somal enzymes showed the highest specific activity in fraction 11. No α-L-fucosidase activity was
detected in any of the fractions from brain of Fuca1(-/-) mice whereas highest specific activity for β -
hexosaminidase was also measured in fraction 11. (E) Specific α-L-fucosidase activity was measured
in kidney homogenates of 3-month-old mice at different pH values. No α-L-fucosidase activity was
detected in Fuca1(-/-) kidney.
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In summary, the Fuca1 gene knock-out was verified on genomic, transcript and enzyme level
confirming the use of the α-L-fucosidase knock-out mice as a valid model for fucosidosis.
4.1.3 Breeding of Fuca1(-/-) mice
A Fuca1(-/-) mouse strain exhibiting a mixed genetic background (C57BL/6 & 129S2/SvPas)
was established by inbreeding. These Fuca1(-/-) mice were used for all analyses reported in
this work. In parallel, the mouse model was crossed back into C57BL/6 over a minimum of
ten generations to reach 99.9 % C57BL/6 genetic background, but the back crossing has not
yet finished.
Nearly 700 mice of the inbreeding strain were born until now, of which 49.7 % were male and
50.3 % were female. The average litter size was 7.1±2.3. 27.6 % wildtype, 51.9 % Fuca1(+/-)
and 20.5 % Fuca1(-/-) animals were obtained. These data match with the expected Mendelian
law, although a slightly reduced outcome of Fuca1(-/-) animals was recorded. It can be as-
sumed, that the Fuca1 gene knock-out has no influence on the distribution between the sexes
and the embryonic development of the mice.
4.1.4 Regulation of other lysosomal proteins
Changes in the lysosomal proteome are characteristic for LSDs (van Hoof and Hers 1968a,
Sandhoff et al. 1971) and were also analyzed in the fucosidosis mouse model. Real-Time PCR
analyses of cDNA from cerebrum revealed a significantly increased transcription of all ana-
lyzed lysosomal genes in Fuca1(-/-) mice (figure 4.3 A). Interestingly, the transcription of these
genes seemed to be regulated in a tissue-specific manner, as the mRNA levels were nearly un-
affected in the kidney with exception of the genes for β -hexosaminidase, α-mannosidase and
α-L-fucosidase 2, which were all significantly down-regulated (figure 4.3 B).
The α-L-fucosidase 2 (Fuca2) transcript was found to be threefold elevated in Fuca1-deficient
cerebrum (figure 4.3 A), but was decreased by 50 % in the kidney (figure 4.3 B). As already
stated in section 4.1.2, no residual α-L-fucosidase activity could be detected in tissue ho-
mogenates and lysosome-enriched fractions whatever pH value was used. It remains unknown
whether Fuca2 is translated or under what conditions the enzyme possesses activity in vivo.
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Figure 4.3: Regulation of lysosomal proteins in Fuca1(-/-) mice
(A and B) The expression of lysosomal hydrolases as well as of the lysosomal marker Lamp1 and the α-
L-fucosidase 2 were analyzed by Real-Time PCR on cDNA from cerebrum and kidney of 5-month-old
wildtype and Fuca1(-/-) mice. (C and D) Enzyme activities for α-mannosidase and β -hexosaminidase
were measured in several tissue homogenates of 5-month-old animals, respectively. (E and F) Cathep-
sin D and Lamp1 were analyzed by immunoblotting of tissue homogenates from kidney and cerebrum
of 5-month-old animals. An organ-specific glycosylation of Lamp1 was seen resulting in different
molecular weights. Hsp70 or Gapdh was used for normalization. *p < 0.05, **p < 0.005, ***p < 0.0005,
ns = not significant
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Besides the transcriptional level, activities of lysosomal enzymes were measured in tissue
homogenates and the α-mannosidase activity was shown to be two- to sixfold elevated in all
analyzed Fuca1(-/-) organs (figure 4.3 C). The activity of the β -hexosaminidase showed a more
tissue-specific regulation. A two- to threefold increase was detected in kidney, spleen, cere-
brum and cerebellum, whereas the activity of the liver was unaffected by the Fuca1 gene
knock-out (figure 4.3 D). Remarkably, the mRNA levels of both genes were significantly
down-regulated in the Fuca1(-/-) kidney, whereas on enzyme level an increased activity was
detected, indicating an enhanced stability of both enzymes.
The amount of cathepsin D protein was analyzed by immunoblotting and was found to be
twofold elevated in Fuca1(-/-) kidney and cerebrum (figure 4.3 E). Also the amount of Lamp1
(lysosome-associated membrane protein 1) was fivefold increased in the cerebrum, whereas
there was only a slight trend towards an enhanced Lamp1 expression in the kidney (figure 4.3
F). An increased amount of Lamp1 protein can be used as a marker for LSDs, as its expression
is often upregulated due to the general enlargement of the endosomal-lysosomal compartment
(Meikle et al. 1997). In summary, the altered regulation of several lysosomal proteins indicated
the formation of a LSD-like phenotype in the Fuca1(-/-) mice.
4.1.5 Macroscopic observations
Fuca1(-/-) mice were viable and fertile, showed a normal growth and weight gain and were
indistinguishable from their wildtype littermates until the age of approximately 6 months. At
older ages, the Fuca1(-/-) mice suffered from a worsening tremor and ataxia. Progressive
problems in movement and coordination were observed resulting in an abnormal posture of
the hind legs (figure 4.4 A and B). Moreover, the animals became progressively hypoactive.
During autopsy, the cerebrum of Fuca1(-/-) mice appeared reduced in size, whereas the cere-
bellum seemed to be swollen (figure 4.4 D and E). In this regard, the superior/ inferior col-
liculus (part of the midbrain; figure 4.4 D and E, marked by arrows) was markedly enlarged
in comparison to wildtype brain. The altered macroscopic appearance of the Fuca1(-/-) brains
suggested a neurological phenotype, which was verified later by histological and behavioral
analyses (sections 4.1.9 and 4.1.10). At 8 months of age, male Fuca1(-/-) mice displayed a
tremendously enlarged bladder with an overall urinary volume of ˜ 3 ml (figure 4.4 C), whereas
only a few female animals were affected. Due to animal welfare, Fuca1(-/-) mice had to be eu-
thanized at 9 - 11 months of age.
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Figure 4.4: Macroscopic observations of Fuca1(-/-) mice
11-month-old wildtype (A) and Fuca1(-/-) (B) mice are shown. The mice were lifted at their tails.
Thus, they spread their hind legs to keep balance. The Fuca1(-/-) mouse showed an abnormal posture
of the hind legs that might be due to problems in movement and coordination. (C) A 9-month-old male
Fuca1(-/-) mouse is shown that displayed a massively enlarged bladder. (D and E) The brain of a 10.5-
month-old wildtype and a Fuca1(-/-) mouse is shown. The heavily enlarged superior/inferior colliculus
is marked by arrows.
4.1.6 Storage pathology of visceral organs
Several visceral organs of wildtype and Fuca1(-/-) mice from 5 to 9 months of age were in-
vestigated in detail by light and, if needed, also by transmission electron microscopy (TEM).
These analyses were performed by Prof. Lüllmann-Rauch (University of Kiel, Germany).
Cytoplasmic storage vacuoles were found in almost all investigated organs of the Fuca1(-/-)
mice. These membrane-enclosed vacuoles appeared mainly translucent indicating water-
soluble compounds as the major storage material accumulating in murine fucosidosis. In
most cases, light microscopy of semi-thin sections was sufficient to visualize the storage phe-
notype. Only in a few cases, e. g. hepatocytes of the liver and cells of the renal proximal
convoluted tubule, TEM was necessary to detect storage material containing more heteroge-
neous material of moderate electron density. Moreover, selected visceral organs were analyzed
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by immunofluorescence staining using a Lamp1 (lysosome-associated membrane protein 1)-
specific antibody. Lamp1 is commonly used as a lysosomal marker and its expression is
massively increased in several LSDs (Meikle et al. 1997) due to the overall enlargement of the
endosomal-lysosomal compartment.
In the liver of Fuca1(-/-) mice, numerous large storage vacuoles were detected in Kupffer cells
and sinusoidal endothelial cells (figure 4.5 B and C), while TEM was necessary to detect stor-
age vacuoles in the hepatocytes which were loacated near the bile canaliculus and contained
heterogenous material of moderate electron density (figure 4.5 D). Using immunostainings,
a massive increase in Lamp1 protein became obvious in the Fuca1(-/-) liver (figure 4.6 A)
indicating an enlarged endosomal-lysosomal compartment. A detailed analysis showed nu-
merous vacuolated cells that were not found in the wildtype liver. By comparison with light
microscopy data, these vacuolated cells were identified as Kupffer cells. Further analysis
was performed by co-staining with the macrophage-specific marker F4/80. Due to technical
reasons, cathepsin D instead of Lamp1 was used as lysosomal marker. These co-stainings con-
firmed that the Kupffer cells contained numerous storage vacuoles (figure 4.6 B) which were
not present in the wildtype tissue.
Figure 4.5: Storage pathology of the liver
The liver of 5-month-old wildtype and Fuca1(-/-) mice was analyzed by light (A and B) or transmission
electron microscopy (TEM; C and D) in cooperation with Prof. Lüllmann-Rauch (University of Kiel,
Germany). (B) Storage vacuoles were found in sinusoidal endothelial cells and Kupffer cells of the
Fuca1(-/-) liver. (C) A Kupffer cell in higher magnification. D: space of Disse. (D) Using TEM,
storage vacuoles were detected in hepatocytes (9-month-old mice) containing heterogeneous material
of moderate electron density. N: nucleus, BC: bile canaliculus.
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Figure 4.6: The endosomal-lysosomal compartment of the liver is enlarged in Fuca1(-/-) mice
(A) Semi-thin sections of the liver of 5-month-old wildtype and Fuca1(-/-) mice were stained with a
Lamp1-specific antibody or (B) were co-staining using a cathepsin D-specific and an α-F4/80 antibody.
Cell nuclei were stained with DAPI (blue). Bars correspondent to 50 µm (low magnification) or 5 µm
(high magnification).
In the kidney of the Fuca1(-/-) mice, the renal cortex was moderately affected. Translucent
storage vacuoles were found in the glomerular podocytes (figure 4.7 B, marked by arrows)
and in the glomerular mesangium cells, while the proximal convoluted tubules contained stor-
age material of moderate electron density (figure 4.7 C). The distal convoluted tubules as well
as the intermediate tubules (Henle’s loop), the distal straight tubules (thick ascending limp of
Henle’s loop) and the distal convoluted tubules were unaffected (data not shown). The collect-
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ing ducts of the outer and inner medulla showed a severe storage phenotype, that worsened
towards the inner medulla. The intercalated cells contained numerous foam-like vacuoles (fig-
ure 4.7 E) and particularly in the inner medulla, intercalated cells composed of a single giant
storage vacuole were found (figure 4.7 E, inset). The principal cells appeared inconspicuous at
the light microscopic level, but storage vacuoles containing moderate electron-dense material
were detected by TEM (figure 4.7 F). Immunofluorescence stainings using a Lamp1-specific
antibody revealed a moderately enlarged endosomal-lysosomal compartment in the renal cor-
tex and medulla (figure 4.8). Highly vacuolated cells were found in the renal inner medulla of
the Fuca1(-/-) kidney but not in the wildtype tissue. After comparison with light microscopic
analysis, these cells were identified as intercalated cells of the renal collecting duct. Similarly
to the light microscopic data, these cells contained mainly small foam-like vacuoles.
Figure 4.7: Storage pathology of the kidney
The kidney of 5-month-old wildtype and Fuca1(-/-) mice was analyzed by light (A, B, D and E) or
transmission electron microscopy (TEM; C and F) in cooperation with Prof. Lüllmann-Rauch (Univer-
sity of Kiel, Germany). (B) In the Fuca1(-/-) cortex, storage vacuoles were found in podocytes (marked
by arrows). (C) Using TEM, storage vacuoles were also detected in the proximal convoluted tubules
(PCT). G: glomerulus, N: nucleus. In the outer medulla (D – F) the collecting ducts (CD) are com-
posed of intercalated cells (IC) and principal cells (PC). (E) The Fuca1(-/-) ICs were vacuolated. (E
inset) Fuca1(-/-) ICs of the inner medulla. (F) Using TEM, storage vacuoles were detected in the PCs.
TAL: thick ascending limb of the Henle’s loop.
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Figure 4.8: The endosomal-lysosomal compartment of the kidney is enlarged in Fuca1(-/-) mice
Semi-thin sections of the kidney of 5-month-old wildtype and Fuca1(-/-) mice were stained with a
Lamp1-specific antibody. Cell nuclei were stained with DAPI (blue). Bars correspondent to 50 µm
(low magnification) or 5 µm (high magnification).
In the Fuca1(-/-) spleen, a moderate storage phenotype and translucent storage vacuoles were
found, which affected lymphocytes, reticulum cells, sinusoidal endothelial cells (figure 4.9
A) as well as trabecular fibroblasts (data not shown). A moderately enlarged endosomal-
lysosomal compartment was also detected by immunofluorescence staining using a Lamp1-
specific antibody (figure 4.9 B).
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Figure 4.9: Storage pathology of the spleen
(A) The spleen of 5-month-old mice was analyzed by transmission electron microscopy (TEM) in
cooperation with Prof. Lüllmann-Rauch (University of Kiel, Germany). The red pulp (left panel) and
the white pulp (right panel) of a Fuca1(-/-) mouse are shown. LC: lymphocytes, RS: reticulum cells,
SE: sinusoidal endothelial cells, EC: erythrocyte. (B) Semi-thin sections of the spleen of 5-month-old
wildtype and Fuca1(-/-) mice were stained with an Lamp1-specific antibody. Cell nuclei were stained
with DAPI (blue). Bars correspondent to 50 µm.
Besides liver, kidney and spleen, several other visceral organs were investigated regarding
their storage pathology. The urinary bladder of Fuca1(-/-) mice was severely affected and par-
ticularly the superficial umbrellar cells were filled with numerous foam-like vacuoles (figure
4.10 B). Some large storage vacuoles containing heterogeneous material of moderate electron
density were detected in the Fuca1(-/-) gall bladder (figure 4.10 D), whereas the acinus cells of
the exocrine pancreas were less affected (data not shown).
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Figure 4.10: Storage pathology of the urinary bladder and gall bladder
The urinary bladder of 9-month-old wildtype and Fuca1(-/-) mice was analyzed by light microscopy
(A and B). UC: umbrella cells. (C and D) The gall bladder of 5-month-old mice was analyzed by
transmission electron microscopy (TEM). N: nucleus. Results were kindly provided by Prof. Lüllmann-
Rauch (University of Kiel, Germany).
In summary, nearly all investigated visceral organs of Fuca1-deficient mice were affected from
storage pathology, but the number, size as well as the nature of the accumulating material dif-
fered in a cell type-specific manner. Remarkably, some organs and cell types were unaffected
from storage pathology, e. g. the renal intermediate tubules, bone cells, skeletal muscle and
heart muscle.
4.1.7 Fucosylated glycoasparagines accumulate in fucosidosis
4.1.7.1 Analysis of storage material by TLC
The histological analysis of the fucosidosis mouse model revealed high amounts of stor-
age vacuoles in many organs. In order to identify the accumulating material, neutral oligo-
saccharides were extracted from different tissues of wildtype and Fuca1(-/-) mice. Using thin-
layer chromatography (TLC), high amounts of different glycocompounds were detected in the
Fuca1(-/-) tissues (figure 4.11 A). As the TLC alone does not allow the identification of the
storage material, TLC-separated material was scraped off the plates and further characterized
by HPLC-MS/MS (performed by Dr. Beck, Odense University Hospital, Denmark). Material
from single bands of the Fuca1(-/-) kidney and cerebrum as well as comparable TLC areas from
wildtype tissues were analyzed. As expected, no glycoconjungates were detected in samples
derived from wildtype tissues. However, the core-fucosylated glycoasparagine Asn-GlcNAc-
Fuc (m/z 482.20 [M+H]+) was identified in TLC material from Fuca1(-/-) tissues. In addi-
tion, the core-fucosylated asparaginyl-linked pentasaccharide Asn-GlcNAc-(Fuc)-GlcNAc-
Man-Man (m/z 1009.39 [M+H]+) was detected and another prominent band contained ma-
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terial of m/z 1177.47, which would fit to a heptasaccharide composed of five hexoses, one
N-acetyl-glucosamine and one fucose residue.
Figure 4.11: Analysis of fucosidosis storage
material
(A) Neutral oligosaccharides were isolated
from 5-month-old wildtype and Fuca1(-/-)
tissues. Samples corresponding to 10 mg
tissue (fresh weight) were analyzed by TLC
and material of single TLC bands (kidney
and cerebrum) was extracted from the plate
and further analyzed by HPLC-MSMS (re-
sults were kindly provided by Dr. Beck,
Odense University Hospital, Denmark).
Fucosylated glycoasparagines (m/z 482.20
[M+H]+ = Asn-GlcNAc-Fuc and m/z 1009.39
[M+H]+ = Asn-GlcNAc-(Fuc)-GlcNAc-Man-
Man) as well as another glycocompound of yet
unknown origin were identified. (B) Spot urine of 5-month-old wildtype and Fuca1(-/-) mice was col-
lected, desalted and 10 µl were directly analyzed by TLC. Neutral oligosaccharides isolated from kid-
ney were loaded as control. (C) Spot urine of 9-month-old wildtype and Fuca1(-/-) mice was collected
and directly analyzed by HPLC-MS. Results were kindly provided by Dr. Beck (Odense University
Hospital, Denmark). The core-fucosylated glycoasparagine Asn-GlcNAc-Fuc as well as other glyco-
compounds of yet unknown origin were detected in Fuca1(-/-), but not in wildtype samples.
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A clinical hallmark of fucosidosis is the excretion of storage material with the urine of hu-
man patients, where the core-fucosylated glycoasparagine Asn-GlcNAc-Fuc (Michalski and
Klein 1999) was found as prominent glycocompound. Hence, spot urine from wildtype and
Fuca1(-/-) mice was collected and analyzed by TLC. Several glycocompounds were exclu-
sively found in the Fuca1(-/-) samples and exhibit comparable retention values to storage ma-
terial of the Fuca1(-/-) kidney (figure 4.11 B). In order to identify these storage materials, spot
urine was directly analyzed by HPLC-MS. As expected, the core-fucosylated glycoasparagine
Asn-GlcNAc-Fuc was detected as the far most abundant glycocompound in the Fuca1(-/-) sam-
ples (figure 4.11 C) and was absent in the wildtype. Also other compounds of so far unknown
origin (m/z 644.25 [M+H]+ and m/z 806.30 [M+H]+) were identified albeit to a much lesser
extend. However, the masses of both compounds did not fit with masses of N-linked oligo-
saccharides of commonly known structures. These results indicate that a mixture of undigested
fucosylated glycocompounds is accumulating in Fuca1(-/-) mice and that the storage material
is also partially excreted with the urine.
4.1.7.2 Analysis of storage material using Aleuria aurentia lectin
In order to detect the fucosidosis storage material in tissue section of Fuca1(-/-) mice, the
Aleuria aurentia lectin was used for immunofluorescence stainings. The lectin binds specifi-
cally to fucose residues linked α1-6 to N-acetylglucosamine, the so-called core structure of
complex N-glycans.
In the liver, an Aleuria aurentia-specific staining of the sinusoid walls (most likely endothelial
cells) was detected, whereas hepatocytes remained unstained (figure 4.12 A). A detailed ana-
lysis of the Fuca1(-/-) tissue revealed another cell type with a vacuolated micro-architecture
that was not found in the wildtype liver (figure 4.12 A, marked by arrow). After comparison
with light microscopic data (figure 4.5 B), these cells were identified as Kupffer cells. Remark-
ably, only the membranes of the storage vacuoles were stained, whereas their lumen remained
unstained, which was explained by the water-soluble properties of the fucosylated storage ma-
terial. It is very likely, that most of the stored glycocompounds were washed out during the
staining procedure. Comparably, translucent storage vacuoles were already detected during
light microscopic analysis (section 4.1.6).
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Figure 4.12: Aleuria aurentia lectin staining of visceral tissues
Semi-thin sections of liver (A), kidney (B) and spleen (C) of 5-month-old wildtype and Fuca1(-/-) mice
were stained with Aleuria aurentia lectin. Bars correspondent to 50 µm (low magnification) or 5 µm
(high magnification). Arrows indicate vacuolated cells. Stars indicate giant storage vacuoles in the
renal collecting ducts.
In the spleen, Aleuria aurentia lectin stained single cells that were homogeneously distributed
throughout the red and white pulp (figure 4.12 C). Detailed analysis revealed that most of
these cells were vacuolated in both, wildtype and Fuca1(-/-) spleen (figure 4.12 C, marked by
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arrows) and could represent macrophages. Again, only the membranes of the vacuoles were
stained and the Fuca1(-/-) spleen exhibited a higher staining intensity.
In the renal cortex and outer medulla the apical cell pole of many tubules was stained in
both genotypes by Aleuria aurentia lectin (figure 4.12 B). These structures might represent
proximal tubules that exhibit a glycocalyx and a high amount of glycoproteins at their luminal
site, whereas the intermediate as well as the distal tubules do not exhibit a glycocalyx. An
aquaporin2-specific antibody was used as a marker for renal collecting ducts and a co-staining
with the Aleuria aurentia lectin was shown. Severely vacuolated cells were found in the
collecting ducts of the inner medulla of the Fuca1(-/-) kidney. It was already shown by light
microscopic analysis that the intercalated cells of the renal collecting ducts are highly affected
from storage and also giant storage vacuoles were found in some of these cells (figure 4.7
E). Similar structures were seen using the Aleuria aurentia lectin (figure 4.12 B, marked by
stars). Remarkably, vacuolated cells were exclusively seen in the Fuca1(-/-) kidney but not in
the wildtype tissue.
Aleuria aurentia lectin staining of the brain resulted in no obvious differences between Fuca1(-/-)
and wildtype littermates. The lectin recognized predominately areas of grey matter, whereas
the white matter remained unstained (appendix A.5).
4.1.8 Urine analysis and haematology
The histological findings of the kidney of Fuca1(-/-) mice are described in section 4.1.6. As
high amounts of storage vacuoles were found in the glomerular podocytes as well as in dif-
ferent tubular segments, the functionality of the kidney was tested with regard to a potential
proteinuria describing an excess of serum proteins in the urine. In healthy individuals, high
molecular weight proteins (≥ 60 kDa) are retained by the renal glomeruli during blood fil-
tration. If the blood-urine barrier, which is composed of podocytes, is not functional, these
proteins are excreted with the urine. In contrast, low molecular weight proteins (≤ 60 kDa)
are initially excreted with the urine and later reabsorbed by the renal tubuli. Thus, a damage
of the tubuli would lead to an increase of low molecular weight proteins in the urine.
Spot urine of wildtype and Fuca1(-/-) mice was monitored in a reducing SDS-PAGE followed
by silver staining (figure 4.13). Remarkably, neither high nor low molecular weight proteins
were excessively excreted with the urine of Fuca1(-/-) mice indicating that the blood-urine
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barrier as well as renal tubular segments were still functional, although they were severely
affected by vacuolation.
Figure 4.13: Analysis of urine
samples
Spot urine from 3- and 5-month-old
wildtype as well as Fuca1(-/-) mice
was collected. The protein concen-
tration was determined and 100 µg
were loaded on a reducing SDS-
PAGE. After gel electrophoresis the
proteins were silver-stained.
Due to the histological findings in liver and kidney of the Fuca1(-/-) mice (section 4.1.6), serum
parameters of 5-month-old animals were analyzed. Due to technical problems, most of the
Table 4.1: Serum parameters from wildtype and Fuca1(-/-) mice (WT: n = 7; Fuca1(-/-):
n = 3), AST: aspartate aminotransferase, GGT: gamma-glutamyl transpeptidase
Parameter Unit Wildtype Fuca1(-/-)
Sodium mmol / l 142.75± 2.49 139.67± 0.47
Calcium mmol / l 2.12± 0.08 2.02± 0.03
Phosphate mg / dl 6.04± 1.04 6.07± 0.38
Chloride mmol / l 110.00± 2.12 104.67± 0.47
Urea mg / dl 50.88± 5.58 52.33± 1.25
Creatinine mg / dl 0.37± 0.03 0.35± 0.01
Albumin mg / dl 1277.38± 104.89 1197.33± 29.94
AST U / l 123.13± 35.00 167.67± 91.69
GGT U / l ≤ 4 ≤ 4
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blood samples were slightly hemolytic, which prevented the analysis of the lactate dehydroge-
nase and the potassium values. Remarkably, no differences in the liver parameters were found
between wildtype and Fuca1(-/-) mice (table 4.1). Also the kidney parameters including urea,
creatinine and albumin values were inconspicuous. In contrast, the electrolytes (sodium, cal-
cium and chloride) were significantly decreased in the Fuca1(-/-) mice, indicating functional
disabilities in the renal collecting ducts caused by the accumulation of storage material. The
collecting ducts are participating in electrolyte homeostasis, as they are responsible for urea
reabsorption. An osmotic gradient is formed that triggers the reabsorption of electrolytes into
the Henle’s loop. Due to the immense accumulation of storage material observed in the col-
lecting ducts, the formation of the osmotic gradient might be insufficient. As a consequence,
the reabsorption of the electrolytes might be inhibited, which would lead to a decreased con-
centration of electrolytes in the blood.
In addition, blood cell parameters were analyzed from wildtype and Fuca1(-/-) mice at 5 months
of age (table 4.2). The number of erythocytes was found to be slightly reduced in Fuca1(-/-)
mice, indicating a milder form of a renal anemia. All other parameters were unaffected by the
Fuca1 gene knock-out.
Table 4.2: Blood parameters from wildtype and Fuca1(-/-) mice (WT: n = 8; Fuca1(-/-):
n = 4)
Parameter Unit Wildtype Fuca1(-/-)
Erythocytes M / µl 8.10± 0.16 7.34± 0.15
Hemoglobin g / dl 12.25± 0.47 11.20± 0.45
Hematocrit % 34.83± 1.05 31.92± 1.28
MCV fl 48.93± 1.27 48.38± 1.60
MCH pg 17.20± 0.51 16.94± 0.58
MCHC g / dl 39.92± 0.63 38.92± 0.50
RDW % 13.49± 0.31 12.79± 0.48
Thrombocytes K / µl 629.24± 270.80 682.30± 56.46
Thrombocrit % 0.23± 0.06 0.24± 0.02
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4.1.9 Neuropathology
4.1.9.1 Storage pathology of the CNS
Pathological alteration of the brain is the leading symptom of human fucosidosis and similar
findings were expected in the Fuca1(-/-) mice. The CNS was extensively studied by light and
electron microscopy in cooperation with Prof. Lüllmann-Rauch (University of Kiel, Germany)
and storage vacuoles were found in all analyzed regions of the Fuca1(-/-) brain. Neuronal
perikarya of the hippocampus (figure 4.14 B) and cerebral cortex (figure 4.14 D) were severely
affected and filled with cytoplasmic translucent vacuoles. Moreover, high amounts of axon
spheroids were identified in the hippocampus (figure 4.14 B (marked by arrows) and C) and
to a lesser extend also in the cerebellum (data not shown). Ultrastructural analysis detected
disorientated neurotubules, neurofilaments and heterogeneous material in the axoplasm of the
spheroids. In the cerebellum, large storage vacuoles containing floccular material of moderate
electron-density were found in Purkinje cells of Fuca1(-/-) mice, whereas Bergmann-glia cells
were filled with numerous small empty vacuoles (figure 4.14 E). The granular cells were also
affected from storage, even through to a much lesser extend (data not shown).
Figure 4.14: Storage pathology of the CNS
The brains of wildtype and Fuca1(-/-) mice were analyzed by light (A, B and D) or transmission electron
microscopy (TEM; C and E) in cooperation with Prof. Lüllmann-Rauch (University of Kiel, Germany).
(A – C) Hippocampus (CA3 region) from 9-month-old mice. (A) wildtype. (B) Neuronal perikarya
from Fuca1(-/-) mice contained storage vacuoles. Abnormal axon spheroids are marked by arrows. (C)
Higher magnification of an axon spheroid. (D) Cerebral cortex of the same mouse as in (B). Storage
vacuoles were found in the neuronal perikarya. (E) Cerebellum of a 3.5-month-old Fuca1(-/-) mice.
Purkinje cells contained large vacuoles filled with some floccular material, whereas Bergmann glia
cells contained numerous small empty vacuoles. ML: molecular layer; PL: Purkinje cell layer; GL:
granular layer.
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An increase in Lamp1 protein (lysosome-associated membrane protein 1) is commonly used
as marker for LSDs (Meikle et al. 1997) and was already shown by immunoblotting in the
cerebrum of the Fuca1(-/-) mice (section 4.1.4). Using immunostainings, a massive increase
in Lamp1 protein was confirmed in the Fuca1(-/-) brain (figure 4.15 A) indicating an en-
larged endosomal-lysosomal compartment in the hippocampus, cerebral cortex and cerebel-
Figure 4.15: The endosomal-lysosomal compartment of the brain is enlarged in Fuca1(-/-) mice
(A) Semi-thin sections of the brain of 3.5-month-old wildtype and Fuca1(-/-) mice were stained with
a Lamp1-specific antibody. The hippocampus, cerebral cortex and cerebellum is shown. Bars corre-
spondent to 200 µm or 5 µm (magnification of the hippocampus). (B) Co-staining of Lamp1-positive
cells with different cell type-specific markers (GFAP for astrocytes, Iba1 for microglia and NeuN for
neurons). Cell nuclei were stained with DAPI (blue). Bars correspondent to 5 µm. Co-stainings using
Iba1 and NeuN were performed by Dr. Damme (University of Kiel, Germany).
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lum. Co-stainings of Lamp1-positive cells with different cell type-specific markers for astro-
cytes (GFAP), microglia (Iba1) and neurons (NeuN) revealed that all tested cell types of the
CNS were affected from storage (figure 4.15 B).
4.1.9.2 Secondary storage material accumulate in the Fuca1(-/-) brain
Secondary storage pathology of lipids is a common feature of many LSDs and contribute to
the complex pathological cascade underlying these diseases as unesterified cholesterol, gan-
gliosides and autofluorescent material were detected in several mucopolysaccharidoses and in
α-mannosidosis (Walkley 2004, Walkley et al. 2010, Damme et al. 2011, Kowalewski et al.
2015). So far, secondary storage pathology was not investigated in detail in human fucosidosis
patients and the fucosidosis dog model.
Figure 4.16: Autofluorescent material accumulate in the Fuca1(-/-) brain
Unstained, semi-thin brain sections of 11-month-old animals were analyzed at different wavelengths
(410 nm, 488 nm, 594 nm). Bars correspondent to 200 µm (left and middle) and 50 µm (right).
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The accumulation of autofluorescent material in Fuca1(-/-) mice was investigated by analyzing
unstained semi-thin section of the brain at different wavelengths, revealing autofluorescent
compounds in cellular structures exclusively in the brain of Fuca1(-/-) mice (figure 4.16). Here,
the hippocampus, cerebral cortex and the cerebellum, particularly the molecular layer was
affected. The accumulation of autofluorescent material was observed only in late stages of
the disease in 11-month-old Fuca1(-/-) mice, while it was absent in younger animals (data not
shown). Although autofluorescent material often accumulates in aging brains, a pathological
storage was shown, as the autofluorescent material was absent in brain sections of wildtype
mice at the same age.
In order to further analyze the autofluorescent material, semi-thin sections were stained with
Sudan Black B, which is a fat-soluble diazo dye and stains lipid-rich structures. It is often
used for detection of lipofuscin, which is known to be composed of oxidized lipids, proteins
and metal ions. The Sudan Black B staining resulted in a general staining of the cerebellar
white matter, but also a moderate staining of macrophage-like structures was detected in the
molecular layer of the cerebellum of Fuca1(-/-) mice but not of wildtype animals at 11 months
of age (figure 4.17). The staining pattern was comparable with the distribution of autofluo-
rescent material, indicating that these storage compounds might be composed lipofuscin. Of
Figure 4.17: Accumulation of Sudan Black B-positive material in the Fuca1(-/-) brain
Semi-thin brain sections of 11-month-old animals were stained with Sudan Black B and Nuclear Fast
Red (counterstaining). Bars correspondent to 250 µm (lowest magnification), 50 µm (medium magni-
fication) or 25 µm (highest magnification).
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note, the accumulation of lipofuscin was only seen in late stages of the disease and was absent
in younger Fuca1(-/-) mice (e. g. 3 and 5 months of age; data not shown).
The Fuca1(-/-) mice were further analyzed with regard to accumulation of gangliosides as sec-
ondary storage material. Semi-thin brain section were stained with an GM2-specific antibody
and GM2-gangliosides were detected in small, vesicle-like structures in the hippocampus,
cerebral cortex and molecular layer of the cerebellum of 3-month-old Fuca1(-/-) mice (figure
4.18). Interestingly, this GM2-staining pattern was nearly completely absent in 11-month-old
animals (data not shown), indicating a progressive loss of that particular storage material.
Figure 4.18: GM2-ganglioside accumulate in the brain of Fuca1(-/-) mice
Immunofluorescence staining on semi-thin brain sections from 3-month-old animals using a GM2-
ganglioside-specific antibody. In the cerebellum, the molecular layer is shown. Cell nuclei were stained
with DAPI (blue). Bars correspondent to 25 µm.
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Filipin is a fluorescent dye that is excitated in the UV-spectrum and binds specifically to un-
esterified cholesterol. Brain sections of wildtype and Fuca1(-/-) mice at 3 and 11 months of
age were analzyed by filipin staining and large deposits of unesterified cholesterol were ex-
clusively detected in the cerebellum of Fuca1(-/-) animals, where the staining pattern was re-
stricted to the molecular layer (figure 4.19). Of note, the filipin staining in 11-month-old
animals did only partially co-localize with the autofluorescent material.
Figure 4.19: Unesterified cholesterol accumulate in the cerebellum of Fuca1(-/-) mice
Accumulation of unesterified cholesterol was found by filipin staining of semi-thin brain sections in
the cerebellum particularly in the molecular layer of 3- and 11-month-old Fuca1(-/-) (upper and middle
panel). Lower panel: Filipin staining (blue) partially co-localize with autofluorescent material (green
and red) in 11-month-old Fuca1(-/-) animals. Bars correspondent to 50 µm.
Accumulation of lipid-rich secondary storage material was monitored also by TLC in 3-, 5-
and 10.5-month-old animals. However, no obvious differences between the genotypes were
observed (appendix A.6), indicating that TLC was not sensitive enough to detect e. g. the
accumulation of cholesterol, GM2-gangliosides or other lipids in Fuca1(-/-) mice.
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4.1.9.3 Fuca1 gene knock-out leads to neuronal loss
Many lysosomal storage diseases that exhibit a neuropathological phenotype are character-
ized by a progressive loss of neuronal cells (Platt et al. 2012). Although neuropathological
alterations are the main symptom in human fucosidosis, only little information is available
Figure 4.20: Neuronal loss in the Fuca1(-/-) cerebrum
(A) Immunofluorescence stainings on semi-thin sections of 5-month-old wildtype and Fuca1(-/-) mice
for the neuron-specific cell marker NeuN. Cell nuclei were stained with DAPI (blue). Bars correspon-
dent to 200 µm and 50 µm (magnification of hippocampus). (B) Cerebral and cerebellar tissue ho-
mogenates of 5-month-old animals were analyzed by immunoblotting using a NeuN-specific antibody.
Hsp70 was used for normalization. *p < 0.05
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regarding neuronal cell death. As numerous storage vacuoles have been found in neuronal
perikarya of the hippocampus and cerebral cortex (figure 4.14 B and D), these cells were
evaluated in more detail by immunofluorescence stainings of the neuron-specific cell marker
NeuN. A slightly decreased staining intensity of NeuN-positive cells in the hippocampus and
cerebral cortex of Fuca1(-/-) mice was detected, while the cerebellum was unaffected (fig-
ure 4.20 A). This result was confirmed by immunoblotting showing a significant decrease in
NeuN-protein in the cerebrum but not in the cerebellum of Fuca1(-/-) mice (figure 4.20 B).
Durand et al. (1969) described a loss of Purkinje cells in a brain biopsy of a severely affected
fucosidosis patients. In the Fuca1(-/-) mice, these cells were also affected and contained several
storage vacuoles (figure 4.14 E). Further analyses were performed by immunofluorescence
stainings of the Purkinje cell-specific marker calbindin in cerebellar sections of mice of differ-
ent ages (figure 4.21). At 3.5 months of age the layer of Purkinje cell perikarya as well as their
dendritic trees in the molecular layer of the cerebellum were comparable between the geno-
types. In contrast, at 7.5 months of age the Purkinje cells were already severely diminished in
Fuca1(-/-) mice, and at 11 months of age they were nearly completely lost as reflected by the
Figure 4.21: Loss of Purkinje cells in Fuca1(-/-) mice
Immunofluorescence stainings on semi-thin sections of wildtype and Fuca1(-/-) mice at 3.5, 7.5 and
11 months of age for the Purkinje cell-specific marker calbindin. Cell nuclei were stained with DAPI
(blue). Bars correspondent to 200 µm.
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absence of Purkinje cell perikarya as well as dentritic trees. The residual immunofluorescence
staining in the cerebellar sections of 11-month-old Fuca1(-/-) mice was most likely due to
autofluorescent material (compare with figure 4.16).
4.1.9.4 Fuca1(-/-) mice exhibit neuroinflammation
Loss of neurons is often accompanied by neuroinflammation and is commonly observed in
LSDs (Vitner et al. 2010). The inflammatory processes are due to an activation of astrocytes
and microglia in response to neuronal cell death. However, only limited data are available
from human fucosidsosis patients. In order to analyze whether the fucosidosis mouse model
exhibits neuroinflammation, the expression of the astrocyte-specific marker GFAP (glial fibril-
lary acidic protein) was determined by Real-Time PCR analysis on whole brain cDNA and was
found to be 6.5-fold increased in Fuca1(-/-) brains (figure 4.22 A). Western blot analysis de-
tected an increase in GFAP protein by 8.5-fold in the Fuca1(-/-) cerebrum and by nearly six fold
in the cerebellum (figure 4.22 B and C). High numbers of GFAP-positive cells were confirmed
by immunofluorescence analysis especially in the cerebral cortex and in the CA3-region of the
hippocampus. An increase in GFAP-positive cells was also shown in the cerebellum. This ef-
fect, however, was closely restricted to the Purkinje cell layer (figure 4.22 D). CD68 and Iba1
(ionized calcium-binding adapter molecule 1) were used as specific markers for macrophages
and microglia and a nearly 17-fold and three-fold increased mRNA expression was detected by
Real-Time PCR on whole brain cDNA, respectively (figure 4.22 A). At the protein level, im-
munofluorescence analysis clearly confirmed a massive increase in CD68-positive cells in all
regions of the brain (figure 4.22 E). Furthermore, the expression of the inflammatory marker
Ccl-3 (macrophage inflammatory protein 1a) was analyzed by Real-Time PCR on whole brain
cDNA and was shown to be massively increased in the Fuca1(-/-) brain. Here, an exact quan-
tification was not possible, as the abundance of Ccl-3 transcript in the wildtype tissue was at
background level and could not be properly determined (data not shown). In summary, these
results clearly show that the Fuca1(-/-) mice exhibit astro- and microgliosis.
4.1.9.5 Myelination is unaffected by the Fuca1 gene knock-out
Myelination defects are commonly described in human fucosidosis as well as in the fucosido-
sis dog model. In order to evaluate the myelination state in the Fuca1(-/-) mice, the
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Figure 4.22: Micro- and astrogliosis in Fuca1(-/-) mice
(A) The expression of markers for astrogliosis (GFAP) and microgliosis (CD68 and Iba1) were ana-
lyzed by Real-Time PCR analysis on whole brain cDNA from 5-month-old wildtype and Fuca1(-/-)
mice. Cerebral (B) and cerebellar tissue homogenates (C) of 5-month-old animals were analyzed by
immunoblotting using a GFAP-specific antibody. Gapdh was used for normalization. ***p < 0.0005,
*p < 0.05. Immunofluorescence stainings on semi-thin sections of 3.5-month-old wildtype and
Fuca1(-/-) mice using a GFAP- (D) and CD68-specific antibody (E). The hippocampus, cerebral cortex
and cerebellum is shown. Cell nuclei were stained with DAPI (blue). Bars correspondent to 200 µm.
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expression of the myelin markers MBP (myelin basic protein) and Plp1 (proteolipid protein 1)
were analyzed by Real-Time PCR on whole brain cDNA (figure 4.23 A). The mRNA level of
Plp1 was unaffected by the Fuca1 gene knock-out, whereas a slight but significant increase
in MBP transcript (1.3 fold) was detected. However, no alterations in MBP expression could
be detected at the protein level neither by immunoblotting of cerebral and cerebellar tissue
homogenates (figure 4.23 B and C) nor by immunofluorescence stainings on brain sections
(figure 4.23 D), suggesting an increase in MBP protein turnover that does not affect the steady-
state protein level.
Figure 4.23: Myelination is not affected in Fuca1(-/-) mice
(A) The expression of the myelination markers Plp1 and MBP were analyzed by Real-time PCR on
whole brain cDNA of 5-month-old wildtype and Fuca1(-/-) mice. (B and C) Immunoblotting of cerebral
and cerebellar tissue homogenates from 5-month-old mice using a MBP-specific antibody. Gapdh was
used for normalization. ***p < 0.0005; ns = not significant. (D) Immunofluorescence staining on semi-
thin sections of 3.5-month-old animals using an MBP-specific antibody. The corpus callosum and
cerebellar white matter is shown. Cell nuclei were stained with DAPI (blue). Bars correspondent to
50 µm.
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4.1.10 Behavior
As neuropathological alterations are often connected with behavioral deficits, Fuca1(-/-) mice
were analyzed at 3 and 7 months of age regarding motor and coordinatory performance, over-
all activity and exploration as well as learning and memory performance. All experiments
described here, were performed by Dr. Stroobants and Prof. D’Hooge (University of Leuven,
Belgium).
A grip strength test was used to analyze the motor performance, where the mice had to grap a
T-shaped bar, that was connected to a digital dynamometer. Fuca1(-/-) mice showed a reduced
forelimb grip strength at 3 months of age (figure 4.24 A) as well as an enhanced rate of paw
misplacements (40 % of Fuca1(-/-) mice (6/15); 7 % of wildtype mice (1/15)) . As the differ-
ences between the Fuca1(-/-) mice and their wildtype littermates were not that significant, the
animals were re-tested at 7 months of age. However, no obvious progression was detected re-
garding the reduced forelimb strength (figure 4.24 A; paw misplacements: 50 % of Fuca1(-/-)
mice (4/8); 0 % of wildtype mice (0/10)). In addition, motor and coordinatory performance
was evaluated using a rotarod test. The animals were placed on a horizontally located, rotating
rod. Rotation was accelerating from 4 to 40 rpm during 5 min and the drop latency of the ani-
mals was measured over four test trials. No differences were detected between wildtype and
Fuca1(-/-) mice at 3 months of age (figure 4.24 D). The drop latencies increased in subsequent
trials indicating a similar motor learning in both genotypes. However, at 7 months of age the
Fuca1(-/-) mice showed a significant decreased drop latency in comparison to their wildtype
littermates (figure 4.24 E). A progressive impairment of motor skills was evident, as all tested
Fuca1(-/-) mice performed worse at 7 months of age (figure 4.24 F).
Hypoactivity was already observed in Fuca1(-/-) mice starting at approximately 6 months of
age (section 4.1.5) and could be confirmed by analyzing the cage activity. Transparent cages
were used, placed between 3 infrared beams and the total number of beam crossings was
recorded over 23 h. The activity of 3-month-old wildtype animals showed an initial ex-
ploratory peak and a characteristic pattern of circadian activity. In contrast, these movement
peaks were less pronounced or completely absent in the Fuca1(-/-) mice, indicating a hypoac-
tive behavior (figure 4.24 B), although no obvious progression was detected in 7-month-old
animals (figure 4.24 C).
The cognitive abilities were analyzed at 7 months of age using a contextual and cued fear con-
ditioning test recording the freezing behavior of the mice (figure 4.24 G). The animals were
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Figure 4.24: Fucosidase knock-out mice show behavioral deficits
(A) Grip strength test: Fuca1(-/-) mice showed a reduced forelimb strength at 3 and 7 months of age.
An age-dependent progression was not detected. (B) and (C) Home cage activity was recorded over
23 h. Both, 3- and 7-month-old Fuca1(-/-) mice showed hypoactive behavior. (D) Using a rotarod test,
no differences between the genotypes were detected at 3 months of age. (E) 7-month-old Fuca1(-/-)
mice showed a decreased drop latency across four subsequent trials. (F) A progressive impairment of
motor function was detected in all investigated Fuca1(-/-) animals. The scatter plot shows the rotarod
drop latency of Fuca1(-/-) mice at 3 and 7 months of age. (G) Contextual and cued fear memory: No
difference in baseline freezing levels or fear acquisition was observed between the genotypes. However,
contextual and cued fear memory is impaired as shown by the decreased freezing percentage during
fear memory evaluations in Fuca1(-/-) mice. HAB = habituation, BL = baseline, FC = fear conditioning,
CON = context fear, preCUE = pre cued fear, CUE = cued fear; n = 15 for 3 months-old mice, n = 10
(WT) and n = 8 (Fuca1(-/-)) for 7 months-old mice. *p < 0.05 ; **p < 0.01
placed in the test environment for 5 min (habituation time). On the next day, the mice were
placed in the same environment and received 2 min of exploration time (baseline-score). No
differences between wildtype and Fuca1(-/-) mice were observed regarding freezing behavior
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during the preparatory phases of the experiment (habituation and baseline). After baseline
scoring, an auditory stimulus (buzzer = conditional stimulus (CS)) was sounded for 30 sec and
an electric foot shock (0.3 mA) was applied for 2 sec (= averse, unconditional stimulus (US)).
After 1 min of exploration, the CS-US was presented for a second time followed by a final
exploration time of 1 min (fear conditioning phase). Fear acquisition was successful, as the
freezing percentage of both genotypes increased during fear conditioning. On the third day,
the contextual fear memory was recorded by placing the animals in the same environment for
5 min. Fuca1(-/-) mice showed a decreased freezing behavior indicating an impaired contex-
tual fear memory. After 90 min the animals were presented to environmental alterations and
received 3 min of exploration (pre-cue phase). Here, no differences were observed between
the genotypes and freezing behavior was similar to the contextual phase, reflecting similar
fear acquisition in the context of the newly created environment. Then the auditory stimulus
(buzzer) was presented for 3 min resulting in substantial increase of freezing in wildtype mice
(cue phase). This reaction was very weak pronounced in the Fuca1(-/-) mice, indicating an
impaired cued fear memory. All these results demonstrate that the Fuca1(-/-) mice suffered
from motor and coordinatory dysfunction and showed reduced activity as well as cognitive
impairment.
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4.2 Production and purification of human α-L-fucosidase
4.2.1 Establishment of an α-L-fucosidase expression system in CHO-K1
cells
Recombinant lysosomal enzymes used for ERTs are commonly produced in CHO-K1 cells
and their derivatives like DG44 (e. g. for ERTs of Morbus Gaucher (Van Patten et al. 2007)
and Fabry disease (Ioannou et al. 2001)). The synthesis of the enzymes results in a high protein
overload of ER and Golgi apparatus of the cells. Hence, the majority of the produced enzymes
escapes the lysosomal transport pathways and is secreted into the cell culture medium. The
conditioned medium is harvested and used for further purification of the enzymes. For human
α-L-fucosidase production, CHO-K1 cells were transfected with an expression plasmid for
the untagged and the C-terminal His6-tagged enzyme, respectively. After selection of stably
transfected cells, the synthesis of the enzyme was tested by culturing the cells in FCS-free
medium for 24 h. α-L-fucosidase activity was measured in the cell culture supernatant and a
cell clone displaying the highest fucosidase secretion capacity (untagged: # C1; His6-tagged:
# C2) was further subjected to a limited dilution procedure in order to establish single cell
clones. After cell propagation, the cell clone displaying the highest fucosidase secretion ca-
pacity (untagged: # C1/A5; His6-tagged: # C2/C1) was expanded and characterized in detail.
No α-L-fucosidase activity was detected in the cell culture supernatant of untransfected cells,
while the stably transfected CHO-K1 cell lines displayed a high α-L-fucosidase synthesis
(figure 4.25 A). Generally, a slightly higher enzyme production was detected in the CHO-K1
cell line expressing the His6-tagged α-L-fucosidase (10.6 mU/ml) than in the CHO-K1 cell
line expressing the untagged enzyme (8.8 mU/ml).
For the initial experiments like the establishment of a purification strategy, only minor amounts
of α-L-fucosidase were needed. For this purpose, an adherent cell culture system was estab-
lished and the optimal production conditions were tested. Using 0.5 % FCS, an optimal cell
survival was achieved. The cell culture supernatant was harvested every second day, as ex-
tended harvest intervals caused a massive decrease in cell survival. The fucosidase secretion
capacity was monitored during the production cycle and was severely reduced after the fourth
harvest. In summary, the optimal α-L-fucosidase production in the adherent cell culture sys-
tem was achieved using culture medium containing 0.5 % FCS with a collecting interval of
two days for four times.
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Figure 4.25: Establishment of CHO-K1 cells overexpressing human α-L-fucosidase
(A) CHO-K1 cells were stably transfected with an expression plasmid for the untagged and the His6-
tagged human α-L-fucosidase, respectively. Cell clones were picked (untagged: # C1; His6-tagged:
# C2). Single cell clones were established by limited dilution (untagged: # C1/A5; His6-tagged:
# C2/C1). Their fucosidase secretion capacity was monitored in comparison to untransfected cells
(UT). Cells were grown for 48 h in FCS-free medium and the α-L-fucosidase activity of the cell cul-
ture supernatant was measured. (B - D) CHO-K1 cells expressing untagged (# C1/A5) or His6-tagged
(# C2/C1) human α-L-fucosidase were inoculated with 3 x 105 and 5 x 105 viable cells/ml (30 ml cul-
ture volume). The cells were grown in suspension and the viable cell density (VCD), the viability as
well as the α-L-fucosidase activity in the cell culture medium was measured daily.
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For ERT purposes, a large-scale production of the human α-L-fucosidase is necessary, which
is achieved by adapting the CHO-K1 cell lines to suspension conditions using serum- and
protein-free medium (Corning R© PF medium). A growth curve was monitored over several
days. The cells were seeded at concentrations of 3 x 105 and 5 x 105 viable cells/ml in 30 ml
culture volume, respectively, and the viable cell density (VCD), the total viability as well as
the α-L-fucosidase activity in the cell culture medium was monitored daily. CHO-K1 cells
expressing the untagged enzyme reached higher cell densities, whereas the cells expressing
the His6-tagged enzyme produced considerably more α-L-fucosidase (figure 4.25 B - E). The
highest cell densities were measured at day four to six. The viability decreased during the
further cultivation period. The highest α-L-fucosidase activities were measured at day ten
with 16 mU/ml for the untagged enzyme (vs. 8.8 mU/ml in adherent system) and 282 mU/ml
for the His6-tagged enzyme (vs. 10.6 mU/ml in adherent system).
4.2.2 Purification of His6-tagged human α-L-fucosidase
The His6-tagged human α-L-fucosidase was purified from ammonium sulfate precipitated cell
culture medium of CHO-K1 cells (# C2/C1) using a Ni2+-affinity chromatography as a first
purification step followed by a strong cation exchange chromatography (SCX) as the second
purification step. Finally, the enzyme was re-buffered into PBS.
The binding affinity of the His6-tagged α-L-fucosidase towards the Ni2+-affinity matrix was
very high and allowed the presence of 50 mM imidazole in the binding buffer. In prior tests, no
α-L-fucosidase activity was detected in flow through and washing fractions, while the enzyme
started to elute at 230 mM imidazole during a linear elution gradient with increasing imidazole
concentration. Taking this into consideration, a purification protocol was established in which
the column was washed with 50 mM imidazole and elution of the His6-tagged α-L-fucosidase
was achieved by flushing the column with 500 mM imidazole resulting in a single and dis-
tinct elution peak (figure 4.26 A), where 95 % - 100 % of the initially loaded α-L-fucosidase
activity was recovered within 4 ml (fractions F2 - F5). As determined by immunoblotting and
on a coomassie-stained SDS-gel (figure 4.26 B), these fractions were highly enriched in α-L-
fucosidase (55 kDa) but still contained some high-molecular weight as well as low-molecular
weight contaminants. Fractions F2 - F5 were pooled and further applied to a SCX column.
The Ni2+-affinity chromatography used a Tris/HCl-buffered system at pH 7.4, while the SCX
was performed at pH 5.0, so that the pooled eluate had to be re-buffered towards the acidic pH.
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Figure 4.26: Purification of His6-tagged human α-L-fucosidase
(A) Ni2+-affinity chromatography: His6-tagged human α-L-fucosidase was purified from coditioned
cell culture medium of CHO-K1 cells (# C2/C1). The reconstituted ammonium sulfate precipitate was
loaded on a HisTrap HP 1 ml column. After washing, the His6-tagged α-L-fucosidase was eluted
using 500 mM imidazole (black line). The UV-absorbance (280 nm, blue line) and the α-L-fucosidase
activity (red line) is shown. The majority of the enzyme eluted at 29 - 32 ml (fractions F2 - F5). (B)
Fractions obtained by Ni2+-affinity chromatography were analyzed on a coomassie-stained SDS-gel
and by immunoblotting using a RGS-His6-specific antibody. α-L-Fucosidase was detected with an
apparent molecular weight of 55 kDa. (C) Strong cation exchange chromatography (SCX): Ni2+-NTA
purified material (F2 - F5) was diluted in SCX binding buffer and loaded on a HiTrap SP HP 1 ml
column. Two washing steps (without NaCl and using 400 mM NaCl) were applied and the enzyme was
eluted using 1 M NaCl (black line). The UV-absorbance (280 nm, blue line) and the α-L-fucosidase
activity (red line) is shown. The majority of the enzyme eluted at 67 - 69 ml (fractions F17 - F19). (D)
Fractions obtained by SCX were analyzed on a coomassie-stained SDS-gel and by immunoblotting
using a RGS-His6-specific antibody. α-L-Fucosidase was detected at 55 kDa. Moreover, F17 - F19
were pooled, re-buffered into PBS, concentrated and analyzed on a SDS-gel by coomassie- and silver-
staining. L: load; FT: flow through; W: washing fractions; PBS: PBS-buffered sample.
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Moreover, 500 mM of NaCl were used in the Ni2+-affinity chromatography and had to be
removed to enable an efficient binding to the SCX column. In order to re-adjust the buffer,
different methods like dialysis and fast diafiltration were tested resulting in a massive loss
of α-L-fucosidase activity. Finally, the buffer exchange was performed by simply diluting
the pooled fractions F2 - F5 in SCX binding buffer (1 : 10). Approximately 10 % of the α-L-
fucosidase activity were lost in this step.
The re-buffered sample was loaded on a HiTrap SP HP 1 ml column and purified by a SCX.
While no α-L-fucosidase activity was detected in the flow through and washing fraction, the
His6-tagged enzyme eluted at 850 mM NaCl during a linear elution gradient of increasing
salt concentration (data not shown). The high binding affinity towards the column matrix
enabled the implementation of an additional washing step using 400 mM NaCl resulting in the
elution of contaminants as indicated by the increase in UV-absorbance (figure 4.26 C), while
no significant loss of the α-L-fucosidase (< 1 %) was observed. Finally, the His6-tagged α-
L-fucosidase was eluted within a single, distinct peak of 3 ml (fractions F17 - F19) using 1 M
NaCl with a recovery of 95 % - 100 % of the α-L-fucosidase activity (based on the SCX load).
The elution fractions were further analyzed by immunoblotting and on a coomassie-stained
SDS-gel (figure 4.26 D) showing that the α-L-fucosidase was highly enriched and exhibited
an apparent molecular weight of 55 kDa. Only some minor impurities of low-molecular weight
were detected.
In order to re-adjust buffer conditions suitable for ERT, the His6-tagged human α-L-fucosidase
was re-buffered into PBS. Although a fast diafiltration of the enzyme from neutral towards
acidic pH resulted in a massive loss of α-L-fucosidase activity (as described above), only
minor amounts (approximately 1 %) were lost during diafiltration from acidic to neutral buffer
conditions. The sample was concentrated to a final volume of approximately 0.5 ml.
Table 4.3 summarizes the results of a typical purification procedure of the His6-tagged human
α-L-fucosidase. Here, 900 ml of conditioned cell culture supernatant were used. Based on
the load of the Ni2+-affinity chromatography, 80.2 % (70 U) of the fucosidase activity were
recovered in the final PBS-buffered sample. The protein concentration of 7.9 mg/ml as well
as a specific activity of 15.4 U/mg were determined, reflecting a 31-fold purification. The
His6-tagged α-L-fucosidase was purified to apparent homogeneity, as shown on a coomassie-
stained SDS-gel (figure 4.26 D). Only a few low-molecular weight contaminants were detected
using a very sensitive silver-staining.
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Table 4.3: Purification of the His6-tagged human α-L-fucosidase using 900 ml condi-
tioned cell culture supernatant
loaded sample
volume
[ml]
α-L-fucoisdase
activity [U]
specific activity
[mU/mg]
protein
concentration
[mg/ml]
Ni2+-affinity chromatogra-
phy
20 87.3 0.5 9.3
strong cation exchange chro-
matography (SCX)
40 71.5 13.1 0.1
buffer exchange via centricon 3 70.8 13.8 1.7
PBS-buffered sample
Volume
[ml]
α-L-fucoisdase
activity [U]
specific activity
[mU/mg]
protein
concentration
[mg/ml]
PBS-buffered sample 0.6 70.0 15.4 7.9
4.2.3 Purification of untagged human α-L-fucosidase
The application of the His6-tagged human α-L-fucosidase in an ERT of human fucosidosis
patients is not feasible, as the His6-tag exhibits a high immunogenicity, so that a large-scale
production of the untagged human α-L-fucosidase is mandatory. However, the establishment
of a purification protocol for the untagged enzyme is challenging, as the specific Ni2+-affinity
chromatography used for purification of the His6-tagged human α-L-fucosidase has to be re-
placed by other separation techniques. Moreover, a Fuca1-specific antibody was not available
at that time. In order to analyze the purification strategies by immunoblotting, the His6-tagged
α-L-fucosidase was used in parallel in some experiments. Different strategies like a fucose-
and a concanavalin A-affinity chromatography as well as different ion exchange chromatogra-
phy protocols were tested and are described below. The enzyme was produced from adherently
grown CHO-K1 cells (cell line # C1/A5). The conditioned cell culture medium was harvested,
precipitated by ammonium sulfate and the resuspended proteins were dialyzed and applied to
various chromatography techniques.
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4.2.3.1 Fucose-affinity chromatography
The purification of the α-L-fucosidase from several human tissues has been reported and was
achieved by a specific fucose-affinity chromatography (Alhadeff et al. 1975b, Turner 1979,
Chien and Dawson 1980). A similar approach was tested in this study by immobilizing N-(ε-
aminocaproyl)-β -L-fucopyranosylamine on CNBr-activated sepharose beads and on a purifi-
cation column containing NHS-activated sepharose (HiTrap NHS-activated HP 1 ml), respec-
tively. Due to technical reasons, the matrices were finally combined. 3.7 U α-L-fucosidase
were loaded on this affinity matrix and 4 % of the enzyme eluted in flow through and washing
fractions. However, loading of higher amounts of α-L-fucosidase resulted in a massively in-
creased elution in the flow through, indicating that the binding capacity of the affinity matrix
was rather low.
The α-L-fucosidase was eluted by addition of 100 mM L-fucose. However, analysis of the
elution fractions by activity measurements was not possible as the L-fucose completely inhi-
bited the α-L-fucosidase activity (figure 4.27 A). The elution fractions were further analyzed
on a silver-stained SDS-gel (figure 4.27 B). The enzyme eluted as a broad smear and con-
Figure 4.27: Fucose-affinity chromatography
(A) CHO-K1 cells overexpressing untagged human α-L-fucosidase were cultured for 72 h in FCS-
free medium. The conditioned medium was quenched with different amounts of L-fucose and the
α-L-fucosidase activity was measured. (B) A silver-stained SDS-gel of an examplified fucose-affinity
chromatography is shown. Results were obtained in cooperation with Michael Weber (Master Thesis).
Untagged α-L-fucosidase was loaded on a fucosyl-affinity column. The enzyme was eluted using 15 ml
of 100 mM L-fucosose including 500 mM NaCl. The expected molecular weight of the α-L-fucosidase
(55 kDa) and a 66 kDa protein (probably BSA) is indicated. L: load; FT: flow through.
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tained high amounts of impurities, although column binding and washing was performed in
the presence of 500 mM NaCl to reduce unspecific interactions. Remarkably, high amounts of
a protein with an apparent molecular weight of 66 kDa were detected, which could be BSA.
In summary, the fucose-affinity chromatography should be further optimized to enable a higher
binding capacity of the affinity column and to reach a higher purity of the α-L-fucosidase.
4.2.3.2 Concanavalin A-affinity chromatography
Concanavalin A (ConA)-affinity chromatography is widely used for the purification of glyco-
proteins. The lectin binds specifically to N-glycans, particularly internal and terminal non-
reducing α-D-glucosyl and α-D-mannosyl residues. For the purification of untagged α-L-
fucosidase, ConA-coupled sepharose beads were tested.
In order to enable an analysis of the purification strategy by immunoblotting, the His6-tagged
human α-L-fucosidase was used in the experiments described below. The enzyme was loaded
on ConA sepharose beads and elution was performed by adding up to 1 M α-D-methylmanno-
side, but almost no elution (< 10 %) of the α-L-fucosidase was achieved.
At neutral pH, ConA forms a protein-ion complex with Mn2+ and Ca2+, which are essential
cofactors for substrate binding. The protein-ion complex is stable at neutral pH even in the
absence of Mn2+ and Ca2+ in the chromatography buffer. However, at acidic pH values below
5.0 the ions are released from the protein. Hence, the ConA sepharose beads were loaded with
α-L-fucosidase in the presence of Mn2+ and Ca2+ at neutral pH. Afterwards, an acidic elution
buffer at pH 4.5 including 500 mM NaCl and 1 M α-methylmannoside was applied, but did not
improve elution as demonstrated by a α-L-fucosidase activity assay (figure 4.28 A). As little
as 2.4 % of the initially loaded fucosidase activity were eluted in the flow through and washing
steps, but only 6.9 % were recovered during elution, which means that 90.7 % still remained
on the column. An aliquot of the ConA sepharose beads was boiled and analyzed by im-
munoblotting showing high amounts of α-L-fucosidase sticking to the beads (figure 4.28 B).
Consequently, the ConA-affinity chromatography was not further considered as purification
strategy as an efficient elution of the α-L-fucosidase was only achieved under denaturating
conditions.
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Figure 4.28: Concanavalin A-affinity chromatography
Experiments were performed in cooperation with Michael Weber (Master Thesis). (A) His6-tagged
human α-L-fucosidase was loaded on ConA sepharose beads under neutral conditions (pH 7.4) in the
presence of Mn+ and Ca2+ as well as 500 mM NaCl. After washing the enzyme was eluted using 5 ml
of acidic buffer (pH 4.5) including 500 mM Nacl and 1 M α-methylmannoside. The elution buffer was
incubated on the column for 5 min and collected as 1 ml fraction. Elution was repeated for 5 times
(A - E) and the α-L-fucosidase activity was determined in each fraction. L: load; FT: flow through; W:
washing fractions. (B) A part of the ConA sepharose beads was boiled and analyzed by immunoblot-
ting using a RGS-His6-specific antibody together with the load, flow through and washing fractions.
The following volume percentages were loaded: L: load 0.2 %, FT: flow through 0.5 %, W: washing
fractions 1 %, B: boiled ConA beads 0.6 %.
4.2.3.3 Ion-exchange chromatography
Ion-exchange chromatography is an easy accessible and low-cost method for a reproducible
purification of recombinant proteins. The purification of the His6-tagged human α-L-fucosi-
dase included a strong cation-exchange chromatography (SCX) as second purification step
(section 4.2.2), in which the enzyme showed a strong affinity towards the column matrix. The
untagged human α-L-fucosidase was expected to show similar binding properties during SCX,
as the RGS-His6-tag was the only difference between both enzymes. Different ion exchange
matrices as well as different purification settings (pH values) were tested for the untagged
α-L-fucosidase. An efficient binding and elution was observed at pH 4.0 - 5.0 for the cation
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Table 4.4: Purification of the untagged human α-L-fucosidase by ion exchange chro-
matography
Column pH % fucosidase activity in
the flow through and
washing steps
% fucosidase
activity in the
elution fractions
elution
concentration
(mM NaCl)
HiTrap HP SP 1 ml 4.0 0 100 590
HiTrap HP SP 1 ml 4.5 0 100 450
HiTrap HP SP 1 ml 5.0 0 100 450
HiTrap HP SP 1 ml 7.4 15.7 84.3 300
HiTrap DEAE FF 1 ml 4.6 99.0 1.0 0
HiTrap DEAE FF 1 ml 8.0 2.5 97.5 240
exchange matrix and at pH 8.0 for the anion exchange matrix. However, all attempts resulted
in a significant lower salt concentration for elution of the untagged α-L-fucosidase than for
the His6-tagged enzyme (table 4.4). As a consequence, it was not possible to separate the
contaminants efficiently. In figure 4.29 a coomassie-stained SDS-gel from an anion-exchange
chromatography using an HiTrap DEAE FF column at pH 8.0 is shown exemplarily.
Figure 4.29: Ion-exchange chromatography of the untagged human α-L-fucosidase
(A) Untagged human α-L-fucosidase was loaded on a HiTrap DEAE FF 1 ml at pH 8.0. After washing
the enzyme was eluted using a linear gradient from 0 - 1 M NaCl over 15 ml. The fractions were ana-
lyzed on a coomassie-stained SDS-gel. The expected molecular weight of the α-L-fucosidase (55 kDa)
is marked by arrows. L: load, FT: flow through, W: washing fractions.
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The analysis of different ion exchange chromatographies uncovered the presence of a promi-
nent contaminant (figure 4.29) with an apparent molecular weight of 66 kDa (most likely
BSA), that could not be removed so far. In a further experiment the adherent CHO-K1
cells were cultured in FCS-free medium and the conditioned medium was either applied
to an ammonium sulfate precipitation or was directly dialyzed over night and loaded on a
HiTrap SP HP 1 ml column, respectively. In both cases the α-L-fucosidase eluted in frac-
tion 7 (figure 4.30 A and C). However, different UV-absorbances were recorded suggesting an
Figure 4.30: Ion-exchange chromatography using precipitated as well as non-precipitated un-
tagged human α-L-fucosidase
Untagged human α-L-fucosidase was produced using adherent CHO-K1 cells (# C2/C1). The cells
were cultured in FCS-free medium for three days. (A) The conditioned medium was precipitated
using ammonium sulfate, reconstituted in binding buffer (pH 5.0), dialyzed and loaded on a Hi-
Trap SP HP 1 ml column. The α-L-fucosidase was eluted using a linear gradient of increasing salt
concentrations (0 - 1 M NaCl, black line) over 15 ml. The UV-absorbance is shown as blue line and
the α-L-fucosidase activity as red line. (B) The purification strategy was analyzed on a coomassie-
stained SDS-gel. The expected molecular weight of the α-L-fucosidase is 55 kDa. (C) The conditioned
medium was directly dialyzed against binding buffer (pH 5.0) and the purification was performed as de-
scribed in (A) and (D) was further analyzed on a coomassie-stained SDS-gel. The expected molecular
weight of the α-L-fucosidase is 55 kDa. L: load, FT: flow through, W: washing fractions.
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altered elution of the contaminants, which was further analyzed on a coomassie-stained SDS-
gel. Similar to the results described above, most of the contaminants from the precipitated
starting material eluted together with the α-L-fucosidase (figure 4.30 B), while some of the
impurities from the non-precipitated starting material eluted at higher salt concentrations than
the enzyme (figure 4.30 D). Further experiments are necessary to analyze this phenomenon
and the experiment should be repeated using conditioned medium from CHO-K1 cells cultured
under FCS-free suspension conditions.
4.2.3.4 Ni2+-affinity chromatography
Berteau et al. (2002) described the purification of an untagged α-L-fucosidase from P. max-
imus (starfish) by Ni2+-affinity chromatography amongst other purification techniques. It was
postulated that the binding of the untagged enzyme was achieved by histidine residues located
at the protein surface. The NetSurfP prediction program, which checks out the protein sur-
face accessibility, predicted that seven out of twelve histidine residues might be located at the
protein surface of the human α-L-fucosidase.
The untagged human α-L-fucosidase was applied to a Ni2+-affinity chromatography on a His-
Trap HP 1 ml column at pH 7.4 in the presence of 500 mM NaCl. 55 % of the α-L-fucosidase
activity was detected in the flow through or washing steps. 45 % of the α-L-fucosidase eluted
specifically by addition of imidazole with the highest enzyme activity at approximately 50 mM
imidazole. The majority of contaminants was detected in the same fractions as the α-L-
fucosidase (figure 4.31). Therefore, the Ni2+-affinity chromatography was not further con-
sidered as purification strategy for the untagged human α-L-fucosidase.
4.2.4 Characterization of the recombinant α-L-fucosidase with regard to
its application in ERT
An aim of this work was the application of the purified human α-L-fucosidase in an ERT
of Fuca1(-/-) mice. Therefore, the recombinant enzyme was characterized regarding its pH
optimum and oligomerization. As the latter might also influence enzyme stability, this as-
pect was also analyzed. Moreover, the glycosylation pattern and especially the mannose-6-
phosphorylation of the recombinant α-L-fucosidase was determined as these properties might
influence the uptake of the enzyme during ERT.
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Figure 4.31: Ni2+-affinity chromatography of untagged human α-L-fucosidase
The untagged human α-L-fucosidase was loaded on a HisTrap HP 1 ml column. The column was
washed and elution was performed using a linear gradient from 0 - 500 mM imidazole over 15 ml.
The highest fucosidase activity was measured in elution fraction 3. All fractions were analyzed on a
coomassie-stained SDS-gel. The expected molecular weight of the α-L-fucosidase (55 kDa) is marked
by arrows.
4.2.4.1 pH optimum of α-L-fucosidase
The standard α-L-fucosidase activity assay is carried out using an acidic citrate buffered sys-
tem. For analysis of the pH optimum of the enzyme, a buffer system described by McIlvaine
(1921) (citrate-phosphate buffer) was used instead, that enabled investigations over a broader
pH spectrum (pH 4.0 - 8.0), than citrate alone. As control, the pH optimum of the genuine α-
L-fucosidase was determined using lysosome-enriched fractions from liver of wildtype mice
with the highest α-L-fucosidase activity at pH 5.5 (figure 4.32 A). At pH 7.0, still 50 % of
the maximal enzyme activity was measured. Next, the untagged human α-L-fucosidase de-
rived from CHO-K1 cells was analyzed and the pH optimum of the recombinant enzyme
slightly differed from that of the genuine enzyme and was recorded at pH 5.0 (figure 4.32 B).
In order to exclude a possible influence of McIlvaine’s buffer on the pH-dependency of the α-
L-fucosidase, the experiment was repeated using the citrate buffer in a suitable pH spectrum
(pH 4.5 - 6.5). Here, the recombinant α-L-fucosidase exhibited a pH-dependency comparable
to that of lysosome-enriched fractions from mouse liver with an pH optimum at 5.5 (figure
4.32 C), indicating that the recombinant enzyme is highly active at lysosomal pH.
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Figure 4.32: pH optimum of the α-L-fucosidase
(A) The α-L-fucosidase activity of lysosome-enriched fractions from liver of wildtype mice was ana-
lyzed over a broad pH spectrum (pH 4.0 - 8.0) using McIlvaine’s buffer system (McIlvaine 1921). (B)
The activity of CHO-K1 cell-derived untagged human α-L-fucosidase was determined using McIl-
vaine’s buffer system adjusted to the stated pH values. (C) Same experiment as in (B). In addition
the α-L-fucosidase activity was determined at pH 4.5 - 6.5 using citrate buffer instead of McIlvaine’s
buffer.
4.2.4.2 Oligomerization
A homooligomerization of the α-L-fucosidase has been reported including dimeric, tetrameric
as well as hexameric forms (Alhadeff et al. 1975b, Turner 1979 and Chien and Dawson 1980).
The fact that the His6-tagged human α-L-fucosidase exhibited an unexpected strong binding
towards the HisTrap HP column as well as the HiTrap SP HP column suggested an oligomer-
ization of the enzyme that accordingly increased the avidity of this interaction. Hence, the
molecular weight of the purified human α-L-fucosidase was determined by size exclusion
chromatography on a Superdex 200 10/30 column using recombinant untagged as well as
His6-tagged enzyme at pH 4.6 and 7.4, respectively. Several standard proteins were also se-
parated at neutral and acidic pH and were used for molecular weight calculation (figure 4.33
A and B). As expected, the His6-tagged human α-L-fucosidase was detected as an oligomer
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Figure 4.33: Oligomerization of the α-L-fucosidase
Experiments were performed in cooperation with Michael Weber and Marcel Strüve (practical in-
ternship). (A and B) Standard proteins were separated by size exclusion chromatography (SEC)
using a Superdex 200 10/30 column and were used for molecular weight calculation. PBS pH 7.4
or McIlvaine’s buffer pH 4.6 supplemented with 140 mM NaCl was used as running buffer. dextran
blue = 2000 kDa; thyroglobulin = 670 kDa; ferritin = 440 kDa; BSA = 66 kDa; ovalbumin = 45 kDa; cy-
tochrom C = 12.5 kDa; aprotinin = 6.5 kDa; His6-tagged human α-L-fucosidase (C) as well as untagged
human α-L-fucosidase (D) was dialyzed against PBS pH 7.4 or McIlvaine’s buffer pH 4.6 supple-
mented with 140 mM NaCl and analyzed by SEC. Fractions of 250 µl were collected. The enzyme
was detected in the elution fractions by α-L-fucosidase activity measurements. (E and F) Lysosome-
enriched fraction were isolated from liver of wildtype mice. The lysosomes were pelleted by centrifu-
gation and were resuspended in either PBS pH 7.4 or McIlvaine’s buffer pH 4.6 supplemented with
140 mM NaCl. The SCX was performed as described above. (E) The α-L-fucosidase was detected by
activity measurements. (F) Plbd2 was detected by immunoblotting. The 25 kDa, 28 kDa and 40 kDa
subunit is visible. Isolated lysosomes (F2) were used as internal control.
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with calculated molecular weights of 276 kDa and 356 kDa at pH 7.4 and 4.6, respectively
(figure 4.33 C). For the untagged human α-L-fucosidase, a pH-dependent oligomerization
was observed with calculated molecular weights of 79 kDa at pH 7.4 and of 355 kDa at pH 4.6
(figure 4.33 D). Moreover, liver-derived murine α-L-fucosidase was analyzed by SEC and
the pH-dependent oligomerization seen before for the recombinant human protein was con-
firmed (figure 4.33 E). At pH 7.4 the monomeric form of the fucosidase was detected (56 kDa),
whereas at pH 4.6 a molecular weight of 312 kDa was determined suggesting a hexamerization
at lysosomal pH. As internal control, the lysosomal protein Plbd2 was confirmed as a dimer
(112 kDa) at pH 4.6 (figure 4.33 F).
4.2.4.3 Stability after short-term storage
In order to analyze the stability of the purified His6-tagged human α-L-fucosidase, the enzyme
activity was measured during short-term storage either at room temperature or at 4 ◦C. After
ten days, only a slight decrease of 22 % (storage at room temperature) and 15 % (storage at
4 ◦C) of α-L-fucosidase activity was observed (figure 4.34 A). Using a coomassie-stained
SDS-gel, a protein degradation was visible after four days of storage at room temperature,
whereas no degradation of the enzyme was detected even after ten days of storage at 4 ◦C
(figure 4.34 B), indicating a high stability of the His6-tagged human α-L-fucosidase.
Figure 4.34: Stability of the His6-tagged human α-L-fucosidase after short-time storage
Purified His6-tagged human α-L-fucosidase was stored at room temperature and 4 ◦C for up to ten
days, respectively. Samples were analyzed at defined time points (0.5, 1, 2, 4, 7 and 10 days). (A)
The α-L-fucosidase activity was measured and (B) the enzyme was analyzed for protein degradation
by SDS-PAGE followed by coomassie-staining.
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4.2.4.4 Glycosylation
Many lysosomal proteins are known to be highly glycosylated. The α-L-fucosidase was pre-
viously reported to exhibit high-mannose as well as complex type N-glycans (Johnson et al.
1992). In order to analyze the glycosylation of the recombinant human α-L-fucosidase, the
purified His6-tagged enzyme was digested with PNGase F and EndoH. PNGase F cleaves high-
mannose as well as complex type N-glycans between the GlcNAc and the asparagine residue,
whereas EndoH only cleaves high-mannose type N-glycans between the two core-GlcNAc
residues. Using immunoblotting, the untreated His6-tagged α-L-fucosidase was detected at
55 kDa (figure 4.35), while the PNGase F digest resulted in a substantial decrease in molecular
weight to 45 kDa. In contrast, a molecular weight of 50 kDa was detected after EndoH digest,
indicating that the His6-tagged human α-L-fucosidase exhibited both types of N-glycans.
Figure 4.35: Glycosylation pattern of the His6-tagged human α-L-fucosidase
Purified His6-tagged human α-L-fucosidase was digested with PNGase F (P) and EndoH (H) respec-
tively. The samples were analyzed by immunoblotting using a Fuca1-specific antibody (A112). UT -
untreated.
4.2.4.5 Mannose-6-phosphorylation
The lysosomal targeting of the α-L-fucosidase was shown to be strictly dependent on the
mannose-6-phosphate (M6P) receptor pathway (Kollmann et al. 2012, Markmann et al. 2015).
Thus, a high M6P phosphorylation of the recombinant enzyme is desired to achieve an efficient
ERT. However, a complete M6P modification of recombinant proteins is often not achieved
in overexpression systems due to high protein overload of the M6P-generating system (Roces
et al. 2004).
The degree of M6P phosphorylation of the His6-tagged human α-L-fucosidase was quantified
using an affinity column with immobilized M6P receptors (Braulke et al. 1990; kind gift of
Siva Kumar, Hyderabad, India). The purified enzyme was loaded and unbound material was
washed off using 5 mM Glc-6-phosphate, the epimer of M6P. 37.1 % of the enzyme eluted
already in the flow-through and washing fractions, whereas only 4 % of the His6-tagged α-L-
fucosidase eluted specifically by addition of 5 mM M6P (figure 4.36 A and B), indicating an
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incomplete elution of the loaded enzyme. The experiment was repeated and additional wash-
ing steps including a stringent acidic elution buffer and 20 % ethanol were performed (figure
4.36 C). Again, the α-L-fucosidase activity could not be completely recovered, but a sub-
stantial amount of the enzyme eluted after addition of 20 % ethanol indicating an unspecific
interaction of the His6-tagged α-L-fucosidase with the column matrix. In order to exclude
that the column matrix was irreversibly damaged, recombinant Scpep1 with a high M6P phos-
phorylation degree was used as positive control (figure 4.36 D). Scpep1 could be specifically
eluted upon addition of 5 mM M6P. These results indicate that a considerable amount of the
His6-tagged α-L-fucosidase was M6P phosphorylated, but the degree of the M6P modification
could not be precisely quantified.
Figure 4.36: Quantification of the M6P phosphorylation of the His6-tagged α-L-fucosidase
(A) Purified His6-tagged α-L-fucosidase was loaded on a MPR-affinity matrix. The flow through (FT)
was collected, the matrix was washed with binding buffer (B) followed by binding buffer containing
5 mM Glc-6-phosphate (W). Elution was performed by addition of 5 mM M6P. 5 % (v/v) of each frac-
tion was precipitated with TCA and analyzed by immunoblotting (RGS-His6-specific antibody). (B)
The α-L-fucosidase activity was determined in each fraction. (C) The experiments described in (A)
was repeated and expanded by additional washing steps with a stringent acidic elution buffer (S) and
20 % ethanol (Et). The α-L-fucosidase activity was determined in each fraction. (D) Recombinant
Scpep1 exhibiting a high M6P phosphorylation degree was used as positive control. The experiment
was performed as described in (A). 5 % (v/v) of each fraction was precipitated with TCA and analyzed
by immunoblotting.
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4.3 Enzyme replacement therapy
4.3.1 In vitro digest of fucosidosis storage material
It is mandatory for an ERT of fucosidosis that the recombinant α-L-fucosidase is able to
digest the accumulated storage material. In order to perform an in vitro digest, storage ma-
terial derived from Fuca(-/-) kidney and cerebrum was isolated, incubated with the purified
His6-tagged enzyme and analyzed by thin-layer chromatography. As shown in figure 4.37,
the in vitro digest resulted in the disappearance or at least a shift of TLC bands towards
higher retention factors indicating that the storage material exhibited less hydrophilic prop-
erties as expected by an elimination of a sugar residue like α-L-fucose. Of note, L-fucose was
Figure 4.37: In vitro digest of fucosidosis storage material
Neutral oligosaccharides were isolated from wildtype and Fuca1(-/-) kidney and cerebrum and were
incubated with purified His6-tagged human α-L-fucosidase or with PBS, respectively. The experiment
was done in technical triplicates and the samples were analyzed by TLC. L-Fucose was loaded as
internal standard.
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loaded as internal standard on the TLC and α-L-fucosidase-treated samples showed an in-
creased intensity of the TLC band corresponding to L-fucose in comparison to the PBS-treated
samples. These results indicate that the His6-tagged human α-L-fucosidase is able to digest
storage material from Fuca1(-/-) mice in vitro.
4.3.2 Endocytosis of recombinant α-L-fucosidase
An efficient uptake of recombinant enzymes into affected cells and tissues is a prerequisite
for a successful ERT. The endocytosis of the His6-tagged human α-L-fucosidase was ana-
lyzed using immortalized wildtype and Fuca1(-/-) mouse embryonic fibroblasts (MEFs). The
purified enzyme was applied to the cell culture medium and the α-L-fucosiase activity was
subsequently measured in the cell lysates. Here, the enzyme activity was increased five to
ten times in the α-L-fucosidase-treated wildtype MEFs compared to PBS-treated cells (figure
4.38 A). As expected, no α-L-fucosidase activity could be detected in PBS-treated Fuca1(-/-)
MEFs, while the amount of endocytosed α-L-fucosidase was comparable to wildtype MEFs.
These results clearly indicate that the recombinant enzyme is endocytosed by wildtpye and
Fuca1(-/-) MEFs.
The endocytosis of the α-L-fucosidase was shown to be dose-dependent (figure 4.38 B), when
different amounts of enzyme were applied to wildtype and Fuca1(-/-) MEFs. The enzyme
activity of the cell lysates increased linearly with increasing α-L-fucosidase concentrations in
the medium. Moreover, a linear correlation was determined for the α-L-fucosidase activity
and the incubation time of the recombinant enzyme (figure 4.38 C). However, the Fuca1(-/-)
MEFs exhibited always a lower endocytosis rate than the wildtype MEFs as depicted by the
flatter slope of the linear regression lines (figure 4.38 B and C). It remains to be analyzed
whether this result is dependent on the Fuca1 gene knock-out or whether it is a feature of the
particular clonal cell lines, which were used to evaluate the dose and time dependency. Other
Fuca1(-/-) MEF cell lines might exhibit a higher endocytosis rates comparable to that of the
wildtype cell line.
Markmann et al. (2015) reported that the lysosomal targeting of the α-L-fucosidase is highly
dependent on the M6P residue. Their study was based on ML II MEFs, which are deficient in
GlcNAc-1-phosphotransferase thereby lacking the M6P modification of lysosomal proteins.
Endogenous lysosomal proteins depending on the MPR-pathway are not transported towards
the lysosome and are secreted. Of note, some hydrolases, but not the α-L-fucosidase reach
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Figure 4.38: His6-tagged human α-L-fucosidase is endocytosed by MEFs
(A) 20 µg/ml purified His6-tagged human α-L-fucosidase or equal amounts of PBS were applied to
the cell culture medium of wildtype and Fuca1(-/-) MEFs (n = 4) for 5 h. The cells were harvested by
trypsination and the α-L-fucosidase activity was measured in the cell lysates. (B) Same experiment as
in (A) but using different concentrations of His6-tagged human α-L-fucosidase (n = 1 for wildtype and
Fuca1(-/-) MEFs). (C) Same experiment as in (A) but cells were harvested after different incubation
times (n = 1 for wildtype and Fuca1(-/-) MEFs).
the lysosomal compartment through M6P-independent pathways, e. g. β -glucocerebrosidase
via Limp 2 (Reczek et al. 2007) or cathepsin D and cathepsin B via Lrp1 (Markmann et al.
2015). Moreover, ML II MEFs are also able to endocytose recombinant proteins that exhibit a
M6P-modification. Here, ML II MEFs were used that harbored the same genetic modification
as described by Markmann et al. (2015). After incubation with recombinant His6-tagged α-L-
fucosidase, a more than 100-fold increased intracellular α-L-fucosidase activity was detected.
Of note, the endocytosis could be inhibited by 96 % by the addition of 5 mM M6P. These re-
sults confirm, that the endocytosis of the α-L-fucosidase in ML II MEFs is highly dependent
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on the MPR-pathway. However, this effect was less pronounced in wildtype and Fuca1(-/-)
MEFs (figure 4.39 A). The addition of 5 mM M6P resulted in a decreased endocytosis by only
37 - 85 % dependent on the individual cell line (n = 2 for wildtype and Fuca1(-/-) MEFs), indi-
cating that the degree of the M6P-dependency might by cell line-specific and other endocytosis
pathways might be involved. The inhibitory effect of M6P was further analyzed by adding dif-
ferent amounts of M6P during the incubation with His6-tagged human α-L-fucosidase. The
α-L-fucosidase activity in the cell lysates was decreased by approximately 50 % when using
0.1 mM M6P, while the maximal inhibition was reached by using 1 mM M6P (figure 4.39 B).
Figure 4.39: Endocytosis of His6-
tagged human α-
L-fucosidase is de-
pendent on the MPR
pathway
(A) ML II MEFs (M; n = 1), wild-
type as well as Fuca1(-/-) MEFs
(n = 2) were treated with His6-
tagged human α-L-fucosidase. The
endocytosis was performed in the
presence or absence of 5 mM M6P.
The cells were harvested by trypsi-
nation and the α-L-fucosidase
activity was determined in the
cell lysates. (B) Wildtpye and
Fuca1(-/-) MEFs (n = 1) were
treated with His6-tagged human
α-L-fucosidase in the presence of
different amounts of M6P. The cells
were harvested by trypsination and
the α-L-fucosidase activity was
determined in the cell lysates.
4.3.3 ERT of the constitutive fucosidosis mouse model
So far, it was shown that the His6-tagged human α-L-fucosidase is able to digest storage ma-
terial from Fuca1(-/-) mice in vitro and that the enzyme is endocytosed by mouse fibroblasts.
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In order to analyze the effect of an ERT in vivo, 250 mU/g body weight of purified His6-tagged
human α-L-fucosidase were intravenously injected into the tail vein of a Fuca1(-/-) mouse. A
short-term ERT was performed by applying two injections within one week (figure 4.40 A).
As a control, a wildtype as well as a Fuca1(-/-) mouse were treated with PBS. After sacrifi-
cing, the mouse tissues were analyzed by enzyme activity assays and TLC for storage material.
As expected, α-L-fucosidase activity was detected in tissue homogenates of the PBS-treated
wildtype, but not of the PBS-treated Fuca1(-/-) mouse. The injection of the recombinant en-
zyme resulted in a massive increase in α-L-fucosidase activity that was more than 400-fold
and 37-fold elevated in homogenates of the Fuca1(-/-) liver and spleen, respectively, compared
to the PBS-treated wildtype tissue homogenates (table 4.5). In the α-L-fucosidase-treated
Fuca1(-/-) kidney, one-third of the enzyme activity of the PBS-treated wildtype tissue was de-
tected. The bioavailability of the α-L-fucosidase in the brain was rather low as only 1/10 of
the enzyme activity of the PBS-treated wildtype brain was detected in α-L-fucosidase-treated
Fuca1(-/-) brain. Of note, the mice were not perfused with PBS prior to sacrifice and a part of
the α-L-fucosidase activity in the brain might be derived from recombinant enzyme that was
still present in the circulation of the mouse.
In order to analyze the benefit of the short-term ERT, neutral oligosaccharides were isolated
from kidney, spleen and brain and separated by TLC. The liver was not analyzed, as the high
amount of glycogen prevented the proper analysis by TLC. As shown in figure 4.40 B, the
storage material was completely absent in the spleen of the α-L-fucosidase-treated Fuca1(-/-)
mouse. In the kidney some TLC bands disappeared or at least shifted towards higher retention
factors, indicating an incomplete degradation of the storage material. However, no effects
were visible in the composition and presence of storage material of the brain.
Table 4.5: α-L-fucosidase activity after short-term ERT
genotype WT Fuca1(-/-) Fuca1(-/-)
injection of PBS PBS hFuca1-His6
α-L-fucosidase activity [mU/mg]
liver 0.13 0.0*
(*below
56.59
kidney 2.64 0.0*
detection
0.96
spleen 0.65 0.0*
limit)
24.01
brain 0.24 0.0* 0.02
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As described in section 4.1.4, the Fuca1 gene knock-out resulted in an altered expression of
lysosomal glycosidases like β -hexosaminidase and α-mannosidase. In order to analyze the
benefit of the short-term ERT on this secondary Fuca1(-/-) pathology, the β -hexosaminidase
activity was determined in tissue homogenates of the ERT-treated mice. As expected, an ele-
vated enzyme activity was found in PBS-treated Fuca1(-/-) tissues in comparison to the PBS-
treated wildtype organs (figure 4.40 C), although the β -hexosaminidase activities slightly dif-
fered from those shown in section 4.1.4. This might be due to the fact, that the animals were
of different ages (5 months of age in the former experiment and 3 months of age in the ERT
study). In kidney and brain, almost no differences were found between the β -hexosaminidase
activities of the α-L-fucosidase-treated and the PBS-treated Fuca1(-/-) mouse (figure 4.40 C).
In contrast, a reduction in β -hexosaminidase activity was found in the liver and spleen of the
α-L-fucosidase-treated Fuca1(-/-) mouse in comparison to the PBS-treated Fuca1(-/-) mouse.
However, the enzyme activities were still elevated in comparison to the PBS-treated wildtype
Figure 4.40: Short-term ERT of the fucosidosis mouse model
3-month-old mice were used for short-term ERT including two injections with 250 mU His6-tagged
α-L-fucosidase per 1 g body weight. As control, similar volumes of PBS were injected into a wildtype
and a Fuca1(-/-) mouse. (A) Injections were performed at day one and five and organs were dissected at
day eight. (B) Neutral oligosaccharides were extracted from kidney, spleen and brain and analyzed by
TLC. (C) β -hexosaminidase activity was measured in tissue homogenates of ERT-treated mice.
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mouse. It was not possible to analyze the significance of this effect, as only one mouse was
used for each condition.
In summary, after short-term ERT with 250 mU/g body weight of His6-tagged α-L-fucosidase,
a high α-L-fucosidase activity was detected in liver and spleen, resulting in a complete diges-
tion of storage material in the spleen. Moreover, the β -hexosaminidase activity was analyzed
as secondary pathology and intermediate values between the activities of the PBS-treated wild-
type and PBS-treated Fuca1(-/-) mouse were found. In contrast, minor α-L-fucosidase acti-
vities were detected in kidney and brain of the α-L-fucoisdase-treated Fuca1(-/-) mouse and
only moderate or no effects were found regarding the digestion of the storage material and the
β -hexosaminidase activities. These preliminary results suggest that the bioavailability of the
His6-tagged α-L-fucosidase is low in the kidney and especially in the brain. As expected, the
major amount of the injected enzyme was taken up by liver and spleen.
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4.4 Generation of an α-L-fucosidase-specific antibody
So far, a monoclonal antibody recognizing the RGS-His6-tag was used to analyze the His6-
tagged human α-L-fucosidase. In order to enable the detection of the untagged human α-
L-fucosidase as well as of the endogenous murine enzyme, a monoclonal α-L-fucosidase-
specific antibody was generated. As a higher immunogenicity of the enzyme was expected in
Fuca1(-/-) than in wildtype mice, Fuca1(-/-) mice were immunized in cooperation with Prof.
Koch-Nolte (University Medical Center Hamburg-Eppendorf, Germany) by ballistic injection
of coated gold particles carrying an expression plasmid encoding the murine α-L-fucosidase.
The resulting antisera were tested by Western blot analysis of lysosome-enriched fractions
from liver of wildtype and Fuca1(-/-) mice and against recombinant α-L-fucosidase, but no
specific reactivity could be detected (data not shown). Nevertheless, the animals received
a final immunization boost using purified His6-tagged human α-L-fucosidase, resulting in a
high specificity of the antisera against the recombinant enzyme in a dose-dependent manner
(data not shown).
The mice were further used to generate hybridoma cell lines secreting monoclonal antibodies
specific for α-L-fucosidase by the fusion of spleen-derived B-lymphocytes with a myeloma
cell line (performed by Prof. Koch-Nolte, University Medical Center Hamburg-Eppendorf,
Germany). The conditioned media of the cell lines were harvested and used to analyze the
specificity of the secreted antibodies. Three hybridoma cell lines produced monoclonal an-
tibodies that recognized the human α-L-fucosidase (A112, A177 and A180), as shown by
immunoblotting of His6-tagged human α-L-fucosidase (data not shown). Immunoblotting
of tissue homogenates (data not shown) as well as lysosome-enriched fractions from wild-
type and Fuca1(-/-) liver did not results in specific signals for α-L-fucosidase. In wildtype
lysosomes, a band slightly above 50 kDa was detected, which could correspondent to the ex-
pected molecular weight of the α-L-fucosidase. However, a similar band was also seen in the
Fuca1(-/-) sample, indicating an unspecific signal (figure 4.41 A, data were shown for A112
only). Moreover, wildtype MEFs were transfected with an expression plasmid for the human
α-L-fucosidase and were analyzed by immunofluorescence staining. While PFA-fixation of
the MEFs and permeabilisation using saponin showed no staining at all, a specific staining
was observed after methanol fixation, in which hybridoma supernatants detected the overex-
pressed human enzyme (figure 4.41 B, data were shown for A112 and A180). Under these
expressing conditions an intensive staining of the ER, but also a slight staining of the lysoso-
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mal compartment was visible. Moreover, one hybridoma supernatant (A112) also recognized
the overexpressed murine enzyme, whereas the endogenous enzyme in untransfected cells was
not detected.
Figure 4.41: Analysis of the specificity of the Fuca1-specific monoclonal antibodies
(A) Experiment was performed in cooperation with Michael Weber (Master Thesis). 25 µg of
lysosome-enriched fractions from wildtpye and Fuca1(-/-) mice as well as 100 ng of purified His6-
tagged human α-L-fucosidase (rec.) were used to analyze the specificity of the hybridoma cell culture
supernatants against the α-L-fucosidase by immunoblotting. The results for the hybridoma cell line
A112 are shown exemplarily. (B) Wildtpye MEFs were seeded on cover slips, were transfected with
an expression plasmid for the human and the murine α-L-fucosidase, respectively, and were further
applied to a methonal fixation. An immunofluorescence staining was performed using cell culture
supernatants of the hybridoma cell lines A112 and A180. Untransfected cells were used as control.
In parallel, MEFs were stained with an Lamp1-specific antibody and used as control for a lysosomal
staining pattern. Cell nuclei were stained with DAPI (blue). Bars correspondent to 10 µm.
The hybridoma cell lines A112 and A180 were further re-selected to establish single cell
clones with a high antibody secretion capacity. The cell clones were screened for specificity
against the His6-tagged human α-L-fucosidase by ELISA tests (re-selection and screening
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was performed in cooperation with Prof. Koch-Nolte, University Medical Center Hamburg-
Eppendorf, Germany). Those cell clones displaying the highest antibody production were
further expanded, the cell culture supernatants were harvested and further analyzed by im-
munoblotting. Both hybridoma supernatants (A112 and A180) detected the His6-tagged hu-
man α-L-fucosidase in a dose-dependent manner (figure 4.42). An optimal dilution to detect
at least 50 ng of the recombinant enzyme was determined with 1 : 1000.
Figure 4.42: Fuca1-specific monoclonal antibodies detect the recombinant enzyme in a dose-
dependent manner
The specificity of the hybridoma supernatants A112 and A180 against the human α-L-fucosidase was
analyzed by immunoblotting using different amounts (10, 20, 30 and 50 ng) of the His6-tagged enzyme.
Different dilutions of hybridoma supernatants were tested (1 : 100 – 1 : 5000).
The specificity of the hybridoma supernatants was further analyzed by immunoblotting of cell
lysates from transfected Neu2A cells. The supernatant of the hybridoma cell line A112 showed
a higher reactivity against the murine enzyme than against the human α-L-fucosidase (figure
4.43 A). However, the endogenous murine enzyme in untransfected cells was not detected.
The supernatant of the hybridoma cell line A180 recognized only the human enzyme (figure
4.43 B). Of note, both monoclonal antibodies detected the purified recombinant His6-tagged
α-L-fucosidase at approximately 55 kDa (figure 4.42), whereas two bands were visible in
transfected cells (52 kDa and 48 kDa; figure 4.43).
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Figure 4.43: Fuca1-specific monoclonal antibodies do not detect endogenous murine α-L-
fucosidase by immunoblotting
Neu2A cells were transfected with an expression plasmid for the human (h) and the murine (m) α-
L-fucosidase, respectively. Untransfected cells (UT) were used as control. The specificity of the hy-
bridoma supernatants A112 and A180 against the α-L-fucosidase was analyzed by immunoblotting of
the cell lysates. Different dilutions were tested (1 : 100 – 1 : 5000). A ponceau S staining was performed
as loading control.
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The lysosomal storage disease is mainly characterized by progressive mental retardation and
neurological deterioration leading to premature death (Durand et al. 1966, Willems et al.
1991). The disease is caused by the deficiency of the lysosomal enzyme α-L-fucosidase
(van Hoof and Hers 1968b) that is responsible for cleaving off fucose residues during the
degradation of fucosylated N-glycans and glycolipids. α-L-Fucosidase deficiency leads to the
accumulation of fucosylated glycocompounds (Michalski and Klein 1999). Here, the genera-
tion and characterization of the first fucosidosis mouse model is described, which resembles
a mild phenotype of the human disease. As an initial step towards a disease therapy, the pro-
duction and purification of a His6-tagged human α-L-fucosidase derived from CHO-K1 cells
was shown. The purified enzyme was finally used in a first ERT approach of the fucosidosis
mouse model, resulting in a complete digestion of the accumulated storage material in the
spleen. These preliminary results provide promising data with regard to a successful ERT of
the fucosidosis disease.
5.1 The fucosidosis mouse model
Although fucosidosis is known since 1966 (Durand et al. 1966), only limited data are available
from human patients. Besides the human fucosidosis, a naturally occurring dog model in
English Springer spaniel was used for disease characterization (Kelly et al. 1983, Kondagari
et al. 2011a, Fletcher et al. 2014), as well as basic studies on an intracisternal ERT (Kondagari
et al. 2011b, Kondagari et al. 2015). Nevertheless, the generation of a fucosidosis mouse
model was addressed, as the mice exhibit several advantages over the dog model e. g. easier
breeding and housing, a controlled genetic background, a shorter life span and a high number
of available animals. With regard to establish an ERT for the fucosidosis disease, particularly
the much lower body weight reduces the expenses of a pre-clinical study in the mouse model.
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5.1.1 Generation and validation of the Fuca1 gene knock-out
Fuca1(-/-) mice were generated by a gene targeting strategy which is a commonly used tech-
nique to introduce genomic modifications in mice (Capecchi 2005), where the open reading
frame of the target gene is disrupted by insertion of the bacterial nptI gene. The Fuca1(-/-)
allele was successfully validated on genomic level by PCR and the precise site of homolo-
gous recombination was analyzed by sequencing. On transcript level, the expression of the
Fuca1 gene was reduced to 1 % in Fuca1(-/-) liver and kidney, whereas still 10 % - 20 % of the
Fuca1 transcript were detected in spleen and brain. As expected, the gene targeting did not
abolish the transcription of the Fuca1 gene. Rather, the insertion of the nptI gene into exon 1
of the Fuca1 gene resulted in the transcription of mRNA harboring a premature termination
codon (PTC). Such mRNAs are recognized by the so-called nonsense-mediated mRNA de-
cay (NMD), a conserved quality control mechanism that degrades mRNAs containing PTC
elements (Chang et al. 2007, Schweingruber et al. 2013). Thus, the Fuca1(-/-) allele is re-
cognized by the transcription machinery but the resulting mRNA is degraded immediately. In
this study, the transcript level was analyzed by Real-Time PCR determining the steady-state
mRNA amounts in tissues, where a part of the newly synthesized mRNA of the Fuca1(-/-) allele
could still be detected before it was recognized and degraded by NMD. As described above,
tissue-specific differences in the extent of Fuca1 transcript reduction in the Fuca1(-/-) mice
were observed and might be caused by differences in the tissue-specific Fuca1 expression. In
tissues with high Fuca1 expression, a larger amount of Fuca1 transcript is synthesized and
subsequently degraded by NMD compared with tissues with low Fuca1 expression, resulting
in a larger extent of Fuca1 transcript reduction.
It is supposed that the transcript degradation is initiated during the first round of translation
(Chang et al. 2007, Schweingruber et al. 2013) resulting in a shortened polypeptide that is not
functional, as only the first 77 out of 452 amino acids of the α-L-fucosidase were translated.
Here, the complete Fuca1 gene knock-out was confirmed by activity measurements for α-L-
fucosidase in tissue homogenates as well as lysosome-enriched fractions demonstrating the
absence of enzyme activity.
5.1.2 The Fuca1 gene knock-out causes a differential regulation of other
lysosomal proteins
N-glycans are degraded stepwise by different exoglycosidases. For complex N-glycans, the
lysosomal α-L-fucosidase catalyzes the initial step in the degradation process (figure 1.3).
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Its deficiency leads to the termination of the degradation process and the accumulation of the
residual N-glycan. These pathological circumstances result in lysosomal storage (Winchester
2005), and as a cellular response, an altered regulation of several lysosomal proteins, besides
the deficient protein, was often observed in LSDs, e. g. changes in the expression of genes
for several lysosomal hydrolases were recorded in a mouse model for MPS VII (Woloszynek
et al. 2004). Moreover, increased specific activities of lysosomal enzymes were measured in
tissues from human LSD patients (van Hoof and Hers 1968b, Sandhoff et al. 1971). With
respect to fucosidosis, an enhanced activity of several glycosidases was detected in the liver
of three human patients (van Hoof and Hers 1968a). In the Fuca1(-/-) mice, the regulation
of lysosomal enzymes participating in the degradation of N-glycans as well as of the lysoso-
mal membrane protein Lamp1 was investigated and an enhanced transcription of all analyzed
genes was found in the Fuca(-/-) brain. The increased gene expression might represent a cel-
lular response to lysosomal storage and lysosomal stress resulting in an activation and nuclear
translocation of the transcription factor EB (TFEB) and / or E3 (TFE3) and an upregulation
of genes harboring one or several CLEAR (coordinated lysosomal expression and regula-
tion) elements. In fact, a CLEAR consensus sequence was reported in the promoter regions
of all genes analyzed in this study, except the Fuca1 itself which lacks the CLEAR motif
(Sardiello et al. 2009). However, the expression of genes for several lysosomal proteins was
tissue-dependent. As mentioned above, a general upregulation was detected in the Fuca(-/-)
brain, while the expression of nearly all analyzed genes was unaffected in the Fuca(-/-) kidney.
Hence, the putative regulation of these genes by TFEB / TFE3 is obviously tissue-dependent
and could be due to a tissue-specific expression of the transcription factors, which has to be
further analyzed. Moreover, other regulatory factors besides TFEB / TFE3 might be involved,
as the expression of nearly all analyzed genes in the kidney was unaffected by the Fuca1 gene
knock-out, whereas the expression of β -hexosaminidase and α-mannosidase was decreased,
indicating a differential regulation of single genes. Interestingly, the enzyme activities of these
two glycosidases were increased in the Fuca(-/-) kidney, indicating an enhanced stability of the
proteins. The half-life of the enzymes might be increased due to the general inhibition of
lysosomal proteolysis, which could result from the high storage burden of the endosomal-
lysosomal compartment (Platt et al. 2012).
An increased amount of Lamp1 protein has been described as a diagnostic marker in a large
subset of LSDs, e. g. in mouse models for α-mannosidosis (Stinchi et al. 1999) and muco-
lipidosis II (Kollmann et al. 2012). Moreover, the amount of Lamp1 protein is increased in
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blood plasma of patients suffering from, e. g., α-mannosidosis, galactosialidosis and several
mucopolysaccharidoses (Meikle et al. 1997). The accumulation of storage material in LSDs
results in a massively increased number and size of lysosomes rising from 1 % of total cell
volume up to 50 % (Meikle et al. 1997). Such an increased amount of lysosomal membranes
needs additional lysosomal membrane proteins like Lamp1. Indeed, elevated levels of Lamp1
protein were also found in several tissues of the Fuca(-/-) mice, indicating the formation of a
LSD-like phenotype in the mouse model.
5.1.3 The phenotype of Fuca1(-/-) mice resembles a mild form of the
human disease
Although there exists a continuous clinical spectrum in human fucosidosis, the disease is
classically divided into a severe type 1 and a milder type 2. Patients suffering from type 1
fucosidosis are characterized by an early onset and rapid progression of clinical symptoms,
particularly of neurodegenerative symptoms, leading to death within the first decade of life. In
contrast, disease progression in type 2 fucosidosis is slower and patients may survive until the
second or third decade of life (Willems et al. 1991). Initially it had been suggested, that type 2
fucosidosis is characterized by development of angiokeratoma corporis diffusum. However,
several type 2 fucosidosis cases lacking angiokeratoma as well as several type 1 fucosidosis
cases with prominent angiokeratoma were described. Hence the occurrence of angiokeratoma
was designated to a third (juvenile) type of fucosidosis (Willems et al. 1991, Kanitakis et al.
2005). In this work, the phenotype of the Fuca1(-/-) mice was characterized. The animals suf-
fered from progressive clinical symptoms leading to premature death in the first half of their
lives. However, an onset of clinical symptoms was not observed before six months of age and
no skin abnormalities were seen so far. Hence, the phenotype of the Fuca1(-/-) mice closely re-
sembled that of the milder type 2 fucosidosis in human. Interestingly, no genotype - phenotype
correlation was found for human fucosidosis (Willems et al. 1991) and as well as other gly-
coproteinoses (except sialidosis; Malm et al. 2013). Comparably, the manifestation of a mild
LSD phenotype was also observed in a mouse model for α-mannosidosis, despite its total lack
of α-mannosidase activity (Stinchi et al. 1999), and was also seen in mice with arylsulfatase B
and arylsulfatase A deficiency, respectively (Evers et al. 1996, Hess et al. 1996).
Willems et al. (1991) reported a continuous spectrum of clinical phenotypes in fucosidosis
patients rather than a strict classification into type 1 and 2 fucosidosis. However the severity
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of the disease is not connected to residual α-L-fucosidase activity or the genetic heterogeneity
of the fucosidosis patients. Other disease modifying factors were suggested to influence the
clinical phenotype. A plausible potential candidate is the second α-L-fucosidase (Fuca2) that
is also referred to as plasma α-L-fucosidase, although it was recently identified as putative
lysosomal protein by analysis of the lysosomal proteome (Sleat et al. 2008) and by localization
studies using mCherry-fusion constructs (Huang et al. 2014). However, a specific activity
assay for α-L-fucosidase 2 as well as data regarding its substrate specificities are not available
so far. However, Sobkowicz et al. (2014) reported activity of the α-L-fucosidase 2 against the
pseudosubstrate 4-MUF under overexpressing conditions in CHO cells, but this fucosidase
activity might also be derived from endogenous α-L-fucosidase 1. Here, the Fuca1(-/-) mice
might serve as an ideal model to study α-L-fucosidase 2 activity, as these measurements are
not influence by activity derived from α-L-fucosidase 1. So far, no α-L-fucosidase activity
could be detected in Fuca1(-/-) tissues and lysosome-enriched fractions whatever pH value was
tested. Hence, the α-L-fucosidase 2 might not be translated or possesses no activity under the
specific conditions of the in vitro assay. In further experiments, the α-L-fucosidase activity in
the plasma of the Fuca1(-/-) mice should be also measured, but so far, there exists no evidence
for α-L-fucosidase 2 as a disease modifying factor for fucosidosis.
5.1.3.1 Storage pathology of visceral organs
The Fuca1(-/-) mice showed accumulation of storage material with variable degree and he-
terogeneous nature in several visceral organs like liver, kidney, spleen, urinary bladder, gall
bladder and pancreas. Most of these findings were comparable to those seen in human fucosi-
dosis patients. The hepatic sinusoidal cells as well as the Kupffer cells contained translucent
foam-like storage vesicles in human patients as well as in Fuca1(-/-) mice. In contrast, mainly
heterogeneous storage material of moderate electron density was found in human hepatocytes.
Interestingly, Freitag et al. (1971) reported that this storage material tended to aggregate in
hepatocytes near the bile canaliculus in a severely affected human patient and a similar lo-
calization of electron-dense storage vacuoles was also observed in the Fuca1(-/-) mice. The
accumulation of storage material in the different human hepatic cell types may contribute to
the hepatomegaly that is observed in approximately 40 % of the fucosidosis cases (Willems
et al. 1991). Here, the Fuca1(-/-) mice resemble the phenotype of the majority of fucosidosis
patients, where no hepatomegaly was observed.
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The spleen of human fucosidosis patients was not investigated so far by ultrastructural ana-
lysis. In English Springer spaniel, a vacuolation of splenic macrophages has been reported
(Kelly et al. 1983), whereas in Fuca1(-/-) mice several cell types of the spleen like macrophages,
sinusoidal endothelial cells as well as reticular cells were found to contain storage vacuoles.
By electron microscopic analysis it was shown that the lymphocytes of Fuca1(-/-) mice are af-
fected. This was also seen in peripheral blood smears of human fucosidosis patients (Durand
et al. 1969). A splenomegaly was not observed in Fuca1(-/-) mice, comparable to the majority
of human fucosidosis patients, as a splenomegaly was observed in only 25 % of all fucosido-
sis cases (Willems et al. 1991). Moreover, pathological alterations of the pancreas had been
described in human patients (Willems et al. 1991) as well as affected English Springer spaniel
(Kelly et al. 1983) and were also seen in the Fuca1(-/-) mice.
In the kidney, foam-like vacuoles were observed in glomerular podocytes and in the collecting
ducts, especially in intercalated cells of Fuca1(-/-) mice. Comparably, vacuolation of renal
tubular cells is also known from a naturally occurring fucosidosis case in a domestic short hair
cat (Arrol et al. 2011) and was also reported in English Springer spaniel (Kelly et al. 1983).
With regard to human fucosidosis, Durand et al. (1969) identified a degeneration of the kidney
as well as storage vacuoles in glomerular epithelial cells in two severely affected children, but
a renal pathology is no common clinical symptom of human fucosidosis so far. Besides the
histological findings, the renal functionality was addressed in the Fuca1(-/-) mice. Glomerular
podocytes represent the blood-urine-barrier of the kidney. Although they were affected from
storage pathology, a proteinuria was not observed indicating that the blood-urine-barrier is still
functional. The clinical chemistry revealed slightly decreased electrolyte concentrations in the
blood serum of Fuca1(-/-) mice. In the collecting ducts, urea is reabsorbed as a prerequisite
for the formation of an osmotic gradient in the interstitium of the kidney, which triggers the
uptake of electrolytes from urine into the blood and disabilities in the formation of the osmotic
gradient due to the severe accumulation of storage material in the collecting ducts might result
in slightly decreased electrolyte concentrations as observed in the blood serum of Fuca1(-/-)
mice. Especially the intercalated cells of the collecting ducts were affected from storage,
which participate in the maintenance of the acid-base homeostasis by secretion of protons.
The pH value of the urine was not analyzed so far in Fuca1(-/-) mice but should be addressed
in further studies. Analysis of clinical chemistry was not reported so far for human fucosidosis
patients, but should be routinely included in examinations of patients, especially as blood and
urine are easy accessible.
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5.1.3.2 Neuropathology and behavior
Human fucosidosis patients are mainly characterized by neurological symptoms like mental
retardation, neurological decline resulting in severe motor disabilities, hypertonia and to a
lesser extent hypotonia as well as seizures (Willems et al. 1991). The underlying pathological
processes remain largely unknown and only a few reports regarding the histological alterations
of the disease are available. A recent MR study (magnetic resonance tomography) reported
increased cerebellar volumes in early childhood of fucosidosis patients (Kau et al. 2011).
Additionally, cerebral and cerebellar atrophy was reported in later stages of the disease (Inui
et al. 2000) and might result from neuronal cell death that was reported in a few fucosidosis
cases (Durand et al. 1969, Galluzzi et al. 2001). The macroscopic inspection of the Fuca1(-/-)
mice revealed several comparable pathological alterations like the swollen cerebellum and the
reduced size of the cerebrum. So far, the observed encephalic volume alterations are based on
only few animals and continued analyses are necessary to confirm these observations.
The microscopic alterations of the brain are well studied in English Springer spaniel, where
foam-like storage vacuoles and axon spheroids were seen throughout the whole brain together
with a progressive neuronal cell death, myelination defects and inflammatory reactions like the
activation of astrocytes and microglia (Kondagari et al. 2011a, Fletcher et al. 2011, Fletcher et
al. 2014). In the Fuca1(-/-) mice, mainly translucent storage vacuoles were found in all regions
of the brain, particularly in the neuronal perikarya of the hippocampus, cerebral cortex and
cerebellum. Moreover, axon spheroids are common to many LSDs and were observed in
mouse models for e. g. α-mannosidosis (Stinchi et al. 1999), mucolipidosis II (Kollmann et
al. 2012), MPS IIIE (Kowalewski et al. 2015) and Niemann-Pick disease type C (NPC; Zervas
et al. 2001). The formation of such axonal swellings is often accompanied with neuronal cell
death (Walkley et al. 2010). In the canine fucosidosis model, an increasing number of axon
spheroids was found in the hippocampus and the cerebellum (Kondagari et al. 2011a) and was
similarly observed in the Fuca1(-/-) mice. In human patients, neuronal ballooning was also
observed by MR analysis (Galluzzi et al. 2001, Oner et al. 2007).
The most prominent neuronal pathology of the Fuca1(-/-) mice was observed in Purkinje cells.
A massive loss of this cell type was shown during disease progression and at 11 months of age
almost no Purkinje cells were found in the Fuca1(-/-) cerebellum. A degeneration of Purkinje
cells is commonly observed in LSDs affecting the CNS, e. g. in Niemann-Pick disease type C,
where this neuronal cell type seems particularly vulnerable to lysosomal storage (Elrick et al.
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2010). The exact mechanisms underlying the early Purkinje cell death remain to be analyzed,
especially as some cells located in the cerebellar lobi X of a mouse model for Niemann-Pick
disease type C are highly resistant to cell death (Chung et al. 2016). Loss of Purkinje cells was
also found in English Springer spaniel suffering from fucosidosis (Kondagari et al. 2011a)
and in brain biopsies of two severely affected human patients (Durand et al. 1969). These
cells are the only efferent neurons of the cerebellar cortex and are essential for the modulation
of motor function. Hence, the reduced number of efferent neurons may contribute to motor
deterioration and coordinatory deficits observed in fucosidosis. In the dog model, prominent
motor deficits, delayed learning and, in late disease, severe mental decline and disorientation
were reported (Fletcher et al. 2014). Detailed behavioral analysis of the Fuca1(-/-) mice were
performed at 3 and 7 months of age indicating motor dysfunction and coordinatory deficits,
reduced activity as well as cognitive impairment. In some behavioral tests (e. g. rotarod test),
differences between the Fuca1(-/-) and control mice were not observed in young animals, but
became more significant at older ages, indicating a disease progression coinciding with the
Purkinje cell degeneration. In the cerebrum, storage vacuoles were seen in neuronal perikarya
and neuronal cell death was observed in the hippocampus and cerebral cortex. These patho-
logical alterations might contribute to the deficits of contextual and cued fear memory. The
neuropathology and behavioral deficits of Fuca1(-/-) mice closely resemble that of human pa-
tients and reflect the main clinical hallmark of fucosidosis.
Neuronal cell loss is often accompanied by inflammatory reactions and inflammation of the
brain as well as an excessive appearance of reactive astrocytes are common features of an
affected CNS in many LSDs (Vitner et al. 2010). This was also analyzed in detail in the ca-
nine fucosidosis model. Kondagari et al. (2011a) reported an increasing number of microglia
during disease progression as well as an increased astrocytosis in the cerebral cortex and the
cerebellum. A recent study based on MRS analysis (magnetic resonance spectroscopy) also
revealed astrocytosis in the brain of a human patient (Oner et al. 2007). Similar results were
shown for the Fuca1(-/-) mice. A prominent microgliosis and astrogliosis was seen in all re-
gions of the brain. Especially in the cerebellum, reactive astrocytes were closely restricted to
the Purkinje cell layer at already 3.5 months of age, which is a disease stage, where the Pur-
kinje cells are still intact. Although neuroinflammation is typically a protective response of the
innate immune system, chronic inflammation and astrocyte activation may contribute to neu-
rodegeneration and loss of Purkinje cells observed in later stages of the disease and may result
from the chronic production of cytokines and chemokines creating a neurotoxic environment
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(Platt et al. 2012, Bosch and Kielian 2015). The contribution of astrocytes to neurodegener-
ation was analyzed in more detail in a mouse model for multiple sulfatase deficiency, which
is caused by mutations in the Sumf1 gene. The mice harbored an astrocyte-specific Sumf1 de-
pletion and the severe lysosomal storage in astrocytes resulted in the degeneration of cortical
neurons in vivo indicating a cell-autonomous mechanism for neurodegeneration (Di Malta et
al. 2012), which was also suggested in a mouse model of Niemann-Pick disease type C (Elrick
et al. 2010).
Over the last decades, information based on MR findings of fucosidosis patients have been
published, revealing neuropathological changes in the white matter as a common feature of the
disease. However, there is an open question, whether these pathological findings were caused
by hypomyelination or demyelination (Galluzzi et al. 2001, Oner et al. 2007, Alexander et al.
2014, Jain et al. 2014). Hypomyelination describes an incomplete myelin formation, whereas
an initial complete myelination is achieved in an demyelinating disease, which subsequently
decreases during disease progression. A hypomyelination was identified in the canine model
(Fletcher et al. 2011). This defect is caused by an early apoptosis of oligodendrocytes for a
yet unknown reason (Fletcher et al. 2014). In contrast, no myelination defects were observed
in the Fuca1(-/-) mice. Real-Time PCR results revealed no differences in the major myelin
structural protein Plp1 mRNA expression between wildtype and Fuca1(-/-) mice, whereas a
significantly decreased expression was detected in the canine model (Fletcher et al. 2011). In
contrast, MBP mRNA expression was increased in the Fuca1(-/-) mice, whereas no differences
in MBP protein expression could be verified, which could indicate an increased MBP protein
turnover. Hence, oligodendrocytes of the fucosidosis mouse model seem to be affected, but
to a lesser extent than in the dog model or in human patients and they may compensate their
deficits by an enhanced turnover of some myelin components like MBP. Interestingly, species-
specific differences in myelination defects were also reported for metachromatic leukodystro-
phy (MLD), a LSD caused by the deficiency of arylsulfatase A. A MLD mouse model as well
as human MLD patients showed prominent pathological alterations in the CNS, especially in
oligodendrocytes, but the mouse model lacks the massive myelin degeneration that is charac-
teristic for the human disease (Hess et al. 1996, Gieselmann et al. 1998).
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5.1.4 Storage material
5.1.4.1 Core-fucosylated N-glycans are the primary storage material in mouse
fucosidosis
The accumulation of fucose-containing oligosaccharides, glycoasparagines and glycosphin-
golipids are a basic feature of human fucosidosis and more than ten different oligosaccharide
and glycoasparagine species were identified, which were also partially excreted with the urine
(Michalski and Klein 1999). As in human patients (Tsay and Dawson 1976, Yamashita et al.
1979, Michalski and Klein 1999), the corefucosylated glycoasparagine Asn-GlcNAc-Fuc is
the major storage material that is excreted with the urine of Fuca1(-/-) mice, while it was not
detected in wildtype animals. This fucosylated glycocompound may serve as a biomarker
for the disease and may improve diagnosis, especially as urine samples of patients are easily
accessible.
Moreover, Asn-GlcNAc-Fuc was also identified as storage material in different tissues of the
Fuca1(-/-) mice along with other glycoasparagines like the asparaginyl-linked pentasaccha-
ride Asn-GlcNAc-(Fuc)-GlcNAc-Man-Man. Both storage compounds are also known from
human patients (Tsay et al. 1976, Tsay and Dawson 1976, Michalski and Klein 1999) and
Asn-GlcNAc-Fuc was also found in tissues of affected English Springer spaniel (Abraham et
al. 1984). However, the nature of some storage conjungates derived from urine as well as from
tissues of the Fuca1(-/-) mice are still unknown, indicating a complex mixture of undigested
fucosylated glycocompounds, which has to be further analyzed. Of note, only single spots
of TLC separated storage material were analyzed so far by mass spectrometry. These ana-
lyses have to be expanded, as considerable more (> 10) oligosaccharide and glycoasparagine
species are known to accumulate in human fucosidosis. So far, the TLC-separated storage
material of the Fuca1(-/-) mice was first derivatized with the fluorescent label 2-AB, was then
applied to a hydrophobic interaction chromatography (HILIC) and analyzed by mass spec-
trometry. However, a derivatization of the storage material is only possible in the presence of
a free reducing end on the oligosaccharides and, hence, asparaginyl-linked oligosaccharides
are not labeled. However, only asparaginyl-linked storage material (non-derivatized), but no
free oligosaccharides were identified so far in Fuca1(-/-) tissues (as discussed below) and the
non-derivatized storage material resulted in very low signal intensities in the mass spectrome-
try. As an alternative, the storage material could be permethylated prior to mass spectrometry,
as a permethylation converts the hydroxyl groups of the sugar residue to methyl ethers, which
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increases the efficiency of the ionization at these positions resulting in an increased signal
intensity (Desantos-Garcia et al. 2011, Harvey 2011) and may enable the detection of more
storage material species. This technique was also used for analysis of storage material in the
urine of patients suffering from aspartylglucosaminuria, a LSD where also asparaginyl-linked
N-gylcans accumulate (Aula et al. 1980).
In Fuca1(-/-) mice, all identified storage compounds represented structures of core-fucosylated
N-glycans that were still linked to the asparagine residue. The presence of the α1,6-(core)-
fucosylation is known to sterically inhibit the lysosomal aspartylglucosaminidase so that the
asparagine residue can not be removed (Noronkoski and Mononen 1997). However, in hu-
man fucosidosis patients, several oligosaccharides with terminal fucose residues but without
the core-fucosylation were identified that lacked the asparagine residue (Tsay et al. 1976, Tsay
and Dawson 1976, Nishigaki et al. 1978, Michalski and Klein 1999). Due to the lack of a core-
fucose residue the asparagine residue became accessible to the aspartylglucosaminidase. How-
ever, storage material with terminal fucose residues was not identified so far in the Fuca1(-/-)
mice and may reflect species-specific differences in the degree of terminal fucosylation of
N-glycans.
In human patients, glycosphingolipid-derived fucose-containing H- and LewisX-antigens were
also found as storage material. In particular, the H-antigen was identified as the major stor-
age product of the liver (Dawson and Spranger 1971, Tsay et al. 1976, Michalski and Klein
1999). However, such storage compounds were not described so far in the canine model and
were not found in the Fuca1(-/-) mice. The Lewis blood group antigens can be divided into
four subtypes: Lea, Leb, Lex and Ley (figure 1.4) and it is reported that mice do not possess
Lex and Ley antigens (Thorpe and Feizi 1984). However, there exists no information, whether
mice exhibit a fucosyltransferase activity that enables the synthesis of Lea and Leb antigens.
Moreover, the expression of Lewis antigens in humans is restricted to tissues originating from
endoderm (e. g. digestive and respiratory mucosa, epithelium of the biliary ducts and the uri-
nary tract; Oriol et al. 1986), whereas little is known about tissue-specific expression of Lewis
antigens in mice. Besides these Lewis antigens, there exist also species-specific differences in
synthesis and availability of the blood group antigens H, A and B between mouse and men.
Comparable with the human ABO system, also mice do express the H-, A- and B-antigens.
However, the murine ABO locus encodes a glycosyltransferase with both A and B transferase
activity and all mouse strains tested by Yamamoto et al. (2001) were of blood group AB. More-
over the tissue-specific localization of the blood group antigens is different. During evolution,
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men and some primates were the only species that adapted blood group antigen expression
on their erythrocytes. The red blood cells of other mammals are completely devoid of ABH
antigens (Oriol et al. 1986). Hence, it is likely that no differences in the glycosphingolipid
content were found between wildtype and Fuca1(-/-) mice by TLC. Nevertheless, at least the
H antigens should be expressed in murine tissues originating from endoderm and in further
studies these tissues should be analyzed in more detail by immunofluorescence staining using
the lectin from Ulex europaeus, which recognizes the H-antigen.
The Aleuria aurentia lectin was used to stain α1,6-core-fucosylated storage material in histo-
logical sections of different organs from Fuca1(-/-) mice. However, this particular lectin stained
only the membrane of storage vacuoles whereas their content remained unstained, which might
reflect the water-soluble properties of the storage material. Most of the accumulated glyco-
compounds might be washed out during tissue fixation and staining, as the majority of storage
vacuoles appeared also empty in light-microscopy analysis and electron-translucent in TEM.
However, the use of the Aleuria aurentia lectin resulted in a stronger staining intensity in the
Fuca1(-/-) tissues which might be due to the increased amount of lysosomal membrane pro-
teins harboring complex N-glycans like Lamp1. Prior to the lectin staining, the tissues were
fixed with formaldehyde, which might result in a cross-linkage of free amino groups (mainly
lysine residues) to other free amino acid residues at the surface of proteins (e. g. arginine,
asparagine, glutamine, histidine, tryptophan, tyrosine; Metz et al. 2004). The cross-linkage
can occur in an intra- and intermolecular manner by formation of methylene bridges. As the
storage material of the Fuca1(-/-) mice is still connected to the asparagine residue, it contains
a free primary amino group. However, formaldehyde does not cross-link two primary amino
groups (Metz et al. 2004). Thus, the storage material can not be linked together but only to
other lysosomal proteins (e. g. lysosomal membrane proteins at the limiting membrane of the
storage vacuoles). Although the majority of the storage material is washed out during tissue
preparation, a proportion may be fixed in close proximity to the lysosomal membrane, which
might result in a brighter lectin staining intensity in the Fuca1(-/-) mice.
In contrast to formaldehyde, glutaraldehyde contains two reactive aldehyde groups resulting in
a different cross-linking mechanism. Only primary amino groups are addressed and connected
intra- and intermolecularly (Migneault et al. 2004). Thus, glutaraldehyde might be able to
cross-link and immobilize storage material that is washed out when using formaldehyde. It
should be noted, that glutaraldehyde can not be used prior to immunofluorescence stainings,
as it leads to a masking of the majority of antigens. However, it is widely used for tissue
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fixation and preparation for electron microscopiy analysis. Indeed, TEM analysis revealed
storage vacuoles in the Fuca1(-/-) mice tissues (e. g. in the renal collecting ducts or in Purkinje
cells) that were partially filled with floccular material of moderate electron density. These
results might represent water-soluble storage material that was cross-linked by glutaraldehyde
thereby forming large aggregates unable to cross the permeabilized lysosomal membrane.
In summary, the biochemical phenotype of the Fuca1(-/-) mice resembled that of human fucosi-
dosis patients and affected English Springer spaniel. Neutral glycoasparagines were found as
the major storage material in the mice and were also partially excreted with the urine. How-
ever, the analysis of the accumulating glycoasparagine and oligosaccharide species should
be extended and especially the investigations of fucosylated glycolipids as storage material
should be addressed in more detail.
5.1.4.2 Secondary storage material
The monogenetic defect of a certain lysosomal hydrolase leads to the accumulation of the cor-
responding primary storage material. However, a LSD is often characterized by accumulation
of secondary storage products unrelated to the enzyme defect. So far, this aspect was not inves-
tigated in human fucosidosis patients and English Springer spaniel. In several mucopolysac-
charidoses and in α-mannosidosis, the storage of lipofuscin-like autofluorescent material was
observed (Walkley 2004, Walkley and Vanier 2009, Damme et al. 2011, Kowalewski et al.
2015) and also the Fuca1(-/-) mice exhibited accumulation of autofluorescent material in the
molecuar layer of the cerebellum, hippocampus and cerebral cortex, which most likely repre-
sented lipofuscin and appeared only during late disease progression. In particular, neuronal
perikarya of the hippocampus and cerebral cortex were heavily affected from Fuca1 gene
knock-out and contained a high amount of translucent storage vacuoles. Hence, the addi-
tional accumulating lipufuscin-like material might result from a more general impairment of
the endosomal-lysosomal system in the affected cell populations resulting in a decreased pro-
teolytic activity (Platt et al. 2012). However, the distribution of the autofluorescent material in
the molecular layer of the cerebellum differed from that of hippocampus and cerebral cortex
and probably occurred in macrophage/microglia-like cells rather than in neurons.
As described in many other LSDs (Walkley 2004, Walkley and Vanier 2009), unesterified
cholesterol and GM2-gangliosides were also identified as secondary storage materials in the
CNS of Fuca1(-/-) mice in small vesicle-like structures. Interestingly, these storage compounds
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were identified by filipin staining and immunofluorescence analysis but could not be detected
by TLC. Similar results were reported for α-mannosidosis, where the accumulation of gang-
liosides was not detectable by TLC but only by immunofluorescence stainings (Walkley 2004).
Moreover, it is known that accumulation of unesterified cholesterol in certain cell-types of the
CNS is not connected to a general increase in total cholesterol, indicating that only the in-
tracellular distribution and trafficking, but not the total amount of these secondary storage
compounds, is altered due to the general impairment of the endosomal-lysosomal compart-
ment in LSDs and the reduced or decelerated vesicle transport and fusion (Walkley and Vanier
2009). Although it was often postulated that cholesterol and gangliosides are sequestered to-
gether from lipids rafts of the plasma membrane, they accumulate in separate vesicles and only
in a few cases a partial co-localization was observed (McGlynn et al. 2004). This indicates,
that the processing of cholesterol and gangliosides might involve different, yet unknown, bio-
chemical routes, although these secondary storage materials often occur within the same cell.
So far, no co-localization studies of unesterified cholesterol and GM2-ganglioside accumu-
lation was performed in Fuca1(-/-) mice, but should be addressed in the future. Moreover,
secondary storage materials might also have an impact on the function of affected cells, as
increased amounts of GM2-gangiosides were reported to result in a depletion of intracellu-
lar Ca2+ stores causing ER stress and apoptosis (Walkley and Vanier 2009). In this context,
accumulation of GM2-gangliosides was only observed in young Fuca1(-/-) mice but was ab-
sent during late stages of the disease, indicating that the affected cell types died and were lost
during disease progression. The exact nature of the affected cell type remains to be analyzed
by co-stainings of GM2-ganglioside and different neural cell type-specific markers.
5.2 Production and purification of human α-L-fucosidase
5.2.1 CHO-K1 cells are a suitable production system for recombinant
human α-L-fucosidase
With regard to a planned ERT of fucosidosis patients, the production of the human form
of α-L-fucosidase was envisaged in this work. The human enzyme has to be synthesized
in a biological active form including proper protein folding and post-translational modifi-
cations, whereby the latter are of particular importance as a proper glycosylation and suffi-
cient mannose-6-phosphorylation is essential for the efficient cellular uptake of the recom-
158
5.2 Production and purification of human α-L-fucosidase
binant enzyme in the patients (Kollmann et al. 2012, Markmann et al. 2015). Moreover,
post-translational modifications influence the pharmacodynamic properties of a recombinant
protein e. g. its solubility, stability, activity and biodistribution (Jayapal et al. 2007). As
prokaryotic systems like Escherichia coli are not able to produce glycosylated proteins, the
use of a mammalian production system was favored, so that CHO-K1 cells were chosen as host
system for the production of recombinant human α-L-fucosidase. Over the last decades, this
cell line has been proven as a safe and robust system for production of therapeutic proteins for
human diseases. Amongst others, also the production of ERT-applied lysosomal enzymes like
e. g. α-glucosidase, α-L-iduronidase, N-acetylgalactosamine-4-sulfatase, α-galactosidase, β -
glucocerebrosidase (Jayapal et al. 2007) is carried out in CHO cells.
In this work, CHO-K1 cells were transfected with an expression plasmid for the untagged
as well as a C-terminal His6-tagged human α-L-fucosidase. Stable transfected cells were
selected and single cell clones were established by limited dilution. As only small amounts of
the recombinant enzyme were needed for initial studies like the establishment of a purification
strategy, an adherent cell culture system was generated. For the His6-tagged enzyme, a two-
step purification procedure yielded 5 mg of α-L-fucosidase out of 1 L conditioned cell culture
supernatant, which was sufficient for initial ERT studies in the mouse model. However, for
extended experiments and especially for a therapy of human patients a large-scale production
is mandatory and thus, cells were adapted to suspension conditions, which would allow further
volumetric scale-up processes and the use of large bio-reactors in a commercial environment.
Moreover, a FCS-free and protein-free medium was used for cultivation, which minimizes
the amount of contaminants and should ease enzyme purification especially with regard to
the untagged α-L-fucosidase. However, purification of untagged and His6-tagged human α-
L-fucosidase from conditioned medium of the suspension culture system was not tested so
far.
In the suspension culture system, densities of 3 x 106 - 4 x 106 cells / ml were reached and for
both enzymes, the untagged and the His6-tagged human α-L-fucosidase, an increased syn-
thesis rate was monitored compared to the adherent culture system, particularly for the His6-
tagged enzyme. In general, CHO-K1 cells producing the untagged enzyme reached higher
cell densities, whereas His6-tagged α-L-fucosidase producing cells yielded more recombi-
nant enzyme. This might be due to the fact, that during transfection the target DNA integrates
randomly into the host genome. The insertion of the cDNA for the untagged enzyme might
have occurred in a transcriptional more inactive genomic region, whereas the cDNA for the
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His6-tagged α-L-fucosidase might have integrated at a DNA locus of high transcriptional ac-
tivity. Moreover, the His6-tagged α-L-fucosidase producing CHO cells might have integrated
a higher copy number of the transfected plasmid resulting in enhanced synthesis rates. In the
future, the re-transfection of the cell lines should be considered. Moreover, the use of the
CHO-DG44 cell line, which is deficient in dihydrofolate reductase, might be of benefit, as
this allows the amplification of the gene of interest by selection with methotrexate resulting
in highly elevated transcription rates (Jayapal et al. 2007, will be further discussed in section
5.4).
5.2.2 Purification of the His6-tagged human α-L-fucosidase
The His6-tagged human α-L-fucosidase was produced in adherently grown CHO-K1 cells
and purified to apparent homogeneity in a two-step purification procedure using a Ni2+-affinity
chromatography (IMAC) followed by a strong cation exchange chromatography (SCX). A 31-
fold purification was achieved resulting in a specific activity of 15.4 U/mg. For comparison,
the specific activities of genuine enzyme purified from human liver and brain were determined
with 24.2 U/mg and 7.5 U/mg, respectively (Alhadeff et al. 1975a, Alhadeff and Janowsky
1977).
The His6-tagged human α-L-fucosidase displayed a comparatively strong binding towards
both column matrices and eluted at 230 mM imidazole from the IMAC and with 850 mM
NaCl from the SCX. In further experiments, a pH-independent oligomerization of the His6-
tagged α-L-fucosidase was detected (will be discussed in section 5.2.4), which might cause
an increased avidity resulting in a strong binding of the enzyme towards the column matrices.
Nearly no α-L-fucosidase activity was detected in the flow through and washing fractions of
both chromatographies and elution of the enzyme was performed by flushing the columns with
high concentrations of imidazole and NaCl, respectively, resulting in a highly concentrated
eluate containing α-L-fucosidase. In both chromatographies, 95 % - 100 % of the loaded ac-
tivity was recovered in the elution fractions, respectively. However, the enzyme had to be
re-buffered between both chromatographies from neutral pH of the IMAC towards the acidic
pH of the SCX, which needed some optimization to prevent loss of enzyme. Finally, the
loss of α-L-fucosidase in this step was minimized to 10 % by diluting the fractions received
during IMAC in binding buffer of the SCX. After the SCX, the enzyme was again re-buffered
towards PBS at neutral pH. Interestingly the first re-buffering from neutral towards acidic pH
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resulted in a substantial loss of α-L-fucosidase when using a centricon, whereas nearly the
entire amount of enzyme was recovered during buffer exchange via centricon from acidic to
neutral pH. In summary, up to 80 % of the initially loaded α-L-fucosidase activity could be
recovered in the final concentrated PBS-buffered sample. 70 U were obtained from 900 ml
cell culture supernatant. In comparison, 250 mU/g body weight of His6-tagged human α-
L-fucosidase were used in a preliminary high-dose ERT of the mouse model. Assuming an
average body weight of 25 g of the mice, up to ten injections could be performed using one
enzyme preparation. As stated above, an even higher enzyme production was monitored in
the suspension culture system, which should result in increased yields of His6-tagged human
α-L-fucosidase.
5.2.3 Purification of the untagged human α-L-fucosidase
Although a purification protocol for the His6-tagged human α-L-fucosidase was successfully
established, the purification of the untagged enzyme is absolutely essential with respect to a
further ERT of human fucosidosis patients, due to the high immunogenicity of the His6-tag.
Several chromatography techniques have been tested for purification of the untagged enzyme
and are discussed below, but a sufficient purification protocol could not be established so far
and should be the issue of further research.
5.2.3.1 Fucose-affinity chromatography
The purification of genuine human α-L-fucosidase had been commonly carried out using a
specific agarose-ε-aminocaproyl-fucosamine affinity matrix (Alhadeff et al. 1974a, Alhadeff
et al. 1975a, Alhadeff and Janowsky 1977, Chien and Dawson 1980), where fucose was cou-
pled to a six-carbon-atom spacer. The affinity matrix, which was used in these studies, is
no longer available. In a similar approach, Bielicki et al. (2000) purified recombinant ca-
nine α-L-fucosidase using an affinity matrix where fucose was coupled to a 24-carbon-atom
spacer, but this matrix is also no longer available. In this study, N-(ε-aminocaproyl)-β -L-
fucopyranosylamine (6-carbon-atom spacer) was immobilized on CNBr-activated sepharose
beads and, alternatively, on a NHS-activated column. However, the coupling efficiency of both
matrices was rather low, as only small amounts of α-L-fucosidase (< 5 U) could be efficiently
bound, whereas increasing amounts resulted in a high α-L-fucosidase activity in flow through
and washing fractions. In further studies, additional coupling conditions should be tested in
order to increase coupling efficiency. Moreover, other commercial available fucose-affinity
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matrices could be tested (e. g. from Vector Laboratories # AC-1002) and the use of another
spacer should be considered. Bielicki et al. (2000) reported, that the length of the spacer in-
fluences the binding efficiency, as the use of a 24-atom spacer resulted in binding of 98 % of
the canine α-L-fucosidase, whereas only 9 % were bound to an affinity matrix, where fucose
was coupled to a one-carbon-atom spacer.
Despite the general difficulties regarding the coupling efficiency, an efficient elution by addi-
tion of L-fucose could not be established so far. The α-L-fucosidase eluted as a broad smear
and contained multiple impurities, particularly a protein with an apparent molecular weight of
66 kDa, which is most likely BSA. An enrichment of the enzyme was not achieved, although
500 mM NaCl were already included in the washing buffer. Similar results were also observed
using other chromatography techniques and might suggest, that the enzyme forms aggregates
with other proteins (will be further discussed in section 5.2.3.3).
5.2.3.2 Concanavalin A-chromatography
In order to establish a purification protocol for the untagged human α-L-fucosidase the use of
a lectin-chromatography (concanavalin A, ConA) was tested. As a matter of fact, no sufficient
elution was achieved and approximately 90 % of the enzyme remained on the column whatever
elution conditions were tested. A comparable study was presented by Gramer et al. (1994), in
which a Tris-buffered system containing 0.5 M α-D-methylmannoside resulted in the elution
of only 41 % of the loaded α-L-fucosidase (produced in CHO cells). Moreover, Alhadeff and
Watkins (1979) used an acidic buffer system at pH 4.0 that resulted in the loss of Mn2+ and
Ca2+ as essential co-factors for substrate binding of the lectin. The application of an acidic
buffer system was considered to cause a complete elution of the bound enzyme, but only 50 %
of human liver α-L-fucosidase were released from ConA material. The binding of the α-L-
fucosidase to the ConA material seemed to be extremely strong, since the enzyme could be
released only under denaturating conditions.
5.2.3.3 Further purification techniques
Besides the affinity chromatographies using immobilized fucose residues as well as ConA ma-
terial, different ion-exchange chromatographies (IEX) as well as a Ni2+-affinity chromatogra-
phy (IMAC) were tested to purify the untagged α-L-fucosidase. Although an efficient binding
of the enzyme could be achieved for the IEX using a HiTrap HP SP column at acidic pH values
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and a DEAE matrix at pH 8.0, the enzyme always eluted together with the majority of impu-
rities independent on the chromatography technique or the chosen pH value. Similar results
were obtained for the IMAC and were also seen during fucose-affinity chromatography (dis-
cussed in section 5.2.3.1). This might be due to a complex formation of the α-L-fucosidase
with several other proteins. Further results suggested that these aggregates might be formed
during the ammonium sulfate precipitation of freshly harvested cell culture supernatants, as
a high amount of contaminants showed an altered elution profile during ion-exchange chro-
matography when the cell culture supernatant was directly loaded onto the SP column. A
formation of aggregates is not reported in the literature, although ammonium sulfate preci-
pitation was often used during purification of α-L-fucosidase from human tissues (Robinson
and Thorpe 1973, Turner 1979, Chien and Dawson 1980). In further experiments, particularly
the use of conditioned medium from suspension cells cultivated in FCS-free and protein-free
medium seems to be promising, as this medium should minimize the amount of contaminants.
5.2.4 Characterization of the recombinant α-L-fucosidase with regard to
its application in ERT
The recombinant human α-L-fucosidase was characterized regarding its enzymatic properties
and suitability for ERT studies. In a first experiment, the pH optimum of the enzyme was de-
termined and the highest α-L-fucosidase activity was observed at pH 5.5, which is comparable
to genuine enzyme from mouse liver, indicating that the recombinant α-L-fucosidase is highly
active at lysosomal pH. A slightly lower pH optimum at pH 5.0 for human α-L-fucosidase was
reported by Robinson and Thorpe (1973), whereas Wiederschain et al. (1973) distinguished
between a low molecular weight form of human α-L-fucosidase with a pH optimum of 4.5 -
5.0 and a high molecular weight form with a pH optimum of 5.5. In contrast, Alhadeff et al.
(1975a) reported a pH optimum of 4.6. These data indicate, that the human α-L-fucosidase
exhibits its pH optimum at lysosomal pH and slight differences between the individual data
might be due to the different enzyme preparation or different sources of the enzyme resulting
in an altered glycosylation pattern that was already shown to slightly influence enzyme activity
and pH optimum (Alhadeff 1978).
In particular, a proper glycosylation of the recombinant human α-L-fucosidase is important
regarding its further use in an ERT, as the glycosylation pattern might influence the pharma-
codynamic properties and biodistribution of the enzyme. The human α-L-fucosidase contains
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four putative glycosylation sites, but the usage of one is unlikely, as it contains a proline
residue in the recognition sequence (Johnson and Alhadeff 1991). The N-glycans were shown
to exhibit high-mannose as well as complex type N-glycans (Johnson et al. 1992). Simi-
lar results were obtained during this study by PNGase F and EndoH treatment of recombi-
nant His6-tagged α-L-fucosidase indicating the presence of a mixed glycosylation pattern.
The proper glycosylation of the recombinant enzyme is of special importance, as it is a pre-
requisite for addition of M6P residues, which are essential for the lysosomal targeting of
the α-L-fucosidase (Kollmann et al. 2012, Markmann et al. 2015). The exact site of M6P
phsophorylation was determined at position 377NTT of the α-L-fucosidase purified from hu-
man brain (Sleat et al. 2005). The transfer of the phosphate residue is carried out by the
UDP-N-acetylglucosamine 1-phosphotransferase (GNPT) that consists of two α and two β -
subunits encoded by the GNPTAB gene as well as two γ-subunits encoded by the GNPTG
gene. The α/β -subunits are responsible for phosphotransferase activity and recognition of the
lysosomal hydrolases, whereas the γ-subunits are supposed to enhance the phosphorylation
of a subset of hydrolases, especially lysosomal glycosidases like α-mannosidase. In contrast
the α-L-fucosidase is efficiently recognized by α/β -subunits and its lysosomal targeting is
not impaired by GNPTG-deficiency (Flanagan-Steet et al. 2016). The degree of mannose-6-
phosphorylation of the recombinant His6-tagged enzyme was analyzed in this study using a
specific M6P receptor affinity matrix. Although a partial elution of the recombinant enzyme
by addition of M6P was shown, the exact degree of mannose-6-phosphorylation could not be
estimated, as an unspecific binding towards the column matrix occurred and only an incom-
plete elution was achieved. Nevertheless, the His6-tagged human α-L-fucosidase was shown
to be partially mannose-6-phosphorylated and hence the enzyme offers great potential regar-
ding ERT studies. Besides the M6P-mediated endocytosis, other glycoprotein receptors could
also participate in the uptake of the recombinant α-L-fucosidase. The mannose-receptor is ex-
pressed in macrophages and dentritic cells as well as in hepatic, spleenic, lymphatic and der-
mal microvascular endothelium and specifically mediates the uptake of glycoproteins with ter-
minal mannose, fucose and N-acetylglucosamine residues (Martinez-Pomares 2012), whereas
the asialoglycoprotein receptor is expressed in hepatocytes and binds terminal galactose and
N-acetylgalactosamine residues (Ashwell and Harford 1982). In this context, an efficient up-
take of the recombinant His6-tagged α-L-fucosidase was observed in MEFs and during ERT
of the mouse model, indicating that the endocytosis is not restricted to the M6P receptors and
other receptors might contribute to the cellular uptake.
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As discussed earlier (section 5.2.2), the His6-tagged human α-L-fucosidase displayed an un-
expected strong affinity towards the IMAC and SCX matrix suggesting an oligomerization of
the enzyme that increased the avidity of this interaction. Indeed, a pH-independent oligomeri-
zation of the His6-tagged enzyme was shown by size exclusion chromatography (SEC), which
might be tag-induced. The molecular weight of untagged human α-L-fucosidase was de-
termined by SEC at 60 kDa at pH 7.5 (Turner 1979), whereas the enyzme was detected at
79 kDa (pH 7.4) in this study. The reason for this difference is still unclear, but might at
least partially represent differences in the degree and type of glycosylation, especially in the
sialic acid content. The human liver α-L-fucosidase is a sialoglycoprotein and seven isoforms
have been isolated, which differ in the sialic acid content and display distinct behavior during
SEC (Alhadeff 1978). In order to exclude unexpected buffer effects during SEC, the lysoso-
mal protein Plbd2 was used as oligomerization control and its dimerization (Lakomek et al.
2009) was also observed in this study, indicating proper conditions for lysosomal proteins
during the SEC. The molecular weight of genuine murine α-L-fucosidase was determined
with 56 kDa at pH 7.4 and is comparable to results from Laury-Kleintop et al. (1987), who
reported two fucosidase isoforms with an apparent molecular weight of 57 kDa and 63 kDa by
SDS-PAGE. The molecular weight differences are probably caused by distinct glycosylation
patterns. However, no SEC studies of the murine α-L-fucosidase are available so far. For
the human α-L-fucosidase the formation of homooligomers has been reported and dimeric,
tetrameric as well as hexameric forms were described (Chien and Dawson 1980; Alhadeff et
al. 1975a and Turner 1979). In this study, the molecular weight of the human enzyme oligomer
was determined with 312 kDa at pH 4.6 and corresponded well with results by Turner (1979),
who also reported a pH-dependent oligomerization of the human fucosidase with a hexameric
form of 305 kDa at pH 5.0 and a fucosidase monomer of 60 kDa at pH 7.5. In summary, the re-
combinant His6-tagged as well as the untagged human α-L-fucosidase exhibited an oligomeric
form at lysosomal pH that might increase the stability of the enzyme. Indeed, a high stability
of the purified His6-tagged α-L-fucosidase was detected during short-term storage in PBS at
4 ◦C, where no protein degradation could be detected after ten days. A similar finding was re-
ported for arylsulfatase A (ARSA), a lysosomal sulfatase, which also exhibits a pH-dependent
oligomerization and forms an octamer at lysosomal pH. Deficiency of ARSA causes the LSD
metachromatic leukodystrophy, e. g. due to a P426L mutation of the ARSA gene. The P426L-
ARSA mutant showed normal activity and lysosomal targeting, but the lysosomal octameriza-
tion is impaired. This caused lysosomal instability of the mutant, as a cathepsin L cleavage
site became accessible which is normally hidden in the octamer (von Bülow et al. 2002).
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5.3 Enzyme replacement therapy of Fuca1(-/-) mice
ERT has been proven as a safe and efficient therapy in a subset of LSDs (e. g. Gaucher disease,
MPS I, MPS II, MPS VI and Pompe disease; Cox 2013). In this study, a high-dose, short-
term ERT of the constitutive fucosidosis mouse model was performed using 250 mU/g body
weight of purified His6-tagged human α-L-fucosidase in two injections within one week. The
therapy resulted in a massive uptake of the recombinant enzyme into visceral organs like liver
and spleen and to a lower extend also into the kidney, but trace amounts were also detected in
the brain. As the ERT-treated Fuca1(-/-) mouse was not perfused prior to sacrifice, the α-L-
fucosidase activity detected in the brain could result from recombinant enzyme that was still
present in the circulation of the mouse, or that was taken up into extra-neural cells of the brain
in the endothelia or meninges. A high bioavailability of the α-L-fucosidase in liver and spleen
was expected, as recombinant α-mannosidase and N-acetylglucosaminidase were also mainly
taken up by liver and spleen in short-term ERTs of α-mannosidase knock-out mice (Roces
et al. 2004) and a mouse model for MPS IIIB (Yu et al. 2000), respectively, whereas the de-
livery into the kidney was also low in both studies. The main critical aspect of ERTs in LSDs
with CNS involvement is the treatment of the brain, as delivery of intravenously administered
enzymes into the CNS is normally prevented by the blood-brain-barrier. However, high-dose
ERT of knock-out mouse models for α-mannosidosis and metachromatic leukodystrophy re-
sulted in an uptake of recombinant α-mannosidase and arylsulfatase A, respectively, into the
CNS, amelioration of the storage pathology and improvement of motor disabilities (Roces
et al. 2004, Blanz et al. 2008, Matzner et al. 2009). Further investigations are necessary to
evaluate, whether the α-L-fucosidase is efficiently delivered into the brain e. g. by using a
higher dosis of the recombinant enzyme or by repeated injections. Another ERT strategy is
the intracisternal injection of the recombinant enzyme directly into the CNS as performed in
the canine fucosidosis model (Kondagari et al. 2011a). However, this method bears a high risk
for CNS infections due to the invasive procedure (Burrow and Grabowski 2013).
Besides the determination of α-L-fucosidase activity, the effects of the ERT were also moni-
tored by analysis of storage material by TLC. The liver was excluded from this experiment, as
the high amount of glycogen prevented its proper analysis by TLC. A complete disappearance
of storage material was detected in the spleen, while a partial digestion of storage material
was detected in the kidney. This might be due to the higher bioavailability of the recombinant
α-L-fucosidase in the spleen in comparison to the kidney and further studies are necessary to
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analyze whether a complete clearance of storage material in the kidney could be achieved by a
higher dosis of the recombinant enzyme or by repeated injections. Comparably, the disappear-
ance of storage material in ERT-treated α-mannosidosis mice was tissue- and dose-dependent
and also relied on the number of injections (Roces et al. 2004, Blanz et al. 2008). As expected,
no effect of the ERT was seen by TLC in the Fuca1(-/-) brain, indicating that the measured α-
L-fucosidase activity was indeed due to residual recombinant enzyme in the circulation of
the mice, or that the amount of administered α-L-fucosidase was too low to detect a benefit
in the CNS. Again, further investigations are necessary to optimize the bioavailability of the
recombinant enzyme. However, these preliminary results are very promising and indicate that
an ERT of fucosidosis might improve storage pathology and clinical symptoms.
As discussed earlier (section 5.1.2), alterations in the regulation of lysosomal proteins are
a common feature of LSDs and an increase in β -hexosaminidase activity was seen in se-
veral organs of the Fuca1(-/-) mice. The elevated levels of β -hexosaminidase activity were
reduced by approximately the half in liver and spleen after ERT-treatment, indicating that
a high bioavailability of the recombinant α-L-fucosidase might not only diminish primary
storage material but might also lead to an improvement of secondary pathologies. Similar
findings were also reported for a mouse model of MPS IIIB, where the treatment with recom-
binant N-acetylglucosaminidase also resulted in reduction of the elevated β -hexosaminidase
activities by approximately the half (Yu et al. 2000).
5.4 Outlook
In this study, the generation of a constitutive fucosidosis mouse model was described. The
Fuca1 gene knock-out was successfully validated and a basic characterization of Fuca1(-/-)
mice was realized. A number of questions remain still open: A detailed analysis of the fucosi-
dosis storage material should be addressed, particularly as it is currently unknown whether the
Fuca1(-/-) mice accumulate fucosylated glycosphingolipids comparably to human fucosidosis
patients. An analysis by TLC revealed no differences in the glycosphingolipid content between
wildtype and Fuca1(-/-) mice, but the TLC might be not sensitive enough. Hence, an analysis
by immunofluorescence staining of different tissues or by mass spectrometry of isolated lipids
should be considered. Here, the liver is of particular interest, as glycosphingolipids bearing
the H-antigen have been found as the major storage material in the liver of human fucosidosis
patients (Michalski and Klein 1999). Also the analysis of the water-soluble storage material
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should be extended, as only a few storage material species were identified so far, whereas
more than ten different fucosylated glycocompounds have been reported in human fucosido-
sis (Michalski and Klein 1999). Of note, Asn-GlcNAc-Fuc was identified in tissues and urine
of Fuca1(-/-) mice and of human fucosidosis patients (Michalski and Klein 1999), respectively
and may serve as a biomarker for the disease. Moreover the analysis of secondary storage
material should be extended. Lipofuscin-like autofluorescent material, GM2-gangliosides and
unesterified cholesterol were already detected in the brain of Fuca1(-/-) mice, whereas the
visceral organs have not been analyzed so far.
The Fuca1(-/-) mouse model was treated by high-dose, short-term ERT using purified His6-
tagged human α-L-fucosidase. A high bioavailability of the recombinant enzyme was ob-
served in liver and spleen, resulting in a complete disappearance of primary storage material
in the spleen as well as an improvement of secondary storage pathology in terms of normal-
ized β -hexosaminidase activity. Certainly, this initial experiment has to be repeated in order
to verify the results and it should be further expanded: An important aspect is the analysis of
pharmacokinetics of the recombinant enzyme like clearance velocity from the serum of the
mice, half life of the enzyme in the mouse tissues, time-dependent depletion of primary stor-
age material as well as duration time between single injections. All these preclinical trials will
help to establish a proper and safe ERT for human fucosidosis patients. As already discussed,
the accessibility of the CNS is of special interest, as neurological implications are the major
clinical symptom of fucosidosis in human. The delivery into the brain could be further op-
timized by generation of an α-L-fucosidase fusion protein with the RTB-lectin, which is the
nontoxic carbohydrate-binding subunit B of ricin AB toxin from Ricinus communis. Recently,
such fusion constructs with human α-L-iduronidase and human β -galactosidase were shown
to amoriliate storage pathology in human MPS I and GM1-gangliosidosis fibroblasts, respec-
tively. The lectin mediated the uptake of the recombinant enzyme by binding to galactose
or galactosamine residues on glycoproteins and glycolipids at the cell surface. The delivery
is not receptor-mediated, but was provided through adsorptive-mediated endocytosis. Due to
this braod spectrum of endocytosis routes, intravenously administered RTB fusion constructs
are believed to enter the CNS, although this was not tested so far in vivo (Acosta et al. 2015,
Condori et al. 2016). Moreover, ERT of the MPS I mouse model using a recombinant fu-
sion construct of α-L-iduronidase and a monoclonal antibody against the murine transferrin
receptor was shown to enhance transport across the blood-brain-barrier and to improve the
CNS storage pathology (Boado et al. 2011). Similar approaches are also feasible regarding
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the fucosidosis mouse model.
The production of the human α-L-fucosidase was performed in CHO-K1 cells. Although the
yield of recombinant enzyme was sufficient to perform an initial ERT study, extended experi-
ments might be limited by the availability of untagged α-L-fucosidase. The production yield
has to be increased especially when aiming a further ERT of human fucosidosis patients. To-
wards this end, the use of the CHO-DG44 cell line is promising, which is deficient in dihydro-
folate reductase (DHFR) resulting in an auxotrophy for glycine, hypoxanthine and thymidine.
The gene of interest (human Fuca1) is cloned into an expression vector containing a func-
tional dhfr gene. Both genes are included into a bicistronic system, so that their expression
is linked. The expression vector is transfected into CHO-DG44 cells and clonal selection is
performed in a growth medium lacking glycine, hypoxanthine and thymidine. Subsequently,
the DHFR system allows the amplification of the cDNA by selection with methotrexate, a
folic acid analogue that blocks DHFR activity. Hence, cell survival is only achieved, when
several copies of the DHFR system are present, which is amplified under increasing selec-
tion pressure. As the expressions of the DHFR and the gene of interest are connected, a high
production CHO-DG44 strain can be generated (Jayapal et al. 2007).
Here, a purification protocol for the His6-tagged human α-L-fucosidase was established, but
sufficient purification of the untagged enzyme proved to be a difficult task. Moreover, the
His6-tagged α-L-fucosidase was used in two injections during ERT of the fucosidosis mouse
model. The immunogenicity of the enzyme was not analyzed so far, but a humoral immune re-
sponse in the Fuca1(-/-) mice and the generation of α-L-fucosidase-specific IgG are expected.
The Fuca1(-/-) mice are completely devoid of α-L-fucosidase resulting in a high immuno-
genicity of the enzyme, regardless of its source or the presence of any tags, as it was recently
described for α-mannosidase knock-out mice receiving repeated injections of recombinant
human α-mannosidase (Damme et al. 2015). The authors reported, that the survival of the
animals was reduced to 50 % after the sixth injection, whereas the α-mannosidase-specific
IgG concentration was already markedly increased after the second injection during high-dose
ERT (500 mU/g). Similar results were also obtained for short-term ERT of arylsulfatase A-
deficient mice (Matzner et al. 2009). Hence, the α-L-fucosidase knock-out mouse model
described in this study is only suitable for analyzing the effects of a short-term ERT, whereas
studying a chronic therapy requires the establishment of an immunotolerant mouse model, as
recently described for α-mannosidosis. Damme et al. (2015) reported the genomic integration
of an inactive form of the human α-mannosidase into the knock-out mouse model which had
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been used in previous studies of short-term ERT (Roces et al. 2004, Blanz et al. 2008). The
human α-mannosidase was inactivated by active site mutagenesis and the knock-in mice dis-
played a comparable phenotype to the former knock-out animals, but tolerated repeated and
even high doses of recombinant human α-mannosidase (Damme et al. 2015). In the context
of the present study, the establishment of a purification strategy for the untagged human α-
L-fucosidase is mandatory, as the His6-tagged enzyme would lead to a high immunogenicity
in a fucosidase knock-in mouse model, whereas the untagged enzyme should be tolerated.
As the purification using a fucose-affinity matrix is the most commonly described technique
(Johnson and Alhadeff 1991), the establishment of an efficient immobilization procedure of
fucose residues or the test of commercially available fucose-affinity matrices (e. g. from Vec-
tor Laboratories # AC-1002) should be addressed.
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Sequences
Figure A.1: Vector map of the expression plasmid for murine α-L-fucosidase
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Figure A.2: cDNA and protein sequences of murine α-L-fucosidase
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Sequences
Figure A.2: cDNA and protein sequences of murine α-L-fucosidase (continued)
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Figure A.3: Vector maps of the expression plasmids for untagged and His6-tagged human α-L-
fucosidase
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Sequences
Figure A.4: cDNA and protein sequences of untagged and His6-tagged human α-L-fucosidase as
well as of its active site mutant (D230N, E294Q)
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Figure A.4: cDNA and protein sequences of untagged and His6-tagged human α-L-fucosidase as
well as of its active site mutant (D230N, E294Q; continued)
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Figure A.4: cDNA and protein sequences of untagged and His6-tagged human α-L-fucosidase as
well as of its active site mutant (D230N, E294Q; continued)
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Additional results
Figure A.5: Aleuria aurentia lectin staining of the brain
Semi-thin sections of the brain of 5-month-old wildtype and Fuca1(-/-) mice were stained with (A) bi-
otinylated Aleuria aurentia lectin, which was detected using DyeLight R© 594-conjungated straptavidin
or (B) as internal control were incubated with DyeLight R© 594-conjungated streptavidin only. Bars
correspondent to 200 µm or 5 µm (inset). Cell nuclei were stained with DAPI (blue).
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Additional results
Figure A.6: Analysis of lipid-rich fractions from mouse tissues by TLC
Lipids were isolated from different tissues of 3-month-old wildtype and Fuca1(-/-) mice, were separated
into polar and neutral lipids and were analyzed by TLC. Identification of the single lipid species was
done by comparison with published results (Kyrklund 1987).
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LB Luria Bertani
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LSD lysosomal storage disease
m murine
M6P mannose-6-phosphate
Man mannose
MBP myelin basic protein
MEF mouse embryonic fibroblasts
ML mucolipidosis
MLD metachromatic leukodystrophy
MPR 40 / 300 mannose-6-phosphate receptor (40 kDa or 300 kDa form)
MPS mucopolysaccharidoses
mRNA messenger RNA
MRS magnetic resonance spectroscopy
MS mass spectrometry
MSD multiple sulfatase deficiency
mTORC1 rapamycin complex 1
MWCO molecular weight cut-off
NCL neuronal ceroid lipofuscinosis
NHS N-hydroxysuccinimide
NMD nonsense-mediated mRNA decay
NPC Niemann-Pick disease type C
p. a. pro analysis purity
PBS phosphate buffered saline
PCR polymerase chain reaction
PEI polyethylenimine
PFA para-formaldehyde
PLL poly-L-lysine
Plp1 proteolipid protein 1
PMSF phenylmethylsulfonyl fluoride
PNGase F peptidyl-N-glycosidase F
pNP para-nitrophenol
pNPF para-nitrophenyl-α-L-fucopyranoside
PTC premature termination codon
PVDF polyvinylidene fluoride
rev reverse
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RNA ribonucleic acid
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SCX strong cation exchange chromatography
SDS sodium dodecyl sulfate
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
Ser serine
S-PBS PBS containing 0.2 % saponin
SUMF1 sulfatase modifying factor 1
TM melting temperature (PCR)
TAE tris/acetate/EDTA buffer
TBS tris buffered saline
TEM transmission electron microscopy
TEMED N,N,N’,N’-tetramethylethylene diamine
TFE3 transcription factor E3
TFEB transcription factor EB
Thr threonine
TLC thin-layer chromatography
Tris tris-(hydroxymethyl)-aminomethane
UCE uncovering enzyme
WT wildtype
U unit(s)
UV ultraviolet
v/v volume per volume
w/v weight per volume
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